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ABSTRACT
The success of cisplatin as an anticancer drug is attributed to the ability of the platinum
compound to damage DNA and subsequently induce apoptosis. Details of the cellular processing
of cisplatin-damaged DNA can provide invaluable insight into the rational design of cisplatin
analogues or combination therapies. Chapter I provides a survey of recent developments in the
understanding of the mechanism of cisplatin action and summarizes relevant platinum-based
anticancer compounds.
Chapter 2 describes a series of estrogen-tethered platinum(IV) complexes (BEPn, n=l -5)
that were synthesized, evaluated for their ability to upregulate HMGB1 and screened for
cytotoxicity against human breast cancer cell lines. All BEPn complexes induced the
overexpression of HMGB I in ER(+) MCF-7 cells. BEP3 was nearly twice as cytotoxic in ER(+)
MC'F-7 cells than in ER(-) HCC-1937 cells. This result suggests the possibility of using
compounds in this class specifically to target ER(+) malignancies, such as breast and ovarian
cancers. In addition, the series of BEPn compounds provide an example of a useful strategy in
the development of platinum-containing anticancer agents, namely, using mechanistic insights to
aid in the rational design of new complexes.
The strategy of exploiting estrogen-induced HMGBI upregulation to sensitize ER(+)
cells to platinum was further pursued in work described in chapters 3 and 4. Chapter 3 reports the
synthesis and characterization of a series of platinum(IV)-estrogen conjugates derived from
4carboplatin. Although these BECPn complexes were moderately cytotoxic in ER(+) MCF-7
human breast cancer cells, no differential cytotoxicity was observed as compared to ER(-) HCC-
1937 cells. However, these compounds represent the first example of a biomolecule-tethered
platinum(IV) complex that reduces to yield carboplatin in cells.
The platinum estrogen conjugate described in chapter 4 was designed not only to induce
upregulation of HMGB I but also to enter ER(+) cells selectively. Unlike the BEP and BECP
compounds, BEEP was designed to maintain affinity for the estrogen receptor and by tethering
platinum to estradiol through the 17c-position of the steroid ring. Compounds with affinity for
the estrogen receptor, which is overexpressed in breast and ovarian cancers, are selectively taken
up into ER(+) cells. Unexpectedly, BEEP had very low affinity for the estrogen receptor and
was therefore equally cytotoxic in ER(+) and ER(-) human breast cancer cell lines.
A common feature of many cancers is overexpression of the folate receptor, which is
responsible for the uptake of folic acid. Therefore targeting the folic receptor is an attractive
method for achieving selective uptake in cancer cells. Chapter 5 describes the synthesis and
biological activity of a folic acid-tethered platinum(lV) compound, which demonstrates the
validity of this premise.
The nuclear protein HMGBI has recently been discovered to function as an extracellular
signaling agent. Because of oxygen deprivation, the core of a solid tumor dies by necrosis and
passively releases HMGB I into the extracellular environment. This characteristic of solid tumors
leads to the hypothesis that extracellular HMGB I is taken up by surrounding viable tumor tissue
and mediates cisplatin sensitivity. The final chapter investigates the capability of exogenously
administered HMGB to modulate the cytotoxicity of cisplatin and trans-DDP in human cancer
cells.
5The Appendix sections provide detailed experimental protocols for several useful
laboratory methods. In Appendix A, a procedure for isolation of nuclei from cisplatin-treated
cells is presented. The nuclei were subsequently used by our collaborators to examine the post-
translational modifications of histones induced by cisplatin exposure. A protocol for isolation of
protein extracts from formalin-fixed paraffin-embedded tissue is described in Appendix B. In
addition, the extracts were probed by western blot analysis to examine the expression levels of
HMGB1 in clinical testicular seminoma samples. Appendix C provides a solid-phase synthetic
methodology for the preparation of peptide-conjugated platinum(IV) compounds.
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Chapter 1
Cisplatin and Related Anticancer Drugs: Recent Advances and Insights.
* This chapter was published in Met. Ions. Biol. Syst.; Sigel A., Sigel H., Eds.; Marcel Dekker,
Inc.: New York, 2004; Vol. 42, pp 143-177
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1. INTRODUCTION
Discovered serendipitously over thirty years ago l, cisplatin (cis-diamminedichloroplatinum(ll))
is used to treat breast, ovarian, bladder, lung, and head and neck carcinomas and affords greater
than 90% cure rates in the case of testicular cancer.- Despite its success, the drug can cause
severe side effects, is active against a limited range of cancers, and is often rendered inactive due
to intrinsic or acquired resistance.3 In order to develop more effective platinum analogs, there
have been extensive studies of the mechanism of action of cisplatin. Over the past three decades,
a great deal has been learned about the mechanism of cisplatin-induced cell death. As shown in
Figure 1.1, cisplatin enters the cell both by passive diffusion and possibly also by an active
transport mechanism.4 -6 Inside the cell, the chloride concentration is substantially lower,
inducing cisplatin to undergo aquation.7 The resulting cationic monoaqua species subsequently
reacts with DNA, forming a variety of cross-links, with 1,2-intrastrand d(GpG) and d(ApG)
cross-links accounting for 90% of all adducts.7 A smaller percentage of the 1,3-intrastrand
d(GNG) and interstrand cross-links also form.7 The related drug carboplatin, or cis-
diammine(l,l -cyclobutanedicarboxylato)platinum(II), forms a substantially greater number of
1,3-intrastrand cross-links.5
Cisplatin-DNA adducts inhibit DNA replication, block transcription by RNA polymerase
11, and ultimately trigger programmed cell death, or apoptosis. 7 9 Furthermore, the 1,2-intrastrand
cross-link induces a pronounced bend in the DNA helix. (' The resulting wide and shallow minor
groove opposite the platinum adduct serves as a recognition motif for a number of cellular
proteins, including DNA repair proteins, histones, and HMG-domain proteins such as
HMGBI.' 7 '1 - - The recognition of cisplatin-modified DNA by such proteins is an important
cellular response to platinum damage because, among other finctions, they signal for the repair
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of cisplatin adducts, shield platinum-DNA cross-links from repair, and initiate apoptosis."
Understanding the role of such recognition proteins in mediating cisplatin cytotoxicity is of great
interest.
This chapter is focused on the most recent developments in the cisplatin arena. In
particular, we limit our discussion to papers that increase our understanding of the mechanism of
action, reveal factors that influence the recognition and repair of platinum damage, and present
new classes of platinum anticancer agents. We also treat exclusively mononuclear Pt(Il)
complexes with cis stereochemistry, since the chemistry and cytotoxicity of trans-platinum
compounds, platinum(IV) complexes, and multinuclear platinum agents have been reviewed
recently.'3 Several excellent reviews on various aspects of cisplatin cytotoxicity are also
available. 4'5' 7'14-18
2. MECHANISM OF ACTION
2.1 Cellular uptake of cisplatin
It has long been accepted that cisplatin enters cells by passive diffusion. Evidence for such a
pathway includes the following three observations: (1) the rate limiting factor for platinum
uptake is drug concentration; (2) cisplatin accumulation is not inhibited by structural analogues;
and (3) the uptake of cisplatin is not saturable.' 9 Cisplatin accumulation also appears to be
mediated by a membrane-associated protein transport system, as well as by additional agents
including aldehydes, metabolic inhibitors and intracellular signaling mechanisms.'9 In some of
these cases, the studies did not clearly delineate uptake from efflux processes. Cisplatin uptake
has never been reported to be specifically inhibited by more than 50%, supporting the conclusion
that passive diffusion must account for at least half of all drug influx, while protein-mediated
23
uptake may account for the remaining half.'9 The debate as to whether cisplatin can enter cells
by facilitated diffusion is now more timely than ever because of a recently discovered
relationship between cisplatin uptake and the copper transporter Ctrl.6
Direct evidence connecting copper transport and cellular cisplatin resistance was first
obtained by the observation that cells transfected with ATP7B, a gene that encodes a copper
transporting P-type ATPase, are resistant to both copper and cisplatin.2' ) The gene product,
ATP7B, is a 1465 amino acid, heavy-metal transporting protein that contains 6 Cu-binding
motifs (GMTCXXC) at its N-terminus. The transfected cell line, KB/WD, was 8.9-fold more
resistant to cisplatin than KB/CV cells (KB-3-1 cells transfected with an empty vector) and
2-fold more resistant to copper. KB/WD cells accumulated 60% less cisplatin than KB/CV cells
and effluxed approximately 20% of the acquired platinum, which may account for the observed
resistance.2 A screen of yeast loss-of-function mutants for cisplatin resistance revealed that the
strain defective in the MAC 1 gene conferred the highest degree of resistance (2.5-fold).2 ' The
number of cells that survived a 2-h treatment of cisplatin was 1000 times greater in the maclA
mutant. All known Maclp target genes (CTR1, FREI, FRE7, CTAI and CTTI) were
individually deleted and only the CTRI mutant, ctrlA, displayed a similar amount of cisplatin
resistance. Additional cytotoxicity assays were carried out with mutants deficient in copper
trafficking and utilization genes (ccc2A, fet3A, lys7A, sod IA, coxl 7A, and soc IA). None of these
mutants showed comparative resistance with the ctrlA strain, indicating that detects in copper
distribution or utilization did not lead to cisplatin resistance. Other copper transporters, Ctr3p,
Ctr2p, and Fet4p, were also investigated; however, they did not lead to substantially increased
levels of cisplatin resistance. Cisplatin accumulation in the ctrlA cell line was 59% of that in
wild-type, suggesting that CTR1 mediates cisplatin uptake. Administration of copper decreases
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cisplatin accumulation and increases cell survival by a factor of two. In addition, cisplatin
diminishes copper uptake by 16% and mimics copper in its ability to trigger internalization and
degradation of Ctrlp. Further experiments were performed with mouse Ctrl knockout cells to
investigate the role of mammalian Ctrlp in cisplatin resistance. Homozygous mutant cells were
8-fold more resistant and acquired 70% less cisplatin than wild-type cells.21
Further evidence linking copper transport with cisplatin uptake was provided in studies
with yeast cells.22 Accumulation of cisplatin and copper was determined in two isogenic S.
cerevisiae strains, a parental line (BY4741) and a subline (ctrl BY4741-YPR124W) in which the
CTRI gene is deleted. Cellular copper was 16-fold reduced in the ctrl line, and accumulation of
cisplatin was 8-fold diminished. Addition of cisplatin to the culture medium also reduced the
accumulation of copper in a concentration-dependent fashion. Moreover, ctrl cells were 1.9-fold
more resistant to cisplatin and formed 2.3-fold fewer platinum-DNA adducts than wild type
cells.22 A connection between cisplatin and copper also occurs in human ovarian carcinoma cell
lines (A2780/CP, 2008/C 13*5.25, and IGROV-I/CP). 23 Cells selected for cisplatin resistance are
also cross-resistant to copper, being between 5.7- and 8.1-fold more resistant to cisplatin and
between 1.5- and 2.1-fold more resistant to CuSO4. The cisplatin-resistant cells lines had reduced
levels of platinum accumulation and 22-56% lower basal levels of copper. Interestingly, there
was no clear correlation between whole cell uptake of cisplatin and DNA adduct formation.
There is no known method to quantitate CTRI, but only one of the three resistant cell lines had
reduced CTR1 mRNA relative to the parent line.23
The exact role that copper transport proteins play in mediating cisplatin resistance is
unknown. Cisplatin uptake may be coupled to endocytosis and degradation of Ctrlp. 2 '
Alternatively, transporters and chaperones used to mediate copper homeostasis may import,
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distribute, and export cisplatin in the same way as copper; however the kinetically more inert
character of Pt(II) compared to Cu(l) or Cu(ll) makes it difficult to understand such a
parallel.6 '2 23 Although there is no known CTR cisplatin binding site, both yCtrl and hCTRI
have three transmembrane segments including an extracellular methionine-rich N-terminal tail
that could bind platinum (Figure 1.2).24-29 It has been suggested that, because platinum binding
affinity to methionine is sufficiently labile to afford transfer to histidine ligands, intracellular
transport of cisplatin via binding to CTR is feasible.2
Investigation of the theory that protein-bound cisplatin serves as a platinum reservoir has
provided much information about platinum-protein interactions.'5 Platinum compounds with
chelating amines can migrate from methionine to histidine in peptides containing both.') 31
There is not yet any evidence, however, that thioether-bound cisplatin will migrate to a histidine
imidazole, much less to DNA.3'3233 The reaction of cisplatin with methionine- and histidine-
containing peptides gives rise only to a variety of peptide chelates and the ammine ligand trans
to the thioether is often dissociated.30' 2 Furthermore, a l:l complex between methionine and
cisplatin does not react with CT DNA, even after 12 h.34 Inside the cell, where glutathione
concentrations can approach 10 mM, platinum thioether complexes are readily converted to
platinum thiolates and subsequently exported from the cell.33'3 These observations raise serious
mechanistic questions about CTR mediated cisplatin transport. Further work is needed to
elucidate the binding affinity of cisplatin to CTR and the fate of any transporter-bound platinum.
More recent studies have further questioned the role of CTR relating to cisplatin
biological activity. The effect of hCTRI expression on the activity of cisplatin was examined in
human ovarian cancer cells.3 6 Cisplatin treatment of cells that overexpress hCTRI resulted in
increased platinum accumulation and decreased cellular growth rates; however, increased
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expression of hCTR1 had limited effect on cisplatin cytotoxicity and platinum-DNA adduct
levels.36 In addition, although cisplatin stimulates endocytosis and degradation of Ctrl in yeast,
the same is not observed in human embryonic kidney cells.37 It appears that hCTRI increases
cellular platinum accumulation, but the platinum is sequestered into vesicles and is unavailable
for DNA-binding.36 '3 7 Therefore, it is unlikely that hCTR1 contributes to the mechanism of
action of cisplatin. Instead, copper-transport proteins may be more involved in resistance
mechanisms of platinum-based anti-cancer drugs. For example, increased expression of ATP7A
and ATP7B, copper-transporters located in the trans-Golgi apparatus, results in decreased
cytotoxicity of cisplatin, carboplatin, and oxaliplatin but does not result in decreased cellular
platinum levels.3 8'39 Confocal microscopy studies reveal that cisplatin indeed co-localizes in
vesicles with ATP7B and as a result cannot bind to DNA.4"
2.2 Interaction of cisplatin with DNA
Cisplatin can bind to RNA, proteins or sulfur-containing biomolecules, but DNA is its primary
biological target.4'5 '7 Understanding the factors that control cisplatin binding to DNA are crucial
in elucidating its mechanism. Recent studies have examined the effects of flanking sequences on
cross-link formation in order to understand the factors that might influence cisplatin sequence
specificity. Cisplatin preferentially binds to poly-G-rich DNA sequences.41 This apparent
sequence specificity may be due to cisplatin targeting of such regions or may simply reflect the
greater number of N7 platinum binding sites. Platination of M13mpl8 viral DNA followed by
examination by double-stranded replication mapping revealed that 89% of all GG sites blocked
replication, indicating that cisplatin binds to most of the available poly-G sites.4 ' Platination of a
plasmid containing an 800 base-pair telomeric (TTAGGG),, repeat revealed the G-rich regions to
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have more adducts than the random sequence segments; however, increased platination of the G-
rich regions corresponded to an increase in platinum binding sites.4 ' These data imply that
cisplatin does not specifically target poly-dG sequences.1
The majority of cisplatin adducts are 1,2-intrastrand d(GpG) and d(ApG) cross-links,
whereas the corresponding d(GpA) adduct does not form.7 Furthermore, the 1,2-intrastrand
d(GpG) cross-link is three times more prevalent than the d(ApG) cross-link.42 It is of great
interest to understand the factors that govern this cisplatin-adduct profile. With the use of
hairpin-stabilized double-stranded oligonucleotides, the kinetics of platinum binding to GG and
AG sequences were determined.4 2 Reactions of cis-[Pt(NH3) 2Cl(OH2)] + and c i s-
[Pt(NH3)2(OH2)2]-2 with d(TATGGTATT 4ATACCATA) (I) and d(TATAGTATT 4A-
TACTATA) (II) were monitored by HPLC. As expected based on charge and labile ligand
availability, the monoaqua species reacts with these hairpin oligonucleotides between 20-150
times more slowly than the diaqua species. The diaqua species reacts 3 times more rapidly with I
than with II. whereas the monoaqua species has similar reaction rates with both sequences. The
relative platination rates of I and II suggest that cis-[Pt(NH3)2Cl(OH2)]+ should form similar
amounts of GG and AG adducts, while cis-[Pt(NH3)2(0H) 2]+2 should preferentially tform GG
adducts with cellular DNA.42 In addition, platination rates of the hairpin oligonucleotides follow
in the order cis-[Pt(NH3)2(OH,)2] '  > ci,-[Pt(NH 3)2(OH2)(OH)] > [Pt(NH3) 3CL]i >> CiS-
[Pt(NH3)2CI(OH2)]', which parallels the hydrogen bond donor ability of the complexes.
Hydrogen bonding between the platinum ligands and the 06 of guanine may stabilize the
transition state for Pt-nucleobase bond formation.42 Such hydrogen bonding is not possible for
adenine and may provide a rationale for the preference of GG over AG adducts. These
observations suggest that the more significant DNA-binding species is cis-[Pt(NH3)2(OH2 )2] 2
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not the more widely accepted cis-[Pt(NH3) 2Cl(OH)]+.42 Preassociation of the monoaqua species
may drive the aquation equilibrium towards the diaqua form. Furthermore, polyanionic DNA
repeals anions, such as Cl-, and concentrates cations, like H30 +, which would favor the formation
of the diaqua species. Thus, the second aquation reaction may occur while the monoaqua
complex is associated with DNA before the first Pt-N7 bond is formed.42
Additional kinetic studies of cisplatin binding to three self-complementary oligo-
nucleotides 5'-d(AATTAGTACTAATT)-3' (-AG-), 5'-d(AATTGATATCAATT)-3' (-GA-), and
5'-d(AATTGGTACCAATT)-3' (-GG-) were carried out with the use of H-'N HSQC NMR
spectroscopy.43 Several kinetic models were used to evaluate the data and the most appropriate
model was one that included a reversible aquation step and a single platinum binding site for the
self-complementary duplex. The monoaqua species is first observed after 2 h, whereas the diaqua
species appears only at 3.5 h. After 30 h at 298 K, 23% of the cisplatin remains and 65% has
been converted to cis-[Pt(NH3)2Cl(OH,)]'. The presence of cis-[Pt(NH 3) 2(0H,) 2] 2 never
accounts for more than 7% of total observable platinum. The rate of cisplatin aquation is slowed
by 30-40% in the presence of DNA, with aquation in the presence of the -GA- oligomer being
the slowest. The diminished rate of aquation may be explained by preassociation between
cisplatin and DNA, leading to decreased solvent accessibility to the platinum center.43 Different
degrees of association between cisplatin and the -GG-, -AG-, and -GA- sequences may explain
the different rates of aquation. The kinetics of cisplatin binding to -GG-, -AG-, and -GA- were
also determined.43 In general, the kinetics of monofunctional adduct formation correlate with the
cisplatin adduct profile.43
The conclusions drawn in these two studies are clearly in conflict with one another. 16 '4 2'43
Using their kinetic models, the latter investigators analyzed the hypothesis that cis-
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[Pt(NH3)2 (OH2 )2]-2 is the most important DNA-binding species. They concluded that reactions
between DNA and the diaqua species only account for 0.9-1 .2% of the platination products. 3 As
discussed earlier, the diaquated species was first detected only after 3.5 h, at which time
platination of DNA by the monoaqua form is already in progress. The chloride concentration in
cancer cells (20-50 mM) probably further suppresses the formation of the diaqua species. ' 43
2.2.1 Structural studies
Many platinum compounds are able to form 1,2-intrastrand cross-links, but their cytotoxicities
do not approach that of cisplatin.4 4 It is therefore of interest to characterize cis-PtA2G2 (G =
guanine derivative, A = amine) adducts in order to assess whether subtle structural differences
induced by the carrier ligand might influence the processing of platinum-DNA lesions and the
attendant cytotoxicity. No two structural analyses of platinum-DNA adducts by NMR solution
methods are the same, and the NMR results conflict with X-ray structures when analyzed in
detail. Dynamic motion about Pt-N7 bonds greatly complicates the study of simple cis-PtA2,G
models by NMR methods. 4 5 Rotation about the Pt-N7 bond can give rise to either a head-to-head
(tto) or head-to-tail (HT) orientation of the cis guanine bases.46 There are two isomers possible
ftr the HIT orientation, AHT and AHT.46 In addition, the phosphodiester backbone can adopt a
normal (1) or opposite (2) backbone propagation direction. These possibilities give rise to four
conformational classes: HHI, HH2, AHTI and AHT2 (Figure 1.3).46 The cisplatin 1,2-(GpG)-
intrastrand cross-link adopts primarily the anti, anti head-to-head, or HHI, conformation, which
minimizes steric clashes with the phophodiester linkage.4 5 In order to study simple cis-PtAG.
models and elucidate the effect of carrier ligands on adduct conformation, the dynamic motion
about the Pt-N7 bond was slowed significantly by using bulky chelating amine ligands.4 5 These
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compounds are termed retro models and have utilized two classes of such ligands. The first class,
known as chirality-controlling-chelate (CCC) ligands, have chiral carbon atoms near secondary
amines so that the amine configurations are restricted to a particular chirality.4 4 45'47 -5 0 The
platinum-bound guanine derivatives can assume a number of conformations in these retro model
compounds because the CCC ligands lack bulk above and below the coordination plane. The
control of Pt-N7 fluxionality arises from rigid bulk along the coordination plane.4i The second
ligand type, chirality-neutral chelate (CNC) ligands, have no chiral carbon atoms.5' 53 In
addition, the CNC ligands have no axial or equatorial NH or alkyl groups, but effectively
minimize rotation about the Pt-N7 bond.5153
The study of retro model compounds by CD and NMR methods has provided valuable
insights into the factors that influence conformer stability. In particular, the stability of isomers
depends on several factors including dipole-dipole alignment (first-to-first sphere
communication, or FFC), phosphate-cis G NIH interactions (second-sphere communication, or
SSC), electrostatic repulsion, phosphate-carrier ligand NH interactions (first-to-second sphere
communication, FSC), and NI H-G 06 hydrogen bonding (FFC).44 '4749 - 51 The carrier ligand can
significantly influence conformer stability in solution, which may be important in modulating
cytotoxicty. In addition, the study of retro model compounds has led to the speculation that cis-
[Pt(NH 3)2(GpG)] may exist as a dynamic mixture. 4 8 Its 31p NMR signal is more upfield shifted
than expected for a purely anti, anti HHI conformer, suggesting that a small population of anti,
syn AHT1 conformer might be present. Furthermore, the downfield H8 proton signal is broad,
which indicates a possible exchange between the anti, anti HH1 and anti, syn AHTI
conformers. 4 8
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The ability of the ammine ligands of cisplatin to form hydrogen bonds to the 06 atom of
guanine has long been argued to be vital for cytotoxicity; however, it has recently been suggested
that it is the small size of the NH3 group, rather than its hydrogen-bonding ability, that is
important. 3 In order to investigate the significance hydrogen bonding, the conformations of
P't(Me2ppz)(GpG) and Pt(Bip)(GpG) were compared.' 3 Pt(Meappz)(GpG) lacks an NH group and
therefore cannot hydrogen bond to guanine, whereas Pt(Bip)(GpG) is capable of hydrogen
bonding. For the AHT conformers, hydrogen-bonding between the carrier ligand amine and the
guanine 06 was weak and not important in stabilizing the interaction. s3 It is plausible that
platinum withdraws electron density from the coordinated guanine base, weakening the
hydrogen-bond accepting ability of the guanine 06.' 3 Additional support for the lack of
importance of hydrogen bonding in stabilizing the 1,2-intrastrand d(GpG) cross-link comes from
examination of the cross-link structure itself. The base pair step adjacent to the platinum adduct,
known as the Lippard base pair step, is unusually distorted. 3 55 As shown in Figure 1.4, the
Lippard base pair step is characterized by a large positive slide and shift, caused by movement of
the 5'-G* base pair relative to adjacent base pairs. 3 '5 5 If the 5'-G* were hydrogen bonding to the
platinum ammine ligand and retained normal base canting, a steric clash would result between
the 5'-G* and the adjacent 5'-residue.53 Therefore, the forces that favor formation of hydrogen
bonds between the guanine 06 and platinum amine are dominated by the need to minimize steric
c lash. 53
Recognition of the Lippard base pair step also helped to reconcile differences between
the numerous NMR and X-ray structures of cisplatin-modified DNA mentioned above. Modeling
cisplatin-modified DNA NMR data with the use of restrained molecular dynamics (RMD)
affirded models with different base stacking, backbone conformation, base step rise, and the
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extent and nature of PtG*2 geometry distortion.56 Furthermore, NMR-derived solution structure
positions differ by as much as 3.5 A in the three-base-pair region 5'-XG*G*-3' compared to a
recently reported X-ray structure.5 5' 56 Marzilli proposes that NMR methods have previously
failed to define the structure of the platinum-damaged duplex because of the unusual and
unrecognized structure of this three-base-pair region.5 6 The distortion significantly limits
modeling by traditional RMD methods. Closer examination of the many reported NMR
structures of cisplatin-damaged DNA revealed that all duplexes have the same structure in the
three-base-pair region. 56 The NMR solution structure that models in the Lippard base pair step is
quite similar to the X-ray structure of platinated DNA bound by the HMGBla protein,
suggesting that cisplatin-modified DNA requires little structural change in order to accommodate
binding of this three-helix domain (see also 2.3.2 below). 5 ' 56
2.2.2. Effect of Chromatin Structure
The majority of studies characterizing cisplatin binding to DNA have been carried out using
purified DNA. In the cell, DNA is condensed into a compact chromatin structure, which may
affect cisplatin binding.57 As a result, recent work has focused on elucidating the interactions
between cisplatin and chromatin DNA. Early work with cisplatin binding to nucleosomal DNA
revealed little effect of the core histones on DNA binding.58 Nuclease digestion of chromatin to
determine the location of platinum adducts indicated that DNA cross-links were favored over
protein cross-links and that, at a low platinum concentration (rb < 0.05), the linker DNA is
targeted.58 63 At high platinum concentrations (rb = 0.1-0.2), however, there was no preference
for linker DNA.6" Current work with nucleosomal DNA utilizes reconstituted chromatin
containing specifically designed DNA sequences. In reconstituted chromatin, cisplatin binds
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preferentially to the nucleosomal linker regions.64 Thus, it appears that the nucleosomal core
region offers some protection against cisplatin-induced DNA damage.64 Nucleosomal core
particles lacking DNA linker regions form cisplatin interstrand cross-links in a similar manner as
free DNA, suggesting that the major groove is still accessible to cisplatin attack.6 ' In one study,
the effect of chromatin structure was investigated in intact human cells, using the epsilon-globin
gene promoter, which contains numerous transcription binding sites, as the target DNA
sequence.6 6 Platination was specifically enhanced at the CACC binding site where a transcription
factor of the Sp 1 family binds.66 It is possible that the binding of transcription factors bends the
DNA, therefore exposing it to cisplatin damage. 66
More recently, the effect of chromatin structure on nucleotide excision repair has been
investigated using a site-specifically platinated nucleosome containing either a d(GpG) or
d(GpTpG) intrastrand cross-link.67 The nucleosome inhibits excision of the d(GpG) platinum
adduct to about 30% of the level observed with free DNA, whereas the d(GpTpG) platinum
addLuct is repaired at only 10% of the efficiency of free DNA. The excision efficiency of the
platinum adducts was two-fold higher in native compared to recombinant nucleosomes,
demonstrating that post-translational modification of the histones can effect the repair of
damaged DNA.P7 This in vitro model provides a powerful tool for examination of the cellular
processing of platinum adducts.
2.3 Role of cellular proteins
2.3.1 HMG-domain proteins bind to cisplatin-modified DNA
Since the initial discoveries over a decade ago, 68'6 numerous HMG-domain proteins have been
found that specifically recognize and bind to cisplatin-modified DNA. - The HMG-domain is an
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80 amino acid structure-specific DNA binding motif.70'7 1 HMGB1 is an architectural protein
important in maintaining chromatin structure. It increases transcription activation and functions
as an extracellular signaling agent during inflammation, cell differentiation, cell migration and
tumor metastasis.72-74 Recent research has focused on understanding the factors that determine
HMGB1 affinity to cisplatin-modified DNA. For example, acetylation of HMGB I increases its
affinity for cisplatin-modified DNA by 6-fold.75 Furthermore, p53 interacts with HMGB1 and
enhances binding to cisplatin-damaged DNA.76 Discerning what governs DNA-protein
interactions is essential for elucidating the roles of such proteins in mediating cisplatin
cytotoxicity. The flanking sequence of cisplatin-modified DNA probes affects the binding
affinity of HMGBI and its individual domains, HMGBla and HMGBlb. The affinity of
HMGBla for purine-rich probes is greatest when AT base pairs flank the GG platination site.77
The preference for A-T flanking sequences is most likely a consequence of the increased
flexibility of the DNA.7 8 Since the minor groove offers relatively few hydrogen-bonding atoms
to assist in protein recognition and binding, it is likely that the intercalating residue serves as a
DNA-recognition tool (Figure 1.5).5 5'7 9 Thus platination of a flexible DNA sequence, like
TGGA, significantly bends DNA and allows facile intercalation for minor-groove binding
proteins. 7 9
Auxiliary ligands on platinum also facilitate HMGBI binding to platinated DNA.80 The
affinity of HMGB la for the platinated DNA probe 5'-CCTCTCTGGATCTTC-3' decreases as
cisplatin > cis-{Pt(NH 3)(NHCba)} 2 > cis- -{Pt(NH3)(2-pic)}2 - cis- {Pt(NH3)(NH2Cy)}2 >
Pt(en)}- >> {Pt(dach)}>2 . When the flanking sequence is AGGC, HMGBla affinity for the
platinated probes is less discriminating. Overexpression of HMGB 1 following steroid hormone
treatment sensitizes cells to cis-[Pt(NH3)(NHCy)C1,], but not to cis-[Pt(dach)C12 ] by the repair-
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shielding mechanism (see below). This result reflects the lack of HMGB1 recognition of
{Pt(dach)'}>-DNA adducts.80 Because HMGB1 is a minor-groove binding protein, it is unlikely
that the amine ligands projecting into the major groove interact directly with the protein.80 It is
possible that bulky, rigid amine ligands restrict DNA flexibility, thereby reducing the affinity of
HMGB 1.80
The TATA-binding protein (TBP) also selectively binds to cisplatin-modified DNA. In
fact, of all known platinated-DNA binding proteins, TBP has the highest specificity for
platinum-damaged DNA."' ' TBP binds to the TATA box located 30 bp upstream from a
transcription start site and recruits other vital transcription factors." Inhibition of transcription by
cisplatin can be restarted upon addition of TBP, suggesting that platinum-DNA adducts are able
to 'hijack' TBI3 from its natural binding sites.8' Platination of DNA containing a TATA-box
significantly increases the binding affinity of TBP. The enhancement of TBP affinity is
maximized when the platinum adduct is positioned near the intercalation site of the TBP
phenylalanine.8' The flanking sequence dependence of TBP is similar to that of HMGBI. In
particular, having the flexible A-T bp flanking the platinum adduct site enhances TBP binding
affinity. s°X TBP very slowly associates to and dissociates from both cisplatin-modified DNA and
the TATA box.82 Consequently, TBP is only able to shield cisplatin-adducts from nucleotide
excision repair when allowed first to form the protein-DNA complex before exposure to the
repair machinery.
A recently discovered transcription factor FACT (facilitates chromatin transcription),
vwhich is a heterodimer of SSRP I and Spt 16, preferentially binds to DNA damaged by cisplatin.>3
Surprisingly, the SSRPI subunit of FACT does not bind to cisplatin-modified DNA; however,
the isolated HMG-domain of SSRPI does bind to the damaged DNA. The Sptl6 subunit has no
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independent affinity for the cisplatin-damaged DNA, but appears to alter the structure of SSRP I,
rendering the HMG domain accessible for DNA binding.8 3
2.3.2 HMG-domain proteins mediate cisplatin cytotoxicity
HMGB 1 and other cellular proteins that recognize platinum-DNA adducts may play a role in the
mechanism of action of cisplatin cytotoxicity, as manifested by two main hypotheses that have
evolved.84 One hypothesis asserts that cisplatin-damaged DNA hijacks proteins away from their
natural binding sites, leading to cellular stress and eventually cell death. The second hypothesis
suggests that binding by cellular proteins shields cisplatin adducts from nucleotide excision
repair (NER), allowing them to persist and drive apoptosis. These two hypotheses are not
mutually exclusive. In support of the repair-shielding hypothesis, it has been demonstrated that
HMG-domain proteins shield cisplatin adducts from repair in vitro and in cells.85'86 Recently, it
was discovered that exposing steroid receptor-positive cancer cells to either progesterone (for
PR+ cells) or estrogen (for ER+ cells) induces upregulation of HMGB 1.87 Furthermore, this
steroid-induced HMGB1 upregulation sensitizes ER+ or PR+ cells by a factor of 2-4 to cisplatin
treatment, presumably by shielding the adducts from NER.87 The timing of steroid hormone and
cisplatin administration is critical for achieving the increased sensitivity. Only when cisplatin
and steroid hormone are co-administered is the desired sensitization observed.87 In order to
achieve sensitization, the upregulation of HMGB1 must coincide with platinum adduct formation
and attempted repair of the adduct. A clinical trial is currently under way to investigate the in
vivo effect of estrogen and progesterone on tumor HMGB1 expression and growth inhibition.
Expression of murine testis-specific HMG-domain (tsHMG) in HeLa cells enhanced
transcription inhibition by cisplatin.88 The effect of tsHMG on cisplatin-induced apoptosis was
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less clear. Short incubation times with cisplatin showed that the presence of tsHMG increased
the apoptotic response; however, for longer incubation times, tsHMG seemed to protect the cell
from apoptosis. 8 8
Although many studies have demonstrated that HMG-domain proteins potentiate
cisplatin cytotoxicity, others reveal that HMG-domain proteins either have no effect or actually
protect the cell from cisplatin damage. The cytotoxicity of cisplatin was investigated in two
mouse embryonic fibroblast cell lines, Hmgbl + ' and Hmgbl-. 89 Unexpectedly, the sensitivity of
the two cell lines to cisplatin was equivalent. In addition, the levels of cisplatin-induced
apoptosis were similar, suggesting that HMGBI levels do not effect cisplatin cytotoxicity in
mouse embryonic cells.8 ) It is possible that HMGB I is engaged in protein complexes and
unavailable for repair shielding of cisplatin-DNA adducts. Alternatively, in the HMGBI
deficient Hmgbl - cells, other proteins such as HMGB2 may play a role in modulating cisplatin
sensitivity.s Other work has indicated that HMGB I is overexpressed in cisplatin-resistant cell
lines and several yeast cell lines deficient in HMG-domain proteins are hypersensitive to
cisplatin.'9 °' Clearly the effect of HMG-domain proteins in modulating the activity of cisplatin
depends upon the cell type and/or context.
2.3.3 Other cisplatin-DNA recognition proteins
3-Methyladenine DNA glycosylase (AAG) was recently discovered to bind to cisplatin-damaged
DNA.< AAG efficiently removes 3-methyladenine, 3-methylguanine, 7-methylguanine, and
l,N 6-ethenoadenine (cA) in vivo; however, in the presence of cisplatin-damaged DNA, the
excision of A by AAG is inhibited.92 Although AAG recognizes and binds to platinum-DNA
adducts, no evidence of attempted repair has been observed.9- Interestingly, the highest mouse
38
levels of AAG mRNA are observed in the testis. 9 2 In addition, the tumor suppression protein p53
binds to cisplatin-modified DNA, but the presence of cisplatin-damage does not reverse its
sequence-specific binding properties.9 3 94 Moreover, platinum-DNA cross-links that form in the
consensus DNA response element decrease p53 binding affinity.94 Nonetheless, the ability of p53
to bind to cisplatin-modified DNA supports a possible role of p53 in potentiating cisplatin
cytotoxicity.
3. CELLULAR DEFENSES AGAINST CISPLATIN
3.1 DNA repair mechanisms
Whether or not cisplatin-DNA adducts are removed by cellular repair mechanisms is a major
determinant in drug toxicity. Cells deficient in DNA repair are hypersensitive to cisplatin,
whereas overexpression of repair factors confers cisplatin resistance. 9' Understanding how
cisplatin is repaired is thus vital for elucidating its mechanism of action and developing more
effective platinum-based anticancer drugs. Cisplatin-DNA adducts are primarily removed by
nucleotide excision repair (NER), which consists of recognition, incision, excision, repair
synthesis and ligation.7 Overexpression of NER factors may lead to cisplatin resistance. For
example, ERCC 1 (excision repair cross complementation group 1) expression at both the mRNA
and protein levels is correlated to cisplatin response in human ovarian carcinomas. 9 6
In general, NER can follow two pathways, transcription-coupled repair (TCR) or global
genome repair (GGR).97 TCR is responsible for repair of DNA damage on the transcribed strand
of active genes. Repair of DNA damage on the non-transcribed strand of active genes or on the
remainder of the nontranscribing genome is performed by GGR. A panel of human cell lines
with various genetic deficiencies in NER were examined for cisplatin sensitivity.97 TCR-
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deficient cell lines were hypersensitive to cisplatin, regardless of GGR status.97 Conversely,
XP-C cells, defective in GGR and proficient in TCR, were not more sensitive towards cisplatin. 9 7
These results suggest that TCR, not GGR, is the primary repair response to cisplatin damage.97
During transcription of a cisplatin-damaged gene, the large subunit of RNA polymerase 11 (Pol It1
LS) stalls upon reaching the cisplatin-adduct, thereby serving as a DNA-damage sensor."
Furthermore, cisplatin-induced transcription arrest signals for the ubiquitination and degradation
of Pol Il LS.9 9' Ubiquitination of Pot II LS may recruit repair proteins and lead to subsequent
removal of the cisplatin-damaged site. On the other hand, inhibition of ubiquitination could
sensitize cells to cisplatin. 9
Cisplatin can also induce caspase-mediated Pol II LS cleavage, which may signal that the
cell has committed to apoptosis.i9 Ubiquitination is observed at early time points (0.25-1 h) after
cisplatin damage, while caspase cleavage occurs at later times (16-24 h).999 Thus, it appears that
ubiquitination of Pol II LS is an initial defense mechanism against cisplatin cytotoxicity. Caspase
cleavage of Pol 11 LS, and therefore apoptosis, may then result from failure to remove the stalled,
ubiquitinated Pot II LS. The proteasome inhibitor N-acetyl leucyl-leucyl norlucinal (ALLnL)
increases cisplatin cytotoxicity by 20-40% in human ovarian carcinomas.l®0 In addition, ALLnL
reportedly enhances platinum uptake, increases platinum adduct formation, and reduces repair of
platinum adducts.100 Proteasome inhibitors block the degradation of ubiquitinated proteins and
promote deubiquitination of the histones H2A and H-12B in nucleosomes.' tI')2 The
deubiquitination of H2A and H2B causes the nucleosome to adopt a higher-order, condensed
structure that may shield cisplatin-adducts from repair. °1 '1 °02 ALLnL also suppresses cisplatin-
induced ERCC mRNA overexpression, suggesting that proteasome inhibitors may sensitize
cells to the drug by depleting NER machinery.l03 It is tempting to speculate that proteasome
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inhibitors sensitize cells to cisplatin by preventing the removal of the stalled Pol II LS, therefore
blocking repair of platinum damage and promotinog apoptosis.
3.2 Cellular resistance to cisplatin
The mechanism of cisplatin resistance is extremely complex and mutlifactorial (reviewed
recently, see refs. 104-107). Factors that appear to mediate cisplatin resistance include reduced
uptake and increased efflux of platinum, increased levels of sulfhydryls (i.e., glutathione and
metallothionein), increased DNA repair, and loss of mismatch repair.106 107 As discussed earlier,
proficiency in NER leads to the effective removal of cisplatin adducts and increased cell
survival. Examination of a series of cisplatin-resistant ovarian cancer cell lines for expression of
NER genes revealed only ERCC1 expression consistently to be correlated with resistance. ~° 8
Recent research has focused on elucidating the genetic basis of cisplatin resistance. A number of
genes have been directly linked to cisplatin resistance, including DNA mismatch repair, p53, and
protein kinase A pathway genes.104 cDNA microarrays were employed to determine what genes
were differentially expressed in a cisplatin-resistant ovarian cancer cell line compared to the
parent line.109 Several genes were overexpressed in the resistant cell line, but only forced
overexpression of dihydrodiol dehydrogenase (DHD) in the parent cell line resulted in a
cisplatin-resistant cell line. 09 At present, it is not clear how DHD would potentiate cisplatin
cytotoxicity.
The role of glutathione in conferring cisplatin resistance is a topic of debate. Although
some studies have shown that increased levels of glutathione lead to cisplatin resistance, others
have revealed no correlation between glutathione concentration and cell sensitivity. In a series of
rat PC12 cell lines with various intracellular glutathione concentrations there was a strong
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correlation between cisplatin cytotoxicity and glutathione concentration." The parent PC12 cell
line was 4-fold more sensitive to cisplatin than was the cell line with the highest intracellular
glutathione concentration. The elevated glutathione concentration did not, however, lead to
decreased cellular platinum content.' ° Depletion of glutathione by buthionine sulfoximine
(BSO) increases DNA platination levels and sensitivity to cisplatin; however, previous work
revealed that BSO has little to no effect on cisplatin cytotoxicity.l'''" 2 Inhibition of glutathione
conjugate export pump and glutathione-S-transferase have no effect on cisplatin cytotoxicity."'
y-Glutamyl-transferase levels are increased in HeLa cells in response to cisplatin treatment, but
overexpression of y-glutamyl-transferase does not confer resistance.' 13
To date, no clear connection has been made between p53 status and cisplatin resistance.
Recent clinical data indicate that ovarian cancer patients previously treated with platinum-based
chemotherapeutics have tumors with increased glutathione levels, p53 positivity, and cisplatin
resistance. 1'4 Ovarian cancer cells transfected with HPV-16 E6 lose p53 function by way of E6
protein-mediated process. l' The p53 deficient cells have similar platinum uptake as wild type
cells, but are more sensitive to cisplatin.l5 The increased cisplatin cytotoxicity is due to loss of
G /S checkpoint control and reduced repair of platinum adducts. 1' It has recently been suggested
that p53 protects against cisplatin-induced apoptosis in TCR-proficient fibroblasts." 
4. NEW' CISPLATIN ANALOGS AS ANTI-CANCER COMPOUNDS
Well over 3000 cisplatin analogs have been synthesized in pursuit of a platinum anticancer agent
with broader tumor action, fewer side effects, and activity against cisplatin-resistant cancers.
Modifications include replacement of chloride ligands with various leaving groups, use of a
plethora of amine and non-amine ligands, and compounds designed only to form monofunctional
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DNA adducts.3 Recent attention has also focused trans-platinum complexes, polyplatinum
compounds, and platinum(IV) analogs (reviewed recently, see ref. 13). We summarize only
briefly several new classes of platinum complexes, none closely related to cisplatin, and
comment on the newest clinically approved platinum agent, oxaliplatin.
4.1 Overview of novel anticancer platinum compounds
Targeting platinum anticancer compounds to specific cell types may increase cytotoxic activity,
reduce unwanted side effects, and diminish resistance due to limited uptake. As illustrated in
Figure 1.6, one strategy for selective delivery of platinum anticancer agents has been to tether
carbohydrate moieties to the platinum center. 17-123 Such compounds have primarily been
designed to target liver cancer because of the galactose receptors on the surface of liver
parenchymal cells. 2" 2 2 Another strategy for targeting liver cancer is the use of bile acids, which
are efficiently taken up by hepatoma cells via a Nat-independent transport carriers.124 A series of
bile acid-platinum conjugates (Figure 1.6) have been synthesized and their cytotoxicity
investigated both in vitro and in mouse models. 124-129 Bamet-UD2 exhibits enhanced uptake in
hepatocytes, an ability similar to that of cisplatin to inhibit tumor growth, and a tendency to
prolong survival time of mice implanted with tumors. 2 6 ' 2 9
Interest in platinum agents designed specifically to target DNA has been recently
resurrected. Such use of DNA-targeting moieties might reduce platinum side reactions with other
biomolecules, potentially reducing side effects.'30 The DNA intercalators employed in this work
may also alter the kinetics and sequence specificity of DNA binding, possibly leading to a
broadened spectrum of activity.'30 DNA-targeting agents such as phenazine-l-carboxamides,
aminoacridines, and distamycin have been tethered to platinum amine ligands,'30 '3 4 following
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earlier design principles.' 3 5' 36 Such platinum complexes show increased cytotoxicity and are
active in vitro against cisplatin-resistant cell lines. In addition, non-cisplatin-type platinum-
acridinylthiourea conjugates have exhibited micromolar toxicitites in leukemia and ovarian cell
lines.378 Research has also focused on the synthesis of hydrophobic cisplatin analogues,
cisplatin-loaded micelles for alternate methods of drug delivery, and oligonLlcleotide-tethered
platinum complexes for targeting specific DNA sequences.3 9 '44
4.2 High-throughput synthetic methodology
Statistically, 10,000 new compounds must be prepared and screened for activity before one
clinically valuable compound is discovered.'4 5 To date, over 3,000 new platinum compounds
have been prepared, and besides cisplatin only carboplatin and oxaliplatin have been approved
fir use in the United States.l45' 146 It would therefore appear that, by significantly increasing the
number of compounds synthesized and tested for cytotoxicity, the likelihood of obtaining an
improved cisplatin analogue should increase. A high-throughput methodology has recently been
developed that allows for the rapid synthesis and screening of platinum complexes.' 47
Combinatorial synthesis was used to prepare over 3,600 platinum complexes, which were
subsequently screened by using a transcription inhibition fluorescence-based assay.' 147 Out of the
3,600 compounds prepared, four species showed promising activity, c i -
[(isopropylamine)2 PtC 1] , cis-[ammine(cyclobutylamine)PtC ,], cis-[(cyclobutylamine), PtC 12],
and cis-[ammine(2-amino-3-picoline)PtCI]. 147 All four compounds had previously been
identified as cytotoxic cisplatin analogues. Furthermore, the picoline-containing platinum
compound is quite similar to ZD0473, currently being developed by AstraZeneca for use in the
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clinic.'48 The high-throughput methodology could potentially serve as a new route for discovery
of active cisplatin analogues.
4.3 Oxaliplatin
In the early 1970s, 1,2-diaminocyclohexane (DACH) platinum complexes became popular
because they were non-cross-resistant with cisplatin.149 Over the past decade, (1R, 2R-
diaminocyclohexane)oxalatoplatinum(ll), or oxaliplatin, has been regaining attention because it
does not induce nephrotoxicity or myelosuppression and has a broader spectrum of activity than
either cisplatin or carboplatin.146 l49-'5 2 The first phase I clinical trial of oxaliplatin was stalled in
the 1980s because of its unusual toxicity for peripheral sensory nerves and the GI tract; however,
the side effects could be modulated by the Circadian time of administration. 49 Oxaliplatin was
approved by France in 1996, China in 1998, and European Union in 1999.149 In August of 2002,
oxaliplatin (EloxatinTM) became the third platinum-based anticancer agent to be approved by the
FDA. At present, oxaliplatin is only approved for treatment of metastatic colorectal cancer that
has progressed or recurred within six months of completion of a first-line therapy.153 Clinical
studies with oxaliplatin have not demonstrated increased survival time or improvement of
disease-related symptoms.153 Instead oxaliplatin was approved by the FDA based on patient
response rate and improved time-to-tumor progression. 53 Clinical trials are currently in progress
to obtain approval of oxaliplatin as a first-line chemotherapeutic agent. Oxaliplatin has shown in
vivo and in vitro activity against non-small cell lung cancer, germ cell malignancies, prostate
cancer, breast cancer, non-Hodgkin's lymphoma, and malignant mesothelima.1 52
At present, it is unclear why oxaliplatin and cisplatin have different cytotoxicities and
range of activity. Paradoxically, oxaliplatin, although more toxic than cisplatin in certain cell
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lines, forms significantly fewer Pt-DNA adducts.'54 The adduct profile formed by oxaliplatin is
similar to that of cisplatin with regard to the types and proportions of adducts formed; however,
oxaliplatin induces more single strand breaks.1 54 The difference in compound toxicity cannot be
explained by differences in drug uptake or in ease of repair. 146'1 54 The recently determined X-ray
structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a duplex DNA dodecamer has
shed some light onto the differing activities of cisplatin and oxaliplatin. 5 The R,R-DACH
ligand binding to the platinum center locks the C-N bond and fixes the position of the amine
hydrogen atoms.1 5 A hydrogen bond is then formed between the ammonia ligand cis to the
3'-guanine and the 06 atom of that nucleobase.'55 The inactive S,S,-DACH complex is incapable
of forming such a hydrogen bond.' 55 Differences in protein-recognition may explain the
spectrum of activity of oxaliplatin as compared to cisplatin. Mismatch repair proteins (MMR)
preferentially recognize cisplatin over oxaliplatin adducts and MMR deficient cells are resistant
to cisplatin.1 -6 Loss of MMR does not confer resistance to oxaliplatin.' 56 HMGB1 also has
reduced affinity towards oxaliplatin-DNA adducts. In addition, cisplatin, but not oxaliplatin,
activates c-Jun N-terminal and c-Abl kinases. The role of c-Jun N-terminal kinases in cisplatin
toxicity is not clear. 146 Some studies suggest that c-Jun N-terminal kinases are required for
cisplatin-induced apoptosis, while others assert that JNKs mediate cell survival. 7 Furthermore,
oxaliplatin-DNA adducts are more easily bypassed by DNA polymerases 13, e, y, and 1 than
cisplatin-adducts during replication.t 5
5. CONCLUSIONS AND FUTURE DIRECTIONS
Significant advances have been made to provide a better understanding of the mechanisms
underlying the cytotoxicity of cisplatin. New methodologies are continually emerging that may
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facilitate further insight and assist in the rational design of new platinum anticancer agents. Mass
spectrometry is being used to study platinum-nucleotide interactions, atomic force microscopy
reveals cisplatin changes the dynamics of DNA, and fluorescent tags may enable the
visualization of cisplatin action in vivo.159-163 Additional mechanistic insights may not only allow
for the design of improved compounds, but may also improve upon combination therapies. For
example, antisense oligonucleotides targeting against resistance genes increase the cytotoxicity
of cisplatin in resistant cell lines.'6 4 The coming years will certainly continue to yield exciting
developments in the arena of cisplatin chemistry in the cancer cell.
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Figure 1.1. Schematic representation of components of the cisplatin mechanism of action.
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Figure 1.2. Model of hCTR I, the plasma membrane copper transporter in humans. The N-
terminus of hCTR I is extracellular and the C-terminus is an intracellular domain. Possible
platinum methionine binding sites are indicated in red. (Reproduced by permission from Ref. 28)
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Figure 1.3. Platinum-guanine adduct conformers. The large arrow represents the guanine base
with the H8 atom located at the arrow tip. The smaller arrow indicates the direction of
phosphodiester linkage propagation. (Reproduced by permission from Ref. 46)
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Figure 1.4. Model of DNA distorted by a Lippard base pair step. (Reproduced by permission
from Ref. 54)
60
Figure 1.5. HMGB Ia bound to cisplatin-modified DNA. Phe37 intercalates in the minor groove
opposite the platinum adduct. (Reproduced by permission from Ref. 55)
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Figutlre 1.6. Several new classes of platinum anticancer agents: (a) Carbohydrate-platinum
conjugate designed to target liver cells; (b) Bamet-UD2, bile acid-platinum derivative for
targeting liver cancer; and (c) acridinylthiourea-tethered DNA-targeted platinum complex.
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Chapter 2
Synthesis, Characterization, and Cytotoxicity of a Series of Estrogen-Tethered
Platinum(IV) Complexes
* The work in this chapter has been published in Chem. Biol., 2004, 11, 557-564.
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Introduction
The anticancer activity of cisplatin was discovered serendipitously over three decades ago.'
Today cisplatin is used to treat testicular cancer, with greater than 90% success rates, 23 as well as
breast, ovarian., bladder, lung, and head and neck carcinomas, either alone or in combination
therapy.4 Because cisplatin has adverse side effects, is limited to a narrow range of cancers and
can be rendered inactive due to acquired resistance, research has focused on elucidating its
mechanism of action to guide the rational synthesis of improved platinum analogues.
Cisplatin can bind to RNA, proteins, and other sulfur-containing biomolecules, but DNA
is its primary biological target. - 7 Various adducts form upon cisplatin binding to DNA, with 1,2-
intrastrand d(GrpG) and d(ApG) cross-links accounting for -90% of such interactions:6 a
smaller number of 1,3-intrastrand and interstrand cross-links also form. These adducts block
transcription, inhibit replication, and ultimately induce apoptosis. 6 The DNA duplex is
significantly distorted upon formation of cisplatin 1,2-intrastrand cross-links.9 The resulting
structure serves as a recognition motif for a variety of cellular proteins, including DNA repair
components, histones, and HMG-domain proteins, such as HMGB I . ®91 The binding of these
proteins to platinum-DNA adducts modulates the cytotoxicity of cisplatin l - 13 and offers new
strategies for improving the chemotherapeutic potential of platinum-based anticancer drugs.14
Recent work from our laboratory revealed that estrogen receptor-positive, ER(+), cells
treated with estrogen are sensitized to cisplatin, ' since estrogen induces overexpression of
HMINGBI, a protein that shields cisplatin-DNA adducts from nucleotide excision repair
(NER).' 1ts. This finding suggested to us that estrogen-tethered platinum(IV) complexes might
prove valuable as novel anticancer drug candidates. The proposed mechanism is illustrated in
Figure 2. . Upon entering the reducing environment of the cell, the platinum(IV) complexes will
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be reduced to platinum(il), simultaneously releasing one equivalent of cisplatin and two
equivalents of a linker-modified estrogen. Subsequent binding of cisplatin to DNA and
hydrolysis of the ester moieties should lead to HMGB1 upregulation, as described above, and
sensitization of the cells due to repair-shielding of the cisplatin-DNA adducts.
The present chapter describes the application of this strategy through the design,
synthesis, and characterization of a series of compounds BEP1 - BEP5 (Scheme 2.2). In these
molecules, estradiol is tethered to the terminal carboxylate groups of cis, cis, trans-
diamminedichlorodisuccinatoplatinum(IV) through polymethylene chains of varying lengths.
This variability was programmed into our study in order to allow for the best match between the
kinetics of estrogen-mediated HMGB I overproduction and cisplatin-DNA adduct formation in
the cancer cell. The ability of the BEPn complexes to upregulate HMGB 1, and their cytotoxic
profile in both ER(+) and ER(-) cells, are reported and discussed.
Experimental Procedures
Materials and Methods
Potassium tetrachloroplatinate(II) was a gift from Engelhard. Cisplatin and cis, cis, trans-
diamminedichlorodihydroxyplatinum(V) were prepared as described in the literature.l7 '18 The
preparation of compounds L2, L3, L4, and L5 were based on a previously reported
methodology.'9 All chemicals and solvents were purchased from commercial sources unless
specified otherwise. 'H and ' 95Pt NMR spectra were recorded on either a Varian 300 MHz or 500
MHz spectrometer at the MIT Department of Chemistry Instrumentation Facility (DCIF). High-
resolution mass spectral analysis was carried out at the MIT DCIF.
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Synthesis of cis, cis, trans-Diamminedichlorodisuccinatoplatinum(IV) (1). Succinic
anhydride (4.1 g, 41 mmol) and cis, cis, trlns-diamminedichlorodihydroxyplatinum(V) (3.3 g,
10 mmol) were dissolved in 5 mL of DMSO. The solution was heated to 70 C for 15 h with
constant stirring, cooled to room temperature, and filtered. The DMSO solvent was removed
from the filtrate by lyophilization to yield a yellow solid. Recrystallization from acetone at
-20 C afforded a pale yellow solid (3.7 g, 6.9 mmol, 69% yield). H NMR (d6-acetone, 300
MHz): 2.45 (n, 4H, CH), 2.53 (m, 4H, CH2), 6.511 (broad singlet, 6H, NH3). 195Pt NMR (500
MHIz): 1226.531. ERMS (ESI) calculated for [M+H] 534.0004 amu, found 534.0001 amu.
Synthesis of 3-tert-Butoxycarbonylaminopropionic acid (L2). Triethylamine (6.2 mL, 45
mmol) wvas added to a solution of 3-aminopropionic acid (2.7 g, 30 mmol) in 50% aqueous
dioxane (30 mt.). BOC-ON (8.2 g. 33 mmol) was added and the reaction stirred for 3 h at room
temperature. The reaction solution was diluted with H20 (40 mL) and ethyl acetate (60 mL). The
aqueous layer was isolated, washed with ethyl acetate, and acidified with a 5% citric acid
solution. The aqueous layer was subsequently extracted with ethyl acetate. The organic fractions
were combined and evaporated to yield L2 as a cream solid (3.6 g, 19 mmol, 63% yield);
mp=67-72 C. H NMR (d6 -DMSO, 300 MHz): 1.35 (s, 91-1, CH 3), 2.33 (t, 2H, CH2), 3.11 (q,
2H, CH,), 6.67 (t, IH, NH). HRMS (ESI) calculated for [M-H]- 188.0928 amu, found 188.0922
amu.
Synthesis of 4-tert-Butoxycarbonylaminobutyric acid (L3). This compound was prepared as
described for L2 from stirring 4-aminobutyric acid (3.9 g, 38 mmol) in 50% aqueous dioxane
with triethylamine (8.0 mL, 57 mmol) and BOC-ON (10.4 g, 42 mmol). A yellow oil was
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obtained that solidified upon addition of hexanes and cooling to -20 C to yield a cream solid
(4.0 g, 19 mmol, 52% yield); mp=54-57 C. H NMR (d6-DMSO, 300 MHz): 1.36 (s, 9H,
CH3), 1.57 (m, 2H, CH,), 2.17 (t, 2H, CH,), 2.90 (m, 2H, CH,), 6.80 (t, 1 H, NH). HRMS (ESI)
calculated for [M-H]- 202.1085 amu, found 202.1075 amu.
Synthesis of 5-tert-Butoxycarbonylaminopentanoic acid (L4). This compound was prepared
as described for L2 from 5-aminopentanoic acid (3.4 g, 29 mmol), triethylamine (6.0 mL, 43
mmol), and BOC-ON (7.9 g, 32 mmol). A cream solid (3.1 g, 14 mmol) was isolated in 49%
yield; mp=44-47 °C. 'H NMR (d6 -DMSO, 300 MHz): 6 1.36 (s, 9H, CH3), 1.43 (m, 4H, 2 CH,),
2.17 (t, 2H, CH2), 2.88 (m, 2H, CH,), 6.73 (t, 1H, NH). HRMS (ESI) calculated for [M-H]-
216.1241 amu, found 216.1244 amu.
Synthesis of 6-tert-Butoxycarbonylaminohexanoic acid (L5). This compound was prepared as
described for L2 from 6-aminohexanoic acid (3.5 g, 27 mmol), triethylamine (5.5 mL, 40 mmol),
BOC-ON (7.5 g, 30 mmol). A pale yellow oil (3.0 g, 13 mmol) was isolated in 48% yield. 'H
NMR (d 6-DMSO, 300 MHz): b 1.20 (m, 2H, CH2), 1.30 (m, 2H, CH), 1.36 (s, 9H, CH 3), 1.46
(m, 2H, CH 2), 2.16 (t, 2H, CH2), 2.87 (m, 2H, CH,), 6.74 (t, 1H, NH). HRMS (ESI) calculated
for [M-H]- 230.1398 amu, found 230.1395 amu.
Synthesis of 17-(Aminoacetoxy)-estradiol-3-benzoate (EL1). Diisopropylcarbodiimide (3.7
mL, 24 mmol) was added to a solution of N-tert-butoxycarbonylglycine (4.2 g, 24 mmol) and 4-
DMAP (3.0 g, 24 mmol) in THF (200 mL). The solution was stirred for 10 min before the
addition of estradiol-3-benzoate (5.0 g, 13 mmol). After being stirred overnight, the solution was
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filtered and the solvent was removed by rotary evaporation. The solid residue was dissolved in a
IM HCI/dioxane solution (265 mL) and stirred for an additional 6 h. Following evaporation of
dioxane, the residue was suspended in 100 mL H20 and the pH was adjusted to 10 with
ammonium hydroxide. The solution was stirred for several hours and filtered to yield a w-hite
solid (4.3 g, 9.9 mmol, 75% yield); mp=125-129 °C. H NMR (d6 -DMSO, 300 MHz): 6 8.12 (d,
2H, ArH), 7.74 (t, IH, ArH), 7.59 (t, 2H, ArH), 7.34 (d, 1H, ArH), 7.01 (d, 1H, ArH), 6.96 (s,
1 H, ArH), 4.66 (t, I H, CH), 3.83 (d, I H, CH), 2.83 (m, 2H, CH), 1.75 (bs, 2H, NH2); 2.3-1.2 (m,
13H, CH2), 0.796 (s. 3H, CH3). HRMS (ESI) calculated for [M+H] 434.2326 amu. found
434.2319 amu.
Synthesis of 17-(3-Aminopropionate)-estradiol-3-benzoate (EL2). A solution of L2 (2.1 g, I I
mmrnol) and 4-DMAP (1.3 g, 11 mmol) was prepared in 100 mL of DMF.
Diisopropylcarbodiimide (1.7 mL, 11 mmol) was added and the solution was stirred for 10 min.
Estradiol-3-benzoate (2.6 g, 6.9 mmol) was added and the reaction was allowed to stir for 7 h.
The solution as filtered, diluted with water, and extracted with ether. The organic fractions
were combined and evaporated to dryness to yield a pink residue. The residue was dissolved in
800 mL of methylene chloride; 120 mL TFA was added and the solution was stirred for 2 h. The
inethylene chloride was evaporated to yield a pink oil, which was dissolved in H,O and the pH
adjusted to 10 with ammonium hydroxide. A white solid began to precipitate and the slurry was
stirred for an additional hour. The solution was filtered to collect a white solid (3 g of crude
material); mp= 156-160 °C. 'H NMR (d6 -DMSO, 300 MHz): 6 8.08 (d, 2H, ArH), 7.73 (t, 1 H,
ArH), 7.58 (t, 2H, ArH), 7.32 (d, 1H, ArH), 7.00 (d, IH, ArH), 6.94 (s, 1H, ArH), 4.67 (t, IH,
CH), 3.04 (t, 21-1, CH,), 2.83 (m, 2H, CH), 2.68 (m, 2H, CH2), 2.30-1.20 (m, 13H,. CH/CH), 1.70
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(bs, 2H, NH,), 0.814 (s, 3H, CH 3). HRMS (ESI) calculated for [M+H] + 448.2482 amu, found
448.2481 amu.
Synthesis of 17-(4-Aminobutanoate)-estradiol-3-benzoate (EL3). This compound was
prepared as described for EL2 using L3 (1.8 g, 8.9 mmol), 4-DMAP (1.1 g, 9.1 mmol),
diisopropylcarbodiimide (1.4 mL, 8.9 mmol), and estradiol-3-benzoate (2.2 g, 5.7 mmol). The
BOC-protecting group was removed by stirring in 700 mL methylene chloride and 100 mL TFA.
A white solid was isolated (2.5 g crude) and used without purification; mp=110-115 C. H NMR
(d6-DMSO, 300 MHz): 8.09 (d, 2H, ArH), 7.73 (t, 1H, ArH), 7.59 (t, 2H, ArH), 7.33 (d, 1 H,
ArH), 7.00 (d, IH, ArH), 6.95 (s, I H, ArH), 4.65 (t, I H, CH), 2.83 (m, 4H, CH2), 2.42 (m, 2H,
CH2), 2.40-2.00 (m, 3H, CH2), 1.81 (m, 4H, CH 2), 1.70 (bs, 2H, NH2), 1.60-1.20 (m, 8H, CH),
0.813 (s, 3H, CH13). HRMS (ESI) calculated for [M+H]+ 462.2639 amu, found 462.2622 amu.
Synthesis of 17-(5-Aminopentanoate)-estradiol-3-benzoate (EL4). This compound was
prepared as described for EL2 using L4 (1.3 g, 6.6 mmol), 4-DMAP (0.82 g, 6.7 mmol),
diisopropylcarbodiimide (1.0 mL, 6.4 mmol), and estradiol-3-benzoate (1.6 g, 4.1 mmol).
Deprotection of the amine was carried out by stirring in 480 mL of methylene chloride and 72
mL of TFA. A white solid was isolated (1.9 g crude); mp=107-113 C. 'H NMR (d6-DMSO, 300
MHz): 8.09 (d, 2H, ArH), 7.73 (t, 1 H, ArH), 7.59 (t, 2H, ArH), 7.32 (d, I H, ArH), 7.00 (d, I H,
ArH), 6.95 (s, I H, ArH), 4.65 (t, I H, CH), 2.83 (m, 4H, CH2), 2.36 (m, 2H, CH,), 2.30-2.00 (m,
3H, CH), 1.90-1.72 (m, 4H, CH) 1.70 (bs, 2H, NH 2), 1.57 (m, 4H, CH,), 1.42-1.20 (m, 6H, CH),
0.815 (s, 3H, CH3). HRMS (ESI) calculated for [M+H]+ 476.2795 amu, found 476.2800 amu.
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Synthesis of 17-(6-Aminohexanoate)-estradiol-3-benzoate (EL5). This compound was
prepared as described for EL2 using L5 (1.1 g, 4.6 mmol), 4-DMAP (0.58 g, 4.8 mmol),
diisopropylcarbodiimide (730 tLL, 4.7 mmol), and estradiol-3-benzoate (0.51 g, 1.4 mmol).
Removal of the BOC-group was achieved by stirring in a solution of TFA (25 mL) in methylene
chloride (240 mL). A white solid was isolated by filtration (0.60 g crude); mp=132-137 °C. H
NMR (d,-DMSO, 300 MHz): b 8.08 (d, 2H, ArH), 7.72 (t, IH, ArH), 7.58 (t, 2H, ArH), 7.32 (d,
IH, ArH), 7.00 (d, 1H, ArH), 6.93 (s, IH, ArH), 4.62 (t, IH, CH), 2.82 (m, 2H, CH,), 2.78-2.77
(m, 4H, CH,), 2.31 (m, 2H, CH,), 2.23-1.72 (m, 6H, CH), 1.70 (bs, 2H, NH,), 1.57-1.20 (m,
10H, CH/CH,). 0.798 (s, 3H, CH3). HRMS (ESI) calculated for [M+H]' 490.2952 amu, found
490.2954 amu.
Synthesis of cis, cis, trans-Diamminedichloro-bi-(17-(N-carbonylmethylsuccinato)-
estradiol-3-benzoate)platinum(IV) (BEP1). Diisopropylcarbodiimide (0.57 mL, 3.7 mmol)
was added to a solution of 1 (0.81 g, 1.5 mmol) and 4-DMAP (0.48 g, 3.9 mmol) in DMF (100
mL). The solution was allowed to stir for 10 min at room temperature before the addition of ELI
(1.6 g, 3.7 mmol). The solution was stirred for 15 h at room temperature, filtered, and the filtrate
was diluted with 200 mL of ether. The resultant solution was cooled at -20 C for 10 h to
facilitate precipitation. The crude product was filtered, triturated with ethanol (30 mL) and
centrifuged (5 times). The tan solid was then triturated with boiling water (10 mL) five times and
centrifuged to yield a pale yellow solid (0.72 g, 0.53 mmol, 35% yield). H NMR (d6-DMSO,
300 MHz): 6 8.33 (t, 2H, NH), 8.10 (d, 4H, ArH), 7.74 (t, 2H, ArH), 7.59 (t, 4H, ArH), 7.34 (d,
2H, ArH), 7.01 (d, 2H, ArH), 6.95 (s, 2H, ArH), 6.56 (bs, 6H, NH3), 4.65 (t, 2H, CH), 3.80 (d,
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4H, CH2), 2.83 (m, 4H, CH2), 2.60-1.20 (m, 34H, CH/CH,), 0.785 (s, 6H, CH3). HRMS
calculated for [M+H]+ 1364.4299 amu, found 1364.4253 amu.
Synthesis of cis, cis, trans-Diamminedichlo ro-bis-(17-(N-(2-carboxyethyl)-succinato)-
estradiol-3-benzoate)platinum(IV) (BEP2). This compound was prepared as described for
BEPI using 1 (0.37 g, 0.69 mmol), 4-DMAP (0.36 g, 2.9 mmol), diisopropylcarbodiimide (430
[tL, 2.7 mmol), and EL2 (1.2 g, 2.8 mmol). Crude BEP2 was purified as described for BEPI to
yield a pale yellow solid (0.13 g, 0.093 mmol, 14% yield). 'H NMR (d6-DMSO, 300 MHz): 6
8.10 (d, 4H, ArH), 7.95 (t, 2H, NH), 7.74 (t, 2H, ArH) 7.60 (t, 4H, ArH), 7.35 (d, 2H, ArH), 7.00
(d, 2H, ArH), 6.95 (s, 2H, ArH), 6.49 (bs, 6H, NH3), 4.65 (t, 2H, CH), 3.23 (t, 4H, CH,), 2.83
(m, 4H, CH), 2.43 (m, 4H, CH,), 2.43-1.20 (m, 34H, CH/CH,), 0.799 (s, 6H, CH3). HRMS (ESI)
calculated for [M+H]' 1391.4591 amu, found 1391.4562 amu.
Synthesis of cis, cis, trans-Diamminedichloro-bis-(17-(N-(3-carboxypropyl)-succinato)-
estradiol-3-benzoate)platinum(IV) (BEP3). This compound was prepared as described for
BEP1 using 1 (0.65 g, 1.2 mmol), 4-DMAP (0.61 g, 5.0 mmol), diisopropylcarbodiimide (760
tL, 4.9 mmol), and EL3 (2.3 g, 5.0 mmol). The crude material was purified as described for
BEPI to yield a pale yellow solid (0.12 g, 0.084 mmol, 7.0% yield). H NMR (d6-DMSO, 300
MHz): 8.12 (d, 4H, ArH), 7.85 (t, 2H, NH), 7.74 (t, 2H, ArH) 7.59 (t, 4H, ArH), 7.35 (d, 2H,
ArH), 7.00 (d, 2H, ArH), 6.96 (s, 2H, ArH), 6.50 (bs, 6H, NH3 ), 4.69 (t, 2H, CH), 3.26 (t, 4H,
CH,), 3.04 (t, 4H, CH,), 2.83 (m, 4H, CH,), 2.47 (m, 4H, CH,), 2.40-1.20 (m, 34H, CH2), 0.805
(s, 6H, CH3). HRMS (ESI) calculated for [M+H]+ 1419.4904, found 1419.4890 amu.
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Synthesis of cis, cis, trans-Diamminedich loro-bis-(17-(N-(4-carboxybutyl)-succinato)-
estradiol-3-benzoate)platinum(IV) (BEP4). This compound was prepared as described for
BEPI using 1 (0.22 g, 0.40 mmol), 4-DMAP (0.15 g, 1.2 mmol), diisopropylcarbodiimide (190
[tL, 1.2 mmol), and EL4 (0.62 g, 1.3 mmol). The crude material was purified as described for
BEPI to yield a pale yellow solid (0.25 g, 0.17 mmol, 43% yield). H NMR (d6-DMSO, 300
MHz): 8.10 (d, 4H, ArH), 7.85 (t, 2H, NH), 7.74 (t, 2H, ArH) 7.60 (t, 4H, ArH), 7.35 (d, 2H,
ArH), 7.00 (d, 2H, ArH), 6.97 (s, 2H, ArH), 6.51 (bs, 6H, NH 3), 4.64 (t, 2H, CH), 3.01 (t, 4H,
CH,), 2.84 (m, 4H, CH,), 2.44 (m, 4H, CH,), 2.30-2.21 (m, 8H, CH/CH,). 2.20-1.20 (m, 34H,
CH-/CH,), 0.804 (s, 6H, CH3 ). HRMS (ESI) calculated for [M+Na] 1469.5036, found 1469.5006
amu.
Synthesis of cis, cis, tras-Diamminedichloro-bis-(17-(N-(5-carboxypentyl)-succinato)-
estradiol-3-benzoate)platinum(IV) (BEP5). This compound was prepared as described for
BEP1 using 1 (0.14 g. 0.26 mmol), 4-DMAP (0. 10 g, 0.83 mmol), diisopropylcarbodiimide (130
[tL, 0.81 mmol), and EL5 (0.40 g. 0.82 mmol). The crude product was purified as described for
BEP1 to yield a pale yellow solid (0.085 g. 0.057 mmol, 22% yield). H NMR (d 6 -DMSO, 300
MHz): 6 8.09 (d, 4H, ArH), 7.81 (t, 2H, NH), 7.71 (t, 21H, ArH) 7.57 (t, 414, ArH), 7.32 (d, 2H,
ArH), 6.98 (d, 2H, ArH), 6.94 (s, 2H, ArH), 6.49 (bs, 6H, NH3), 4.62 (t, 2H, CH), 2.98 (t, 4H,
CH), 2.82 (m, 4H, CH), 2.40 (m, 4H, CH,), 2.30-2.20 (in, 12H, CH/CH,), 2.10-1.20 (m, 34H,
CH/CH,), 0.7c99 (s, 611, CH3). HRMS (ESI) calculated for [M+H] 1475.5530 amu, found
1475.5551 amu.
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Cell Culture Studies. MCF-7 cells were grown in DMEM (GIBCO/BRL) supplemented with
10% FBS, X antibiotic/antimycotic solution (GIBCO), and 2 mM L-glutamine. HCC-1937 cells
were grown in RPMI-1640 media (ATCC) containing 10% FBS and 1X antibiotic/antimycotic
solution. All cells were incubated at 37 C under a 5% CO2 atmosphere.
Overexpression of HMGB1 Induced by BEPn Complexes. MCF-7 cells were grown to 70%
confluence on 12-mm glass cover slips in 24-well plates. The cells were treated with either
estradiol or BEPn and incubated for 4 h. The cells were then fixed and permeabilized with 25%
acetic acid in methanol for 10 min at RT, washed with PBS, and incubated with a 1:100 dilution
of anti-HMGBl I polyclonal antibody (PharMingen) for Ih at 37 C. The cells were subsequently
incubated with a 1:200 dilution of goat anti-rabbit IgG conjugated to FITC (Biosource
International) for I h at 37 C. The cover slips were then placed on microscope slides, fixed with
gelvatol, and incubated at 4 C for 12 h. HMGB levels were then visualized inder a fluorescent
light microscope (Nikon) equipped with a digital camera (Diagnostic Instruments).
Cytotoxic Profile of BEPn. The cytotoxicities of the BEPn compounds were evaluated by using
two methodologies, SRB and colony counting assays. For the SRB assay, MCF-7 and HCC-1937
cells were seeded onto 96-well plates at a density of 1000 cells per well and allowed to grow for
24 h. Cells were treated with compounds BEPI - BEP5 at the following concentrations: 1, 2, 3,
4, 5, 6, 8, 10 tM. The 96-well plates were covered with Breathe-Easy gas permeable membranes
(Diversified Biotech) and the cells incubated at 37 C for 96 h. After the incubation period, the
cells were fixed by addition of 25 [L of 50% TCA and subsequent incubation at 4 C for 30 min.
The viable cells were then stained by addition of 100 tL of sulforhodamine B in 0.1% acetic
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acid followed by incubation for 30 min at RT. The cells were washed with 1% acetic acid and
allowed to dry overnight. The SRB was solubilized by the addition of 100 [tL of 10 mM Tris (pH
10.:5) followed by shaking for 5 min. The number of viable cells was then quantified by
measuring the absorbance at 492 nm.
For the colony counting assay, MCF-7 and HCC-1937 cells were seeded onto 6-well
plates at a density of 1000 cells per well in 2 mL media and allowed to grow- for 24 h at 37 C.
Cells were then treated for 72 h with the BEPn complexes at the following concentrations: 0, 2,
4 6, 8, 10 [IM. After 72 h, cells were washed with PBS, and fresh medium was added. After 7
days the colonies were counted by staining with a 1% methylene blue/50% ethanol (vol/vol)
solution.
Results and Discussion
Synthesis and Characterization of BEPI - BEP5
The preparation of several steroid-tethered platinum complexes has been reported.2' 4 None of
these compounds enables the release of unmodified estrogen inside cells nor is any expected to
eftfct the expression of HMGBI because of their low affinity for the ER. All previously
synthesized platinum-estrogen conjugates were designed to accumulate specifically in ER(+)
cells by taking advantage of known steroid transport mechanisms. 2 -2 The present study
describes the first report of a hormone-conjugated platinum(IV) complex linked at the 17r-
position. We chose this particular strategy for several reasons. Platinum(IV) complexes are
relatively inert to ligand substitution, which allows for oral administration and differentiates their
pharmacokinetic properties from those of cisplatin. t7 '25 In addition, the designed platinum(IV)
complexes assure simultaneous delivery of cisplatin and estrogen to the same population of cells.
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Furthermore, release of cisplatin and unmodified estradiol may be achieved by use of the
platinum(IV) platform. The concurrent delivery of cisplatin and estrogen allows for the selective
targeting of ER(+) cells by achieving both DNA damage and HMGB l-induced repair shielding.
Upon entering the cell, BEPn will be readily reduced by glutathione or other intracellular agents
to afford cisplatin and two equivalents of the linker-modified estrogen. -28 The linkers were
designed to be susceptible to hydrolysis by intracellular esterases, because the estrogen receptor
does not recognize estrogens modified at the 1 7f-position. 9'30 Although the dose of the estradiol
delivered to the cell cannot be optimized, the varying length of the estrogen-linkers permits
control over the kinetics of estrogen hydrolysis.
Initial attempts to prepare the estrogen-tethered complexes involved the synthesis of an
ester-linked compound. A variety of coupling methodologies were tried to attach cis, cis, trans-
diamminedichlorodisuccinatoplatinum(IV) directly to estradiol-3-benzoate; however, the desired
compound could not be obtained. Next, 17-hemisuccinate-estradiol-3-benzoate was synthesized
and numerous attempts were made to couple it to cis, cis, trans-
diamminedichlorodihydroxyplatinum(IV), but without success.3' Ultimately, the first member of
the BEPn family of estrogen-tethered platinum(IV) complexes, BEP1, was obtained through
coupling of a linker-modified estrogen with cis, cis, trcns-diamminedichloro-
disuccinatoplatinum(IV).
Cisplatin is readily oxidized by hydrogen peroxide to produce cis, cis, trans-
diamminedichlorodihydroxyplatinum(IV).'7 As shown in Scheme 2.1, this trans-
dihydroxyplatinum(IV) complex can be further modified by reaction with succinic anhydride to
yield a trans-dicarboxylatoplatinum(IV) complex that is amenable to additional derivatization.
The preparation of the trans-dicarboxylatoplatinum(IV) complex presented here is a variation of
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a previously reported synthesis3 2 that affords a similar yield, requires less stringent conditions,
and leads to product in 15 h versus 24-48 h. The resulting cis, cis. trans-diamminedichloro-
disuccinatoplatinum(IV) complex was characterized by ESI-MS. H NMR, and '19Pt NMR
spectroscopy. The platinum ammine proton resonances appear as a broad singlet at 6.51 ppm, a
value that is consistent with the ammine chemical shifts of other trans-
dicarboxylatoplatinum(IV) complexes.'2 The succinato protons and ammine protons integrate in
a 4:3 ratio, indicating the presence of two succinato ligands per platinum center. The '95Pt NMR
resonance at 1226 ppm is consistent with other known platinum(IV) carboxylates. 3 '34
The preparation of the polymethylene linkers (Ln) was based on previously published
methodology. 9 Their 'H NMR spectra agreed those with published previously (data not
shown).'9 The series of linker-modified estrogens (ELn) were obtained by coupling estradiol-3-
benzoate and BOC-protected aminoalkyl carboxylic acids (Ln) using diisopropylcarbodiimide,
followed by removal of the BOC-protecting group. The free amine provides a suitable handle for
coupling to the trLns-disuccinatoplatinum(IV) complex. Because of their poor solubility, the
ELn compounds were used without purification. Formation of the desired linker-modified
estrogens was confirmed by ESI-MS and 'H NMR spectroscopy (Table 2.1). A 'H1 NMR
spectrum of ELI is shown in Figure 2.2. A significant downfield shift of the 1-117 proton
resonance is observed upon formation of the new ester linkage.
As shown in Scheme 2.2, the amine-modified estrogens are easily coupled to trans-
dicarboxylatoplatinum(IV) utilizing diisopropylcarbodiimide, a common peptide coupling
reagent. The ESI-MS and H NMR spectroscopic data (Table 2.1) confirm the presence of the
desired estrogen-tethered platinum(IV) complexes. A 'H NMR spectrum of BEPI is shown in
Figure 2.3. Coupling of the series of amino-modified estrogens to cis, cis. tratns-
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diamminedichlorodisuccinatoplatinum(IV) yielded the desired amide-linked compounds.
Formation of the amide bond is evident from the appearance of a characteristic amide proton
resonance at 7.80-8.33 ppm (H,2 ). The 'H NMR data provide quantitative evidence for the
presence of two estrogen moieties for every platinum center. The integrated intensity of the
methyl protons (Ha8) of the two estrogen groups match that of the platinum-ammine protons
(H2 3). In addition, there are an equal number of amide (H22 ) and estrogen 17-a protons (HI 7 ).
The experimentally determined masses for BEP - BEP5 are in excellent agreement with the
calculated values ( 0.003%). The synthetic methodology presented provides a convenient route
for preparing a variety of platinum(IV) compounds for testing as anticancer drugs and has the
potential to target such complexes to specific tissue or cell types.
Overexpression of HMGB1 in MCF-7 Cells Following BEPn Treatment
The ability of compounds BEP1 - BEP5 to upregulate HMGB1 levels was investigated by
immunofluorescence microscopy. As shown in Figure 2.4, 4-hr incubation with 200 nM BEP1 -
BEP5 induces the overexpression of HMGB1 in MCF-7 cells. Treatment with BEPI, BEP2,
BEP3, or BEP4 increases HMGB1 expression to a similar degree as treatment with an equal
amount of estradiol, whereas BEP5 treatment induces considerably less protein expression. The
ability of these estrogen-tethered platinum(IV) compounds to upregulate HMGB 1 implies that all
are taken into the cell and reduced to a Pt(II) species with concomitant release of the linker-
modified estradiol. Moreover, hydrolysis of the linker-modified estradiol ester group must occur
to allow for interaction of free-estradiol with the ER. Although hydrolysis of the estrogenic
moiety alone could result in upregulation of HMGB 1, reduction of Pt(IV) is required for DNA-
77
binding activity.26 It is unlikely, however, that ester hydrolysis will precede platinum(IV)
reduction because of the kinetics associated with these processes.25 2
Estrogen interaction with the hormone-binding domain induces the formation of ER
homodimers, which then associate with the estrogen response element (ERE).35 The exact
mechanism by which estrogen binding to the ER induces overexpression of HMGBI is not
known; however, the presence of HMGBI1 is required for ER interaction xwith the ERE. 3' 37
HMGBI may facilitate ER interaction with the ERE either by bending the element to provide a
binding site for the ER or by stabilizing the distorted DNA of the ER-ERE complex. 3'37 The
ability of the ER to bind to the ERE may also be affected by the intracellular levels of IIMGB 1
or by the number of free HMGB I binding sites.37 In addition, the transcriptional activity of the
ER is increased by HMGB 1.3
Selective Cytotoxic Behavior of BEP1 - BEP5 in ER(+) versus ER(-) Cells
The ability of BEP1 - BEP5 to stimulate upregulation of HMGB I suggests that ER(+) cells will
be more sensitive than ER(-) cells towards these compounds. The cytotoxic behavior of BEP1 --
BEP5 and cis, cis, trans-[Pt(NH 3)2CI(succinato)2] was evaluated in human breast cancer cell
lines MCF-7 and HCC-1937, which are ER(+) and ER(-), respectively. Cell viability was
evaluated using both the sulforhodamine B (SRB) and colony counting assays. The two methods
provided comparable dose response curves, with the SRB assay resulting in less variance in the
results. The colony counting method afforded more reliable data for BEP5, however. Since, in a
control experiment (Figure 2.5), the sensitivitvities of the MCF-7 and HCC-1937 cells (IC50 = 4.0
[tM) to cis, cis, /rans-[Pt(NH 3)2CI2(succinato)2], the synthetic precursor of the BEPn family that
carries no steroid appendage, were nearly identical, any difference in the ability of the
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derivatized complexes to kill the two different cell lines can be attributed to the release of
estrogen and subsequent upregulation of HMGB1. As illustrated in Figures 2.6 and 2.7, the
induction of HMGB1 overexpression following treatment with the estrogen-tethered
platinum(IV) complexes did not always translate to sensitization of MCF-7 cells. Instead, as
shown in Table 2.2, the sensitivity of these cells to compounds BEPI - BEP5 varies with linker-
length. The cytotoxicities of BEPI and BEP2 were quite comparable in MCF-7 and HCC-1937
cells, whereas BEP5 was more cytotoxic to the HCC-1937 cells. One possible explanation for
these results is that the elevated levels of HMGB I produced by these complexes do not lead to a
significant amount of platinum-DNA adduct repair-shielding. The cytotoxic profile of BEP5
may be explained by the relatively low level of HMGB 1I overexpression induced upon treatment
of the MCF-7 cells. As shown in Figure 2.6, BEP3 is significantly more cytotoxic in the MCF-7
cells. Based on IC5( values, MCF-7 cells were 1.8- and 1.3-fold more sensitive towards BEP3
and BEP4 treatment, respectively, than they were to HCC-1937 cells. The differential toxicity
towards MCF-7 and HCC-1937 cells observed with BEP3 and BEP4 suggest that these
compounds can upregulate HMGB1 in a manner that is kinetically competent to shield cisplatin-
DNA adducts from repair and sensitize the cells. It is significant that BEP3 is nearly two-fold
more active in MCF-7 cells, because this degree of differential cytoxicity is similar to the
enhancement achieved by cisplatin/estradiol co-treatment. 
The importance of the kinetics of HMGB I upregulation in determining the toxicities of
compounds BEPI - BEP5 can be understood in the light of previous work from our laboratory
demonstrating that estrogen-induced cisplatin sensitization was only achieved when the two
compounds were co-administered.1 5 In addition, sensitization to carboplatin was maximized
when MCF-7 cells were pre-treated for 24 h with the platinum compound before administration
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of estradiol. These observations suggest that the kinetics of HMGBI overexpression and
platinum-DNA adduct formation are critical for achieving an optimal level of repair shielding.
The rate of ester hydrolysis depends upon the length of the substituent attached at the estrogen
17[-position.3°0 The timing of hormone interaction with the ER and subsequent HMGBI
overexpression are therefore expected to be dependent upon the length of the ester linker chain.
The inability of BEP5 to induce significant HMGBI upregulation after a 4 h treatment may be a
consequence of the kinetics of ester hydrolysis. It is likely that compound BEP3 stimulates
HMIGB1 overexpression at such a time that repair-shielding of the platinum DNA-adducts is
maximized, whereas BEP1 and BEP2 induce HMGBI overexpression, but the timing is
insufficient to sensitize the cells to cisplatin-DNA lesions.
Conclusions
Despite the sensitization of ER(+) cells towards BEP3 treatment, the degree of cytotoxicity
achieved with cisplatin/estrogen co-treatment was not attained (ICo0 = 1.0 SUM). The diminished
cytotoxicity of BEP3 compared to cisplatin/estrogen co-administration may be a consequence of
reduced uptake or of the different pharmacokinetics of the estrogen-tethered platinum(IV)
complex. The concentration of estrogen delivered to the cell may also be a factor. When treating
cells with cisplatin and estrogen alone, 200 nM concentrations of estradiol are used, whereas
BEPn complexes deliver micromolar concentrations of the hormone. It is also possible that the
estrogen dose administered by BEPn treatment itself induces a degree of cell proliferation.
Alternatively, the micromolar concentration of estrogen could induce increased HMGB1
overexpression. which may actually inhibit cell death instead of leading to enhanced apoptosis.3
Despite these caveats, the BEPn compounds provide a new model for the development of
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platinum(IV) complexes designed to target and treat a variety of cancers in a specific manner,
based on known cellular pathways. Animal studies are in progress to investigate further the
potential utility of BEP3 as an anticancer agent.
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Table 2.1: 'H NMR data
Hi
EL1 7.34
d, 1H
EL2 7.32
d. 1II
EL3 7.33
d. 11I
EL4 7.32
d. 111
EL5 7.32
d, IH
BEP1 7.34
d, 2H
BEP2 7.35
d, 2H
BEP3 7.35
d. 211
BEP4 7.35
d. 21I
BEP5 7.32
d, 2H
H2 H4
7.01 6.96
d. 1H
7.00
d. 111
7.00
d. IlI
7.00
d. 111
7.00
d. 111
7.01
d. 211
7.00
d. 2H
7.00
d. 211
7.00
d. 211
6.98
d, 2H
s. IH
6.94
s. IIt
6.95
s. II
6.95
s. IH11
6.93
s. 111
6.95
s. 2H
6.95
s, 2H
6.96
s. 211tl
6.97
s. 2H
6.94
s, 2H
(ppm) for estrogen ligands and platinum complexes
H6 H 17 H18
2.83 4.66 0.796
m. 2H t, IH s, 3H
2.83 4.67 0.814
m. 2-1 t. 111 s. 311
2.83 4.65 0.813
m. 2H t. 11I s. 3H
2.83 4.65 0.815
m. 21- t. IIf s. 3I
2.82 4.62 0.798
m. 211 t. 11[ s. 311
2.83 4.65 0.785
m. 4H t, 2H s, 6H
2.83 4.65 0.799
m. 4H t. 2H s, 6H
2.83 4.69 0.805
m. 411 t. 21-1 s. 61
2.84 4.64 0.804
m. 411 t. 211 s. 611
2.82 4.62 0.799
m, 4H t. 2H s, 61
in d6-DMSOa
H19 Ho H2 H H H2 Hb
8.12 7.59 7.74 1.75 3.83
d. 2H t, 2H t, 1H bs. 2H
8.08
d. 2H
8.09
d. 21l
8.09
d. 211
8.08
d. 211
8.10
d, 4H
8.10
d. 4H
8.12
d. 4 I
8.10
d. 411
8.09
d, 4H
7.58
t. 211
7.59
t. 21-1
7.59
t. 211
7.58
t. 2 1-1
7.59
t. 4H
7.60
t, 41-1
7.59
t. 411
7.60
t. 4f1
7.57
t. 4H
7.73
t. 11I
7.73
t. 1l1
7.73
t. 1II
7.72
t. 11I
7.74
t. 2H
7.74
t, 2t1
7.74
t. 2 1-
7.74
t. 211
7.71
t, 2H
1.75
bs. 211
1.70
bs, 211
1.70
bs. 2HI
1.70
bs. 211
8.33
t. 211
7.95
t, 2H
7.85
t. 211
7.85
t, 21I
7.81
t, 2H
6.56
bs. 6H
6.49
bs, 6H
6.50
bs. 611
6.51
bs. 611
6.49
bs. 611
d, 2H
3.04
t. 21f
2.83
m. 211
2.83
m. 2H
2.78
m. 211
3.80
d, 4H
3.23
t, 4H
3.04
t. 411
3.01
t. 411
2.98
t. 4H
2.68
m. 2H
2.42
m. 211
2.36
m. 211
2.31
m. 211
2.43
m, 4H
2.47
m. 411
2.44
m. 4-1
2.40
m, 4H
a See Scheme 2.2 for atom labeling diagram
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Table 2.2. IC5o values (IM) for BEP1 - BEP5
Compound MCF-7 HCC-1937 Cytotoxicity Ratio
(HCC-1937: MCF-7)
BEP1 3.2 0.1 3.4 + 0.4 1.1
BEP2 3.0 0.2 3.6 + 1.2 1.2
BEP3 2.1 + 0.4 3.7 + 0.9 1.8
BEP4 3.7 + 0.5 4.8 _ 0.5 1.3
BEP5 5.5 + 1.7 3.0 ± 0.2 0.55
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Figure 2.1. Proposed mechanism of action for estrogen-tethered platinum(IV) complexes. The
reducing environment of the cell will convert platinum(IV) to platinum(I1), releasing cisplatin
and two equivalents of a modified estrogen. Upregulation of HMGB 1 will shield cisplatin-DNA
cross-links from repair, enhancing cell death.
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Figure 2.2. 1H NMR spectrum of ELI in d6-DMSO. See Scheme 2.2 for atom labeling diagram.
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Figure 2.3. IH NMR spectrum of DEPt in d6-DMSO. See Scheme 2.2 for atom labeling diagram.
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Figure 2.4. Expression of HMGB I in MCF-7 cells as monitored by immunofluorescence
microscopy. MCF-7 cells were grown on cover slips and subsequently incubated with 200 nM
BEPn or estradiol for 4 h. The cell membrane was permeabilized and the cells were treated with
anti-HMGB I primary antibody followed by treatment with a FITC-conjugated secondary
antibody to allow for HMGB I visualization.
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Figure 2.5. Cytotoxicity of cis, cis, tracns-diamminedichlorodisuccinatoplatinum(IV) in MCF-7
and HCC-1937 cells. Cell survival is monitored by the SRB assay. Error bars represent one
standard deviation.
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Figure 2.6. Effect of BEP3 treatment on MCF-7 and HCC-1937 cell survival, as monitored by
the SRB assay (+ SD). Cells were treated continuously for 72 - 96 h. Experiments were carried
out on at least three separate days with triplicate cultures for each drug concentration.
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Figure 2.7. Cytotoxic investigation of BEP1, BEP2, BEP4, and BEP5 in ER(+) MCF-7 and
ER(-) HCC-1937 human breast cancer cells. Cell survival was determined by the SRB assay.
Error bars represent one standard deviation.
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Chapter 3
Synthesis and Biological Activity of a Series of Carboplatin-Based Estrogen-
Tethered Platinum(IV) Compounds
96
Introduction
Carboplatin, or cis-diammine(1,I-cyclobutanedicarboxylato)platinum(1I), is a widely used
second-generation platinum anticancer drug. Developed by Bristol-Myers Squibb in
collaboration with the Institute of Cancer Research and Johnson-Matthey, carboplatin was
approved by the FDA in 1985 as a primary line of treatment for ovarian cancer., Today,
carboplatin is used alone or in combination therapy to treat a variety of malignancies, including
head and neck, testicular, bladder, cervical, and small cell lung cancer.' 2 Because of its lower
toxicity, carboplatin can be administered at 8-15 fold higher doses than cisplatin and is effective
in treating the same range of cancers.' Although cisplatin is generally regarded as the more
potent therapeutic agent, carboplatin is often preferentially administered because of milder side
effects associated with treatment. Unfortunately, carboplatin is often rendered inactive by the
same resistance mechanisms as cisplatin and is not effective against cisplatin-resistant tumors.'
The mechanism of carboplatin biological activity is generally similar to that of cisplatin.
As with cisplatin, the primary biological target of carboplatin is DNA; however, the kinetics of
nucleotide binding and adduct profile differ between the two compounds.'246 The chelating
cyclobutanedicarboxylate (CBDCA) ligand is less labile than the cisplatin chloride ligands.6 As a
consequence, the DNA binding kinetics of carboplatin are considerably slower.4 Upon reaction
with DNA, carboplatin preferentially forms 1,2-intrastrand d(GpG) and d(ApG) cross-links,
which account for approximately 50% of all adducts.4 '5 Interestingly, detailed analysis of DNA
adduct profiles in CHO cells revealed that carboplatin forms more 1,3-intrastrand and interstrand
cross-links (40% of total adducts) than cisplatin (9% of total adducts).5 Formation of the 1,2-
intrastrand d(GpG) cross-link distorts the DNA helix, giving rise to a wide and shallow minor
groove that serves as a recognition site for a number of cellular proteins, including HMGB 1.7-9
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The interaction of HMGB1 with cisplatin-modified DNA prevents removal of the platinum
damage by nucleotide excision repair (NER).'l° l
In estrogen receptor-positive, or ER(+), MCF-7 human breast cancer cells, the
cytotoxicity of cisplatin is enhanced 2-fold upon co-treatment with the steroid hormone
estradiol.' 2 Treatment of ER(+) cells with estradiol induces the overexpression of HMGBI 2-4 h
after hormone treatment. The upregulation of HMGBI is transient, with restoration to basal
protein levels occurring 24 h after estrogen treatment. Estradiol treatment also enhanced
carboplatin cytotoxicity by 2-fold when the hormone was administered 24 h after platinum
treatment.l2 The different requirements for the timing of estradiol delivery reflect the different
kinetics of carboplatin and cisplatin aquation and DNA-binding.6"' 3 Furthermore, the influence of
hormone treatment timing emphasizes the importance of optimizing the kinetics of DNA
platination and HMGB I upregulation. In order for shielding to occur, the expression of HMGB 1
must be elevated at the time of platinum-DNA damage repair.12
The importance of optimizing the kinetics of HMGB I upregulation and formation of Pt-
DNA adducts was also manifest in studies of the biological effects of a series of estrogen-
tethered platinum(IV) complexes (Figure 3.1).14 Because of their ability to interact with the ER
and subsequently induce HMGB1 upregulation, the BEPn compounds were expected to have
enhanced cytotoxicity in ER(+) cells (vide supra). The series of compounds were designed to be
reduced intracellularly resulting in the release of cisplatin and a linker-modified estrogen, which
will be processed by intracellular esterases.' 4 The rate of ester hydrolysis, and therefore the rate
of interaction with the ER and subsequent HMGBI overexpression, is influenced by the length
and nature of the substituent tethered at the 17-position. 1-i 17 Therefore, the length of the linker
between the estrogen and the platinum center was varied from I to 5 methylene units in an
98
attempt to systematically alter the timing of HMGBI upregulation. Compounds BEP1-BEP4,
but not BEP5, were able to induce the overexpression of HMGB1 in MCF-7 cells after a 4 h
incubation. In addition, the cytotoxic properties of BEP1-BEP5 varied with linker length. Only
BEP3 displayed enhanced cytotoxicity in ER(+) MCF-7 cells compared to ER(-) HCC-1937
cells. 4
The success of the BEP3 compound inspired the synthesis of an analogous series of
platinum(IV) compounds that would be reduced in vivo to yield carboplatin. The CBDCA
leaving group may endow the series of compounds with greater stability and fewer side effects
than the cisplatin analogues. In addition, this work represents the first example of a biologically
relevant platinum(IV) compound derived from carboplatin. This chapter describes the synthesis,
characterization, and biological activity of a series of carboplatin-based estrogen-tethered
platinum(IV) compounds.
Experimental Procedures
Materials and Methods
Potassium tetrachloroplatinate(II) was a gift from Engelhard. Carboplatin was prepared as
described in the literature.' s The preparation of compounds L2, L3, L4, and L5 were based on a
previously reported methodology.l9 The syntheses of ELI-EL5 were described elsewhere in this
work (Chapter 2). N-Boc-N'-succinimidyl-4,7,1 0-trioxatri-decane-1,1 3-diamine, or L 17, was
prepared as described in the literature and its purity was confirmed by H NMR spectroscopy. 20
All chemicals and solvents were purchased from commercial sources unless specified otherwise.
'H and '95Pt NMR spectra were recorded on either a Varian 300 MHz or 500 MHz spectrometer
at the MIT Department of Chemistry Instrumentation Facility (DCIF). High-resolution mass
99
spectral analysis was carried out at the MIT DCIF. FT-IR spectra were recorded on a Thermo
Nicolet Avatar 360 spectrometer with OMNIC software.
Synthesis of cis, cis, trans-Diamminecyclobutanedicarboxylatodihydroxoplatinum(IV) (1,
Scheme 3.1). A solution of carboplatin (2.4 g, 6.4 mmol) in 15% aqueous HO (22 mL) was
allowed to stir in the dark for 2 h at 70 C and then for an additional 30 min at 60 C and
subsequently cooled to RT. A white solid was isolated by centrifugation and dried in vacuo (0.74
g, 1.8 mmol, 28% yield); mp = decomposes above 230 C. 'H NMR (d6-DMSO, 300 MHz): 6
1.7 (m, 2H, CH,), 2.5 (m, 4H, CH,), 5.5 (bs, 6H, NH 3), 10.2 (s, 2H, OH). FT-IR (KBr, cm-):
3425 (s), 3296 (s), 3119 (s), 2961(m), 2313 (m), 2018 (w), 1650 (s), 1620 (s), 1344 (s), 1229 (w),
1095 (m), 909 (m), 775 (w), 548 (m), 467(w).
Synthesis of cils, cis, tranls-Diamminecyclobutanedicarboxylatodisuccinatoplatinum(IV) (2).
Succinic anhydride (1.7 g, 17 mmol) and 1 (1.7 g, 4.3 mmol) were dissolved in 25 mL of DMSO.
The solution was heated to 70 C for 2.5 h with constant stirring, cooled to RT, and the DMSO
solvent was removed by lyophilization to afford a sticky yellow solid. The crude product was
rinsed with 20 mL of 1:1 acetone/ether, 30 mL of ether, and 30 mL of acetone to yield an off-
white solid (1.6 g, 2.6 mmol, 60% yield). H NMR (d6-DMSO, 300 MHz): 6 1.8 (in, 2H, CH,),
2.2-2.6 (m, 121H, CH2), 6.4 (bt, J-N = 50.25 Hz, 6H, NH 3), 12.1 (s, 2H, COOH). 15Pt NMR
(HO, 500 MHz): 6 1893 (m, Jpt-N 250 Hz). ESI-MS calculated for [M+Na]' 628.3 amu, found
628.0 amu.
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Synthesis of EL17 (Scheme 3.2). Diisopropylcarbodiimide (0.016 mL, 1.0 mmol) was added to
a solution of L17 (0.75 g, 1.8 mmol) and 4-DMAP (0.12 g, 1.0 mmol) in DMF (4 mL). The
solution was allowed to stir for 15 min at RT before the addition of estradiol-3-benzoate (0.17 g,
0.45 mmol). The reaction was allowed to stir for 16 h, diluted with 15 mL of H2O, and cooled to
4 C for an hour. The BOC-protected product was isolated by filtration and dried in vaculo. The
white solid was dissolved in 10:1 dichloromethane/TFA (13.2 mL) and stirred for 2 h. Solvent
was removed under reduced pressure. The resultant white solid was resuspended in water, the pH
adjusted to 10 with ammonium hydroxide, and the suspension was stirred for 16 h. An oily white
solid was isolated by centrifugation, dried in vacuto, and used without further purification (0.24 g,
0.35 mmol, 78% yield). H NMR (d6 -DMSO, 300 MHz): 0.80 (s, 3H, CH 3), 1.2-2.0 (m, 12H,
CH/CH,/NH,), 2.0-2.45 (m, 9H, CH/CH,), 2.82 (m, 4H, CH,), 3.0-3.6 (m, 16H, CH,), 4.61 (t,
1H, CH), 6.95 (s, H, ArH), 7.0 (d, H, ArH), 7.35 (d, H, ArH), 7.60 (t, 2H, ArH), 7.75 (t, 1H,
ArH), 7.85 (m, 1H, NH), 8.15 (d, 2H, ArH). ESI-HRMS calculated for [M+H]+ 679.3953 amu,
found 679.3965 amu.
Synthesis of cis, cis, trans-Diamminecyclobutanedicarboxylate-bis-(17(N-carbonylmethyl-
succinate)-estradiol-3-benzoate)platinum(IV) (BECP1). Diisopropylcarbodiimide (0.10 mL,
0.63 mmol) was added to a solution of 2 (0.15 g, 0.25 mmol) and 4-DMAP (0.08g, 0.634 mmol)
in DMF (5 mL). The solution was allowed to stir for 10 min at RT before the addition of ELI
(0.22 g, 0.51 mmol). The solution was stirred for 15 h at room temperature, filtered, and the
filtrate was diluted with 50 mL of ether. The resultant solution was cooled to -20 C for an hour
to facilitate precipitation. The crude product was then triturated with ethanol (3x5 mL), boiling
water (3x5 mL), and methanol (x5 mL) and centrifuged for 3-5 min at 3000 rpm to yield a
101
white solid (0.17 g, 0.12 mmol, 48% yield); mp, decomposes above 197 C. H NMR (d6-
DMSO, 500 NMHz): 0.783 (s, 6H, CH3), 1.2-1.6 (m, 4H, CH/CH-), 1.60-1.95 (m, IOH,
CH/CH,), 2.0-2.7 (m, 14H, CH/CH,), 2.83 (m, 4H, CH,), 3.81 (d, 4H, CH2), 4.65 (t, 2H, CH),
6.32 (bt, 6H, NH 3), 6.95 (s, 2H, ArH), 7.01 (d, 2H, ArH), 7.35 (d, 2H, ArH), 7.60 (t, 4H, ArH),
7.73 (t, 2H, ArH), 8.12 (d, 4H, ArH), 8.31 (t, 2H, NH). ESI-HRMS calculated for [M+H]-
1437.5211 amu. found 1437.5208 amu.
Synthesis of cis, cis, trans-Diam minecyclobutanedicarboxylate-bis-(17(N-(2-carboxyethyl)-
succinate)-estradiol-3-benzoate)platinum(IV) (BECP2). This compound was prepared as
described for BECP1 using 2 (0.17 g, 0.28 mmol), 4-DMAP (0.09 g, 0.70 mmol), DIPC (0. 1
mL, 0.70 mmol), and EL2 (0.25 g, 0.56 mmol). Crude BECP2 was triturated with ethanol (3x10
mL) and boiling water (3x10 mL) and centrifuged for 3-5 min at 3000 rpm to yield a white
powder (0.24 g 0.16 mmol, 57% yield); mp, decomposes above 191 C. H NMR (d6 -DMSO,
500 MHz): 6 0.794 (s, 6H1, CH3), 1.2-2.6 (m, 44H, CH/CH2), 2.84 (m, 4H, CH2), 3.27 (t, 4H,
CH,), 4.64 (t, 21H, CH), 6.42 (bt, 6H, NH3), 6.96 (s, 2H, ArH), 7.01 (d, 21H, ArH), 7.36 (d, 2H,
ArI), 7.60 (t, 4H, ArH), 7.75 (t, 2H, ArH), 7.95 (t, 2H, NH), 8.11 (d, 4H, ArH). ESI-MS
calculated for [M+Na] 1487.5344 amu, found 1487.5308 amu.
Synthesis of cis, cis, trans-Diamminecyclobutanedicarboxylate-bis-(17-(N-(3-
carboxypropyl)-succinate)-estradiol-3-benzoate)platinum(IV) (BECP3). This compound was
prepared as described for BECPI using 2 (0. 10 g, 0. 17 mmol), 4-DMAP (0.05 g, 0.41 mmol),
DIPC (0.065 mL, 0.41 mmol), and EL3 (0.12 g, 0.26 mmol) in 3 mL DMF. Crude BECP3 was
purified as described for BECP2 to yield a white powder (0.044 g, 0.030 mmol, 18% yield). H
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NMR (d6-DMSO, 500 MHz): 6 0.801 (s, 6H, CH 3), 1.0-2.0 (m, 26H, CH/CH 2), 2.0-2.2 (m, 2H,
CH), 2.2-2.6 (m, 16H, CH/CH2), 2.83 (m, 4H, CH2), 3.04 (m, 4H, CH,), 3.26 (m, 4H, CH,), 4.64
(t, 2H, CH), 6.36 (bt, 6H, NH3), 6.96 (s, 2H, ArH), 7.01 (d, 2H, ArH), 7.47 (d, 2H, ArH), 7.60 (t,
4H, ArH), 7.74 (t, 2H, ArH), 7.85 (t, 2H, NH), 8.11 (d, 4H, ArH). ESI-HRMS calculated for
[M+H]' 1493.5838 amu, found 1493.5856 amu.
Synthesis of cis, cis, trans-Diamminecyclobutanedicarboxylate-bis-(17-(N-(4-carboxy-
butyl)-succinate)-estradiol-3-benzoate)platinum(IV) (BECP4). This compound was prepared
as described for BECPI using 2 (0.17 g, 0.28 mmol), 4-DMAP (0.09 g, 0.70 mmol), DIPC (0.11
mL, 0.70 mmol), and EL4 (0.27 g, 0.56 mmol). Crude BECP4 was purified as described for
BECP2 to afford a white powder (0.20 g, 0.13 mmol, 46% yield); mp, decomposes above 185
C. H NMR (d6 -DMSO, 500 mHz): 0.800 (s, 6H, CH 3), 1.2-2.6 (m, 52 H, CH/CH2), 2.84 (m,
4H, CH,), 3.03 (m, 4H, CH,), 4.64 (t, 2H, CH), 6.34 (bt, 6H, NH 3), 6.96 (s, 2H, ArH), 7.01 (d,
2H, ArH), 7.34 (d, 2H, ArH), 7.61 (t, 4H, ArH), 7.74 (t, 2H, ArH), 7.84 (m, 2H, NH), 8.10 (d,
4H, ArH). ESI-HRMS calculated for [M+Na]+ 1543.5970 amu, found 1543.5960 amu.
Synthesis of cis, cis, trans-Diamminecyclobutanedicarboxylate-bis-(17-(N-(5-carboxy-
pentyl)-succinate)-estradiol-3-benzoate)platinum(IV) (BECP5). This compound was prepared
in a similar manner as described for BECPI using 2 (0.17 g, 0.28 mmol), 4-DMAP (0.09 g, 0.70
mmol), DIPC (0.11 mL, 0.70 mmol), and EL5 (0.27 g, 0.56 mmol). The solution was stirred for
15 h at RT and diluted with 45 mL water. The resultant solution was cooled to 4 C for I h to
facilitate precipitation. Crude BECP5 was purified as described for BECP2 to afford a white
powder (0.099 g, 0.064 mmol, 23% yield); mp, decomposes above 182 C. H NMR (d6 -DMSO,
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500 mHz): 6 0.801 (s, 6H, CH 3), 1.2-2.6 (m, 56H, CH/CH,), 2.84 (m, 4H, CH,), 3.00 (m, 4H,
CH,), 4.64 (t, 2H, CH), 6.33 (bt, 6H, NH3), 6.96 (s, 2H, ArH), 7.01 (d, 2H, ArH), 7.35 (d, 2H,
ArH), 7.61 (t, 4H, ArH), 7.75 (t, 2H, ArH), 7.81 (m, 2H, NH), 8.11 (d, 4H, ArH). ESI-MS
calculated for [M-H]- 1547.7 amu, found 1547.0 amu.
Synthesis of cis, cis, trans-Diamminecylcobutanedicarboxylate-bis-17-(N-(trioxa-
tridecanediamine-succinyl)-succinate)-estradiol-3-benzoate)platinum(IV) BECP17. This
compound was prepared in a similar manner as described for BECPI using 2 (0.11 g, 0.18
mmol), 4-DMAP (0.06 g, 0.46 mmol), DIPC (0.07 mL, 0.460 mmol), and EL17 (0.25 g, 0.37
mmol). The solution was stirred for 24 h at RT, diluted with 50 mL ether, and cooled to -20 C
tor 1.5 h. A white solid was collected by filtration, washed with boiling water, and dried in vacuo
(0.15 g, 0.078 mimol, 43% yield): mp=105-110 C. H NMR (d 6-DMSO, 300 MHz): 6 0.793 (s,
6H.. CH 3), 1.2-2.0 (m, 24H, CH/CH2), 2.0-2.45 (m, 18H, CH/CH,), 2.45-2.50 (m, 12H, CH2),
2.82 (m, 8H, CH,), 3.0-3.6 (m, 32H, CH,), 4.61 (t, 2H, CH), 6.3 (bs, 6H, NH 3), 6.97 (s, 2H,
ArlI), 7.00 (d, 2H, ArH), 7.35 (d, 2H, ArH), 7.62 (t, 41t-, ArH), 7.75 (t, 2H, ArH), 7.86 (m, 4H,
NH), 8.15 (d, 41-1, ArH). ESI-HRMS calculated for [M+Na]-- 1949.8444 amu, found 1949.9074
am ii.
Cell Culture Studies. MCF-7 cells were grown in DMEM (GIBCO/BRL) supplemented with
10°%o FBS. 100 units/mL of penicillin (GIBCO), 100 [tg/mL of streptomycin (GIBCO), and 2
mMNl L-glutamine. ICC-1937 cells were grown in RPMI-1640 media (ATCC) containing 10%
FBS, 2.0 mM L-glutamine, 10 mM HEPES, 1.0 mM sodium pyruvate, 2 mM glucose, 100
104
units/mL of penicillin (GIBCO), and 100 [tg/mL of streptomycin. All cells were incubated at 37
C under a 5% CO 2 atmosphere.
Overexpression of HMGB1 Induced by BECPn Complexes. MCF-7 cells were grown to 70%
confluence on 12-mm glass cover slips in 24-well plates. Cells were treated with 200 nM
BECPn for 4 h, rinsed with PBS, and further incubated for 20 h. The cells were fixed with 2%
paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) for 1 h at RT and washed in PBS for 30
min. Cells were permeabilized with 0.1% Triton-X100 in PBS for 10 min, rinsed with blocking
buffer (PBS, 0.1% goat serum, 0.075% glycine), and incubated with a 1:100 dilution of anti-
HMGBI polyclonal antibody (Chemicon) for I h at 37 C. The cells were subsequently
incubated with a 1:1 00 dilution of rabbit anti-mouse IgG conjugated to FITC (Chemicon) for 1 h
at 37 C. The cover slips were then fixed on microscope slides with mounting medium (O.1%p-
phenylenediamine in 75% glycerol) and incubated at 4 C for 12 h. HMGBI levels were then
visualized under a fluorescent light microscope (Nikon) equipped with a digital camera
(Diagnostic Instruments).
Cytotoxic Profile of BECPn Compounds. Cell survival was analyzed by the MTT assay.
MCF-7 or HCC-1937 cells were seeded into 96-well plates at a density of 1000 or 1500 cells per
well, respectively. After 24 h, cells were treated with 0-30 pM BECPn and further incubated at
37 C. After incubating for 96-120 h, 20 LtL of a 5 mg/mL MTT solution (PBS) was added to
each well and incubated at 37 C for 5 h. The media was then removed from each well and the
cells were redissolved in 100-200 tL of DMSO. The absorbance of each well was measured at
550 nm using a plate reader (SpectraMax 340pc, Molecular Devices). Percent cell survival was
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calculated for each concentration by the ratio of the measured absorbance to the absorbance of
the untreated wells.
Results and Discussion
Design, Synthesis, and Characterization of BECPI-5 and BECP17
The synthetic strategy in the present study mirrors that used in the preparation of the series of
estrogen-tethered platinum(IV) complexes, BEPn, presented elsewhere in this work (Chapter
2).14 As discussed earlier, the BECPn complexes will be reduced intracellularly, releasing
carboplatin and a linker-modified estrogen. After BECPn reduction, carboplatin is available for
DNA binding and the linker-modified estrogen will undergo esterase-facilitated hydrolysis to
yield free estradiol. Since the kinetics of estradiol release are important, a longer ethylene glycol-
based linker as prepared. To our knowledge, these compounds are the first example
platinum(IV) complexes having the CBDCA ligand.
Carboplatin is readily oxidized by hydrogen peroxide to yield a trans-
dihydroxyplatinum(IV) complex which was characterized by I H NMR and IR spectroscopy (Fig.
3.21. The platinum ammine protons are shifter significantly downfield as compared to their
positions for carboplatin, which is consistent with the more positive formal oxidation state of
platinum.2 Oxidation of carboplatin to I is supported by the presence of the characteristic IR
bands assigned to the OH stretch at 3425 cm-l and the PtO stretch at 548 cm- l.2 The tran.s-
dihydroxy complex was further characterized by X-ray crystallography, as described
elsewhere.22 As illustrated in Scheme 3.1, 1 reacts with succinic anhydride in DMSO to afford
the trianIs-dicarbo)xylato complex 2, which was characterized by 1'5Pt and H NMR spectroscopy.
The '|'Pt NMR resonance at 1893 ppm (Fig. 3.3) is similar to other known platinum(IV)
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carboxylates.23 The platinum ammine proton resonances appear as a broad triplet at 6.4 ppm, a
value that is in agreement with previously reported platinum(IV) complexes.-4,25 As shown in
Figure 3.4, the ammine and succinato carboxylate protons integrate in a 3:1 ratio, indicating the
presence of two succinato ligands per platinum center. The experimentally determined mass for 2
was in agreement with the calculated value to within 0.05%.
Synthesis of the ethylene glycol linker-modified estrogen EL17 was achieved following
the same protocol used to prepare EL1-EL5. 14 Formation of the ester linkage was confirmed by
the significant downfield shift of the H17 proton resonance in the 'H NMR spectrum of the
product (Table 3. 1). Isolation of the desired EL17 compound was verified by ESI-MS; the value
for the calculated mass was in excellent agreement with the experimentally determined mass
within 0.00003%.
The synthesis of BECPn (n=1-5, 17) was achieved using the same methodology
described for the preparation of the BEPn (n=1-5) compounds. 4 As illustrated in Scheme 3.2, 2
and the amine-modified estrogens are easily coupled using standard peptide coupling reagents to
yield an amide-linked product. Purification of the BECP compounds is facile, with impurities
being removed by washing the solid with water and ethanol. ESI-MS and H NMR confirm the
presence of the desired estrogen-tethered platinum(IV) compounds (see spectral analyses in
Table 3.1). A 'H NMR spectrum of BECP1 is shown in Figure 3.5. Formation of the amide
linkage between the estrogen and the platinum(IV) center is confirmed by the appearance of
amide proton resonance H22 at 7.8-8.3 ppm. The H NMR data also provide evidence for the
presence of two estrogen substituents per carboplatin center. The platinum ammine protons (H2 3)
integrate with a 1:1 ratio to the 18-postion methyl group of the estrogen (H8). Finally, the
calculated masses for the BECPn compounds are in agreement with the experimentally
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determined data to within 0.04-0.00002%. The synthetic methodology presented further extends
previously presented strategies by providing a facile route for the preparation of carboplatin
analogues suitable for targeting specific cell types.
Overexpression of HMGBI in MCF-7 Cells Following BECPn (n=1-5, 17) Treatment
Immunofluorescence microscopy vwas used to evaluate whether or not the BECPn compounds
induce overexpression of HMGBI in MCF-7 cells. As discussed earlier, the kinetics of
carboplatin binding to DNA is considerably slower than those of cisplatin. Therefore, the
expression of H[MGB 1 was examined 24 h after addition of BECPn. As shown in Figure 3.6, a
modest degree of HMGBI upregulation occurs following 200 nM BECPn treatment.
Qualitatively, the amount of HMGB I overexpression achieved upon incubation with the BECP
complexes does; not equal the degree of protein upregulation observed with BEPn treatment.
The ability of the BECP compounds to induce overexpression of HMGBI implies that the
platinum(IV) centers are reduced inside the cell and that ester hydrolysis and subsequent release
of free estradiol does occur. The modest degree of HMGB I upregulation observed suggests that
the kinetics of protein overexpression may not be optimized for achieving repair shielding.
Cytotoxicity Profiles of BECPn in ER(+) MCF-7 and ER(-) HCC-1937 Human Breast
Cancer Cells
The cytotoxicity profiles of BECPn wvere evaluated in ER(+) MCF-7 and ER(-) HCC-1937
human breast cancer cells by the MTT assay. Unlike its cisplatin analogue, the cis, cis, trans-
diarnminecyc lobLltanedicarboxylatodisuccinatoplatinum(IV) complex has different cytotoxicities
(see Figure 3.7) in MCF-7 (IC50 = 8.4+0.7 [tM) and HCC-1937 (12.1±2.8 tIM) cells. The
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differential cytotoxicity of 2 is likely due to cell line differences in the uptake of the anionic
compound. As shown in Figure 3.8, the cytotoxicities of the BECP compounds vary with linker
length; however, the ER(+) MCF-7 cells are not more sensitive than the ER(-) HCC-1937 cells to
any of the BECP compounds. This observation implies that no HMGB 1 induced repair shielding
of platinum-damaged DNA occurs in the ER(+) MCF-7 cells. The variation of compound
cytotoxicity (see Table 3.2) may be due to the increased lipophilicity associated with longer
linker length, favoring increased compound uptake. Interestingly, BECP3 and BECP17 were
both more 1.5-fold more cytotoxic in the ER(-) HCC-1937 cell line. This observation may
indicate that the concentration of hormone delivered to the cell may be sufficient to induces cell
proliferation and reverses the trend seen for BEP3 (Chapter 2).
Examination of the immunofluorescence data provides some insight into the lack of
differential cytoxicity observed with the BECP compounds. The modest degree of HMGB I1
upregulation observed after 24 h incubation may not be sufficient to affect the repair of platinum
damaged DNA. As demonstrated in previous work, cisplatin-based compounds tethered to EL1-
EL4 induced significant upregulation of HMGBI after 4 h.14 Therefore, it is not unexpected that
BECP1-BECP4 would only moderately effect the expression of HMGBI after 24 h. Because of
the slower DNA-binding kinetics of carboplatin, it was predicted that longer linkers, which
afford slower kinetics of HMGBI upregulation, would be required to target ER(+) cells
selectively. Unexpectedly, BECP5 and BECP17 did not improve upon the persistance of
HMGBI upregulation in MCF-7 cells (Figure 3.6, Table 3.2).
The DNA adduct profile of carboplatin provides another reason why the BECP
compounds do not selectively kill ER(+) MCF-7 cells. As discussed earlier, carboplatin forms
more 1,3-intrastrand and interstrand cross-links than cisplatin.4'5 HMGBI binds with specificity
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to 1,2-intrastrand platinum-DNA cross-links, but the protein does not recognize either the 1,3-
intrastrand or the interstrand cross-link with high affinity.7 Therefore, HMGB I may not be as
effective in promoting the cytotoxicity of carboplatin compared to cisplatin. In support of this
hypothesis, HeLa cells whose expression of HMGB1 was silenced by RNAi were 2.8-fold
resistant to cisplatin, but only 1.6-fold less sensitive to carboplatin. 6
Conclusions and Future Directions
A series of carboplatin-based estrogen-tethered platinum(IV) complexes, or BECPn, have been
synthesized and characterized by H NMR spectroscopy and ESI-MS. The synthetic
methodology developed will allow for the facile preparation of other biomolecule-tethered
carboplatin analogues. The BECP compounds induced a moderate degree of HMGBI
upregulation in ER(+) MCF-7 cells. The ability of BECPn to induce HMGB1 overexpression
did not translate to increased cytotoxicity in ER(+) MCF-7 cells compared to ER(-) HCC-1937
cells.
Future work could involve the synthesis of additional linker-modified estrogens, such as
polyethylene glycol-based compounds, that would induce HMGB1 overexpression 24 h after
treatment. Detailed kinetic analysis of the rate of ester hydrolysis of substituents attached at the
17f;-position could provide insight into the design of more appropriate linkers. Alternatively,
synthetic estrogen agonists could be screened for their ability to act as long-lived steroid
hormones. Additional work with tethering the steroid hormone progesterone may also provide
useful carboplatin analogues.
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Table 3.1: H NMR data (ppm) for estrogen ligands and platinum complexes in d6-DMSO at
25 Ca
Hi II, 11t4 HIh l17 tlls 11 o I I [I2 1 1123 fI1
EL,17 7.35 7.00 6.95 2.82 4.61 0.800 8.15 7.60 7.75 -- -- --
d. 11I d. III s. 1i m, 211 t. II s. 311 d. III t, l t. f
BECPI 7.35 7.01 6.95 2.84 4.65 0.783 8.12 7.60 7.73 8.31 6.32 3.81
d. 211 d. 211 s. 211 rn. 411 t. 211 s. 61I d. 411 t. 411 t. 211 t. 211 bt. 611 d. 411
BECP2 7.36 7.01 6.96 2.84 4.64 0.794 8.11 7.60 7.75 7.95 6.42 3.27
d. 211 d. 21 s. 211 m. 411 t. 211 s. 611 d. 411 t. 411 t. 211 t. 211 bt. 611 t. 411
BECP3 7.47 7.01 6.96 2.83 4.64 0.801 8.11 7.60 7.74 7.85 6.36 3.26
d. 21-1 d. 211 s. 2H m, 4H t. 2H s. 611 d. 4H t, 4H t. 2H t. 2H bt, 611 m. 4H
BECP4 7.34 7.01 6.96 2.84 4.64 0.800 8.11 7.61 7.74 7.84 6.34 3.03
d. 211 d. 211 s. 2H m. 4H t, 2H s. 611 d. 4H1 t. 4H t. 2t1 t. 21-1 bt, 611 m. 41-
BECP5 7.35 7.01 6.96 2.84 4.64 0.801 8.11 7.61 7.75 7.81 6.33 3.00
d. 27 d, 21 s. 21-1 m. 4H t. 2H s, 6H d, 4H t. 4H t. 2H t, 2H ht. 611 m. 41-1
BECP17 7.35 7.00 6.97 2.82 4.61 0.793 8.15 7.62 7.75 7.86 6.30 --
d. 21 d. 211 s. 211 m. 411 t. 211 s. 611 d. 411 t. 411 t. 211 m. 211 bt, 611
a See Scheme 3.2 for atom labeling diagram
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Table 3.2. IC50 values (tM) for BECP1-5 and BECP17
Compound MCF-7 HCC-1937 Cytotoxicity Ratio
(HCC-1937: MCF-7)
2 8.4 +- 0.7 12.1 + 2.8 1.4
BECP1 9.5 + 1.8 9.7 + 1.1 1.0
BECP2 12 1.4 11 4.2 0.93
BECP3 18 + 2.5 11 + 3.0 0.65
BECP4 5.7 1.0 5.5 1.3 0.96
BECP5 5.6 ± 1.2 5.5 + 0.9 0.97
BECP17 7.4 ± 1.5 4.8 ± 1.0 0.64
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Figure 3.6. Expression of HMGB I as visualized by immunofluorescence microscopy. Cells were
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h before analyzing protein levels by immunofluorescence.
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Chapter 4
Design, Synthesis, and Biological Evaluation of an 17a-Ethynylestradiol-
Tethered Platinum(IV) Complex Designed to Target Estrogen Receptor-
Positive Cells
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Introduction
Receptor-mediated uptake is a promising strategy in the quest for development of cancer-cell
specific drug delivery. A prominent difference between cancer and healthy cells is the variable
expression of different receptors, including the estrogen receptor (ER).1-3 Both ERa and ER[I are
expressed in human breast cancer; but each receptor is differentially expressed in specific disease
types.4 '6 For example, ERG is expressed in both normal mammary gland and in benign breast
tumors, whereas the expression of ERca is limited in normal mammary tissue.4 ERa appears to
be involved in the initiation of malignancy and is overexpressed in ductal carcinoma, but not in
medullary breast cancer. On the other hand, the expression of ER[ is upregulated in both ductal
and medullary breast cancer. 4 Because ERa and ER{ have different functions, many of which
have yet to be elucidated, the binding affinity for both receptors of compounds that target them
should be evaluated.
A number of hormone-tethered compounds that bind the ER have been prepared for
evaluation as breast cancer imaging agents or as components of chemotherapeutic drug
candidates (Figure 4.1).7-12 Structure-activity relationships have revealed that ER-binding affinity
is maintained when estradiol is modified at the 7a-, 1 i-, or 17a-position. 0° A series of 7a-
modified estrogens have demonstrated high relative binding affinities (RBA) for the ER.9'101' 3
For example, enhanced cytotoxicity in ER(+) cells was observed for a 7a-estradiol-tethered
mustard (Figure 4.1A).9'4 In addition, selective uptake into ER(+) cells has been demonstrated
with a porphyrin-estradiol conjugate linked through the 1l-position (Figure 4.IB). 8'1 l
Modification of estradiol at the 17a-position has also yielded potentially useful compounds with
high RBAs.7,12"' For instance, a 17a-alkylamide-tethered platinum(II) estradiol conjugate
(Figure 4.1C) is twice as cytotoxic in ER(+) cells as compared to ER(-) cells.' 6
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The differential cytotoxicity of the aforementioned compounds in ER(+) cell lines is
often attributed to increased uptake in the target cell line or, alternatively, to other ER-dependent
responses.9.'5 Although increased uptake of estradiol occurs in ER(+) tissue, the mechanism is
unknown.' In the blood, estrogens are bound to the plasma proteins albumin and sex hormone-
binding globulin and therefore have low clearance rates, which could affect tumor uptake.
Studies with radioactive steroids confirm that estradiol is selectively taken up and concentrated
in the breast. In addition, malignant breast tissue accumulates more estradiol than the healthy
breast. Binding of estradiol to the ER in the cytoplasm results in translocation of the complex to
the nucleus. 
In addition to enhanced uptake into ER(+) cell lines, compounds with affinity for the ER
may also elicit their cell-type dependent action by induction or down-regulation of estrogen-
dependent genes.17'ls In the absence of estradiol, the ER is bound by heat shock proteins (HSP)
and can only undergo ligand-independent activation controlled by growth factor receptor
6
signalling. Binding of estradiol to either ERct or ERP3 initiates signal transduction cascades
through induction of conformational changes that result in release of HSP and subsequent
receptor dimerization. 1, Zinc-finger DNA-binding domains mediate interaction of the ER dimer
with estrogen responsive elements of target genes.6 Estrogen stimulation in MCF-7 cells
regulates the expression of 105 genes including (Table 4.1 ) genes responsible tor the control of
DNA replication and repair, transcription, cell cycle, cellular signaling, extracellular matrix,
protein degradation and synthesis, and apoptosis. 7 A number of these genes (e.g., DNA
polymerase, HMGBI, XRCC5, caspase 7, and metallothionein) have been associated with
cisplatin activity or resistance. 19-24 Previous work from our laboratory demonstrated that estrogen
treatment induces the overexpression of HMGB1 in ER(+) MCF-7 cells and, in turn, sensitizes
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the cell to cisplatin treatment. HMGB1 binds to cisplatin 1,2-intrastrand d(GpG) cross-links
and shields the Pt-DNA adducts from repair. 26 Therefore, a platinum complex with affinity for
the ER could be selectively target ER(+) cells by either of two mechanisms: increased uptake or
the regulation of estrogen-dependent genes, such as HMGB1, that influence cell survival. This
chapter describes the synthesis and characterization of one such complex, 1 7a-ethynylestradiol-
tethered platinum(IV), and its effect on ER(+) breast cancer cells.
Experimental
General Considerations. The synthesis of cis, cis, trans-diamminedichlorodisuccinato-
platinum(IV) is described elsewhere in this work (Chapter 2). 17ca-(Benzylamine)-ethynyl-
estradiol was prepared as described in the literature and characterized by ESI-MS and H NMR
spectroscopy.27 'H NMR spectra were recorded on a Varian 300 MHz spectrometer at the MIT
Department of Chemistry Instrumentation Facility (DCIF). High-resolution mass spectral
analysis was carried out at the MIT DCIF. Platinum atomic absorption spectral analysis (Pt
AAS) were performed on a Perkin Elmer AAnalyst spectrometer equipped with a HGA-800
graphite fumance system and a AS-72 autosampler.
Synthesis of bis-Ethynylestradiol-cis-diamminedichloroplatinum(IV), BEEP. A solution of
cis, cis, trans-diamminedichlorodisuccinatoplatinum(IV) (0.299 g, 0.560 mmol), EDC (0.539 g,
2.81 mmol), and HOBt (0.382 g, 2.83 mmol) was prepared in 5 mL of DMF. After 10 min, a
solution of 17cc-(benzylamine)-ethynylestradiol (0.670 g, 1.67 mmol) in DMF (5 mL) was added
and the reaction was allowed to stir at RT for 16 h. The reaction solution was diluted with 40 mL
of diethyl ether and cooled to -20 C to facilitate precipitation. The crude product was isolated
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by centrifugation and washed with water (5x20 mL). The tan solid was then triturated with 75%
ethanol in water and centrifuged to yield a pale tan solid (270 mg, 0.21 mmol, 37% yield); mp,
decomposes above 165 C. 'H NMR (d6 -DMSO, 300 MHz): 8.97 (bs, 2H, OH), 8.37 (t, 2H,
NHi), 7.26 (m, 8H, ArH), 7.05 (d, 2H, ArH), 6.45 (bs, 6H, NH 3), 6.48 (d, 2H, ArH), 6.41 (s, 2H,
ArH), 5.46 (s, 2H, OH), 4.22 (d, 4H, CH,), 2.68 (m, 4H, CH,), 2.4-1.6 (m, 25H, CH/CH,), 1.4-
1.2 (m, 9H, ClH/CH2), 0.791 (s, 6H, CH3 ). HRMS calculated for [M+Na] 1323.4323 amu, found
1323.4194 amu.
Cell Culture. MCF-7 cells were grown in DMEM (GIBCO/BRL) supplemented with 10% FBS
(GIBCO/BRL), I mM sodium pyruvate, 100 units/mL penicillin, and 100 gig/mL streptomycin.
HCC-1937 cells were grown in RPMI-1640 media (ATCC) containing 10% FBS, 2 mM L-
glutamine, I mM sodium pyruvate, 100 units/mL penicillin, and 100 tcg/mL streptomycin. All
cells were incubated at 37 C under a 5% CO, atmosphere.
Overexpression of HMGB1 by Treatment of Cells with Estrogen-Containing Compounds.
MCF-7 cells were grown to 70% confluence on 12-mm glass coverslips (Fischer Scientific) in
24-well plates. The cells were treated with either 200 nM -estradiol, 1 7(x-ethynylestradiol or
BEEP and incubated for 4 h. The cells were washed with PBS (3x), fixed in 2%
paraformaldehyde in 0. 1 M phosphate buffer (pH 7.4) at RT for I h, and rinsed again in PBS
(3x). The cells were then permeabilized with 0.1% Triton-X100 in PBS for 10 min at RT,
washed in blocl.ing buffer (PBS, 0.1% goat serum, 0.075% glycine), and incubated with a 1:100
dilution of anti.-HMGBl polyclonal antibody (PharMingen) for I h at 37 C. The cells were
subsequently washed in blocking buffer and incubated with a 1:200 dilution of goat anti-rabbit
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IgG conjugated to FITC (Biosource International) for I h at 37 C. The coverslips were then
placed on microscope slides, fixed with 0.1%p-phenylenediamine in glycerol, and stored O/N at
4 C. HMGB 1 levels were visualized tinder a fluorescent light Nikon Eclipse TSI00 microscope
using a FITC-HYQ filter cube (excitation 460-500, bandpass 510-560 nm). Images were
captured with an RT Diagnostics camera operated with Spot Advanced software.
Estrogen-Receptor Binding Affinity. Human recombinant ERoC or ERf3 (0.50 tM,
Calbiochem) was incubated with 5.0 [iM BEEP at 4 C in TE buffer (10 mM Tris, 1.5 mM
EDTA, pH 7.4) for 18 h. The solution was diluted to 3 mL total volume and free and ER-bound
BEEP were separated by dialysis using a MWCO 8000 dialysis cassette (Pierce) against PBS for
4 h at 4 C. The concentration of ER-bound BEEP was determined by using Pt AAS.
Uptake of BEEP into ER(+) MCF-7 and ER(-) HCC-1937 Cells. MCF-7 and HCC-1937 cells
were seeded onto 10-cm plates and grown until 80-90% confluent. Cells were incubated with 10
VIM BEEP for 4 h at 37 C, harvested, and washed extensively with PBS. The total protein
content was determined by the bicinchoninic acid protein assay and the platinum concentration
by Pt AAS. The degree of BEEP uptake was expressed as a ratio of platinum concentration
(mg/L) to the total protein concentration (mg/L) of the isolated cell pellet.
Cytotoxicity Studies. In a 96-well plate, MCF-7 cells were seeded at a density of 1000 cells per
well in 100 [tL of DMEM. After 24 h, the cells were either treated with 0-20 [tM cisplatin alone
or co-treated with 200 nM 17ct-ethynylestradiol and 0-20 FM BEEP. The cells were incubated
for 96 h at 37 C and evaluated for survival by the MTT assay.2 8 Briefly, cells were treated with
20 [tL of 5 mg/mL MTT (PBS, pH 7.4) and incubated for 5 h at 37 C. The media was removed
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and the cells resuspended in 100-200 tL of DMSO. The absorbance of each well was measured
at 550 nm by a plate reader (SpectraMax 340 pc, Molecular Devices). Percent cell survival was
calculated for each concentration by the ratio of the measured absorbance to the absorbance of
the untreated wells.
Results and Discussion
Effect of 17a.-Ethynylestradiol on the Cytotoxicity of Cisplatin. For our strategy to be
effective, it was important to establish that 17c-ethynylestradiol upregulates HMGB1 and
sensitizes ER(+) cells to cisplatin treatment to the same degree as f3-estradiol.2 5 Figure 4.2
demonstrates that incubation of the cells with 200 nM 17ct-ethynylestradiol for 4 h induces the
overexpression of HMGB 1I to a similar degree as estradiol alone. In addition, co-treatment of
ER(+) MCF-7 breast cancer cells with cisplatin and 17c-ethynylestradiol sensitizes cells to
platinum treatment by nearly a factor of three (Figure 4.3). In addition to maintaining affinity for
the ER, 17(t-ethynylestradiol also recapitulates the activity of -estradiol in its ability to
modulate the expression of HMGB I.
Synthesis of a 17a-Ethynylestradiol-Tethered Platinum(IV) Complex. The synthesis,
characterization, and biological activity of a series of 1713-estradiol-tethered platinum(IV)
complexes, known as BEPn, designed to target ER(+) cells were described in Chapter 2. Like
these compounds, the 17c-ethynylestradiol-tethered platinum(IV) complex (BEEP) will be
reduced intracellularly to yield cisplatin and a linker-modified estrogen.29 The BEP compounds
differ from BEEP mainly in the nature of the steroid tether. As discussed earlier, compounds
with affinity for the ER are selectively taken into ER(+) breast cancer cells. Because the BEP
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compounds are linked at the 17p-position of the steroid ring, they cannot bind the ER.
Interaction with the ER will only occur after reduction of BEP and subsequent hydrolysis of the
linker-modified estrogen. The resultant free estradiol can then bind the ER and cause HMGB 1
upregulation. BEEP was designed to have binding affinity for the ER prior to these processing
steps in order to take advantage of both ER(+)-dependent mechanisms, selective uptake and
HMGB1 upregulation. Since the linker-modified estrogen released upon BEEP reduction
contains a non-hydrolyzable component, it is critical that the estrogen-tethered complex itself
binds to the ER.
The synthesis of bis- 17a-ethynylestradiol-cis-diamminedichloroplatinum(IV), BEEP,
was achieved by coupling two readily available intermediates: 17ca-(benzylamine)-
ethynylestradiol and cis, cis, trans-diamminedichlorodisuccinatoplatinum(IV). The preparation
of 17a-(benzylamine)-ethynylestradiol was based on a previously reported methodology.27
3-Bromobenzylamine was first BOC protected and subsequently allowed to react with sodium
iodide to yield the more reactive 3-iodobenzyl-carbamic acid tert-butyl ester. Sonogashira
coupling of the BOC-protected benzylamine and 17uc-ethynylestradiol, followed by deprotection
of the amine group, afforded 17(c-(benzylamine)-ethynylestradiol in 67% overall yield. The
experimentally determined mass for the desired benzylamine-modified estradiol (IM+HI+= 402.2
amu) is in exact agreement with the calculated value ([M+HI+=402.2 amu).
Scheme 4.1 summarizes the synthesis of BEEP. The amine-modified 17ca-
ethynylestradiol is coupled to cis, cis, trans-diamminedichlorodisuccinatoplatinum(IV) using
common peptide coupling reagents, EDC and HOBt. Isolation of the desired platinum-estradiol
conjugate was confirmed by H NMR spectroscopy (see Figure 4.4) and ESI-MS. Formation of
the amide linkage is supported by a new proton resonance at 8.37 ppm, which is consistent with
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known platinurm(V) bioconjugates.30 The amide proton (Hb) integrates in a :lI ratio with the
estradiol -OH group (H3). Finally, the experimentally determined mass was in excellent
agreement with the calculated value (+ 0.0009%).
Biological Studies of BEEP
JFje t of BEEP Treatment on the Erpression of HMGBI. The ability of BEEP to upregulate
HMGBI was investigated by immunofluorescence microscopy. As shown in Figure 4.2,
treatment with 200 nM BEEP for 4 h does not induce overexpression of HMGB I in MCF-7
cells. The failure of BEEP to induce HMGBI upregulation suggests that the compound may
ha,,e no affinity for the ER.
Bincling Affinity- of BEEP for ERca and ER. The binding affinity of BEEP for ERct and ERA
was approximated by incubation of the isolated receptors with BEEP and subsequently
separating free from bound platinum by- dialysis. The results (Table 4.2) indicate that BEEP has
very low affinity for ERca (Kd -970 nM) and none for ERA.
Because of the high number of ER molecules expressed per cell (103-104), a relative
binding affinity (RBA) of -l1% would be sufficient for providing some degree of ER(+)-cell
targeting.' The Kd value for estradiol binding to the ER is 0.05-0. 10 nM and therefore the RBA
of BEEP is 0.005-0.01%. This very low RBA of BEEP explains the failure of BEEP to induce
HMGB I regulation in MCF-7 cells, and implies that BEEP will not achieve any ER(+)-selective
targeting of the compound.
Whole C'ell Uptake of BEEP into ER(+) AC'F-7 and ER(-) HC-1937 C'ell.. In spite of the low
ER binding affinity of BEEP, its uptake was evaluated in MCF-7 and HCC-1937 cells. Cells
were incubated with 10 ptM BEEP for 4 h at 37 C, washed with PBS, and harvested. The
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whole-cell platinum content was determined by AAS and compared to the total protein content
of the isolated cell pellet. For ER(+) MCF-7 cells the concentration of platinum to total protein
content ratio was 0.004 + 0.002, and for ER(-) HCC-1937 cells the ratio was 0.02 0.01.
Therefore, it is clear that BEEP is not selectively taken up by ER(+) cells, a result is that reflects
the low ER binding affinity observed for BEEP.
Cytotoxic Profile of BEEP in ER(+) MC'F-7 tand ER(-) HCC-1937 Cells. The cytotoxicity of
BEEP was evaluated in ER(+) MCF-7 and ER(-) HCC-1937 human breast cancer cell lines by
the MTT assay. As shown in Figure 4.5, the cytotoxicity of BEEP is nearly identical in MCF-7
(IC 50=1.8 0.1 KIM) and HCC-1937 (IC5(=2.2 0.1 BLM) cells. This observation is consistent
with the inability of BEEP to induce HMGB 1 overexpression and to bind to the ER.
A number of platinum-estrogen conjugates have been prepared to obtain a compound
suitable for targeting ER(+) breast cancer. 32-4 Although some compounds maintained affinity for
the estrogen receptor and are cytotoxic in ER(+) cell lines, evidence for estrogen-mediated
selective-targeting of platinum compounds is scarce. With the exception of the 17cL-alkylamide-
tethered estrogen-platinum(ll) conjugate discussed earlier (Figure 4. IC), most compounds have
similar cytotoxicities in ER(+) and ER(-) cell lines.'6 Two 17c-ethynylestradiol platinum(I)
conjugates designed for selective uptake into breast cancer cells were recently reported.4' The
complexes had poor affinity for the ER (RBA <1%) as a result of their hydrophilic character and
no cytotoxicity data were presented. As with the present compounds, it is possible that the
hydrophilic nature of the succinate linker hinders binding to the ER.4'
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Conclusions and Future Prospects
A 17c-ethynylestradiol platinum(IV) complex designed to specifically target ER(+) cells was
synthesized and characterized by H NMR and ESI-MS. BEEP had low affinity for the ER and,
therefore, could not induce overexpression of HMGB I in ER(+) human breast cancer MCF-7
cells. In addition, no selective uptake of BEEP into ER(+) MCF-7 cells occurred. BEEP is
moderately cytotoxic in MCF-7 cells, but has no differential toxicity compared to ER(-)
HCC-1937 human breast cancer cells.
Future work could target the synthesis of a 7c- or 1 lp-estradiol-tethered platinum
complex. We attempted to prepare a 7-estradiol-tethered platinum complex, but the igand
synthesis proved problematic because of low product yields. An alternative would be to obtain a
more hydrophobic linker for attachement at the 17uc-position. Modification at this site is more
readily achieved, so a variety of linkers could easily be screened for ER binding affinity.
Hlowever, in light of the general failure of platinum-estrogen conjugates to target ER(+) cell
lines, attention should be focused on other targeting moieties such as peptides, carbohydrates, or
folic acid.
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Table 4.1. Selected estrogen-regulated genes in MCF-7 human breast cancer cells.)
Adapted from Lobenhofer, E.K., Bennett, L.l Cable, L., Li, L., Bushel, P.R., and Afshari
C.A., Mol. Enclocrinology (2002), 16: 1215-1229.
Function/Protein Affected
DNA Replcation/Repair
DNA polyrnerase c
DNA polymerase A
Uracil-DNA glycosylase
Dihydrofolate reductase
XRCC5
Transcription/Chromatin Structure
Sp3 transcription factor
HMGB 1
H2B
JUN B
STAT 1
Cell Cycle
Cdc28 protein kinase 2
Cyclin Dl
Cyclin A2
Tubulin
Cyclin-dep(endent kinase
Cellular Signaling
Protein kinase inhibitor [
Tyrosine kinase receptor C
Ephrin-A 1
TGF-32
Extracellular matrix/cell structure
Filamin B
l aminin 3
Vitronectin
Protein de-radation/Synthesis/Targeting
Karyopherin (x2
Heat shock I 0-kDa protein I
Mannose-6-phosphate receptor
_Aoptosis
Caspase 7
NF-KB
Am ,loid P precursor protein
Miscellaneous
Sterol A-7-reductase
Metal lothio ne in
Effect on Expression
+
++1-
+±+
+
+
+
+
+
" Increased expression is indicated by + and decreased expression is denoted by -.
_ · _ __
-
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Table 4.2. Binding affinity of BEEP for ERa and ER]A. BEEP was incubated with ER and ER at
4 C for 18 h. Free receptor-bound BEEP were separated by dialysis against PBS and the
concentration of the latter was determined by Pt AAS.
Sample [BEEP] (nM) [ER] (nM) [BEEP-ER] (nM) -Kd(nM)
ERa 830 83 71 970
ER13 830 83 0 --
HN,.O H
H3 N,,,.pt\CI 0
0 H3NI "'Cl
HO0
. _ -··--·-···IL-·----·--· _ . . ~ ~ _ A__ ... , . .- - - -_ ,H
NH2
OH -
HO
HO-
BEEP
Scheme 4.1
EDC, HOBt
DMF
141
A
HO
7(x
B
-NH
(CH2 )3 / N
CI
C
111 
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Figure 4.1. Compounds designed to target ER(+) cells: (A) 7(-Estradiol-tethered mustard4; (B)
Porphyrin-estradiol conjugate linked through the 11 3-position i; (C) 17(t-alkylamide-tethered
platinum(Il) estradiol conjugate. 16
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Control ~Estr:ldiol 17a-Ethynyle~tr:ldiol BEH
Figure 4.2. Expression of HMGB I as visualized by fluorescence microscopy. MCF-7 cells were
grown on glass coverslips and incubated with 200 nM B-estradiol, 17cl-ethynylestradiol, or
BEEP for 4 h at 37 e. The cells were fixed, permeabilized, and treated with a 1: 100 dilution of
anti-HMG B I antibody followed by a I: 100 dilution of anti-IgG antibody conjugated to FITe.
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Figure 4.3. Cytotoxicity of cisplatin with or without 17cx-ethynylestradiol co-treatment in MCF-7
cells. Cell survival was evaluated by the MTT assay. Error bars represent one standard deviation.
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Figure 4.4. IH NMR spectrum of BEEP in d6-DMSO.
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Figure 4.5. Survival of ER(+) MCF-7 and ER(-) HCC-1937 human breast cancer cells treated
with 0-20 tM BEEP as monitored by the MTT assay. Error bars represent one standard
deviation.
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Chapter 5
Targeting Platinum(IV) Complexes to Cancer Cells Through Folate Receptor-
Mediated Uptake
147
Introduction
The vitamin folic acid is essential for one-carbon transfer reactions and is required for nucleotide
base biosynthesis and cell growth. '" Mammalian cells cannot synthesize folic acid, therefore
efficient uptake mechanisms exist to ensure an adequate supply of the nutrient.2 The folate
receptor (FR) is responsible for the major folic acid uptake pathway. The mechanism for
receptor-mediated uptake of folic acid may involve via clathrin-coated pits, caveolae, or
submicron domains, but the exact process in unclear at present. 3-7 As shown in Figure 5.1, once
folic acid is internalized the pH of the encapsulating endosome drops to between 4.3-6.9,
releasing a portion of bound folate"'8 The remainder is recycled back to the extracellular
environment.' Although the efficiency of folic acid internalization is only 15-25%, folate-
receptor mediated endocytosis can import -2x 105 molecules per cell per hour.'
There are three isoforms of the folate receptor: FRct, FRP, and FRy.9 Both FRct and FRP
are anchored to the cell membrane through a glycosylphosphatidylinositol (GPI) linkage.
whereas the less abundant FRy lacks the GPI moiety and is soluble. ' 9 The c- and -isoforms
differ with respect to their affinities for folic acid and are differentially expressed. FRuc,
considered the high affinity isoform (Kd0.1 nM), is moderately expressed in the kidney,
placenta, and choroid plexus. The expression of the low affinity FRY isoform (Kd-l nM) is
limited to hematopoietic and non-epithelial cells (i.e., spleen, thymus).' In addition to expression
in normal tissue, both FRct and FRr5 are overexpressed in a variety of malignancies.' 7 "' l As
shown in Table 5.1, the distribution of FR isoforms varies considerably and FR(t is significantly
upregulated in a number of cancers including ovarian, uterus, endometrium, brain, kidney, head
and neck, and rnesothelium.1 2 In fact, overexpression of FRct is a marker for ovarian cancer. 3
The overexpression of FRfi is mostly limited to myelogenous leukemia and sarcomas.l
148
Because the expression of the FR is upregulated in such a wide variety of cancers,
targeting anti-cancer drugs through FR-mediated uptake is an attractive proposition. The
relatively low expression of the FR in normal tissue suggests that folate-tethered anti-cancer
compounds would be selectively taken up in malignant tissue, which would allow for higher
dosing with fewer side effects. '"12 In addition, the expression of the FR in healthy tissue is
limited to the apical membrane surface, meaning that the receptor is directed towards the body
cavity. Therefore, access to the FR is prohibited through the blood stream and primarily occurs
through the urine and airways. In malignant tissue epithelial cells lose their polarity and, as a
result, the FR is accessible to folate-tethered compounds in the blood.' In vivo studies with
radionuclide folate conjugates have confirmed high levels of uptake in tumor masses.7
Unfortunately, significant uptake of the radiolabeled folic acid also occurs in the kidneys, which
could result in unwanted nephrotoxicity. However, the high clearance rates of such compounds
make kidney toxicity less likely.7
The use of folic acid conjugation has provided many potentially useful compounds with
the ability to target cancer cells selectively in vitro and in vivo.7,14-'8 A cisplatin folic acid
conjugate may be particularly powerful for treating a variety of cancers. Previous work has
afforded a carboplatin folate conjugate; however, the compound failed with respect to enhanced
uptake and selective cytotoxicity.'9 One shortcoming of the compound was that the carboplatin
and folic acid moieties were connected through a polyethylene glycol (PEG) linker. Although the
use of PEG linkers have been successful in some cases, the bulky nature of the linker can result
in poor release from internalized endosomes.' 4 The stability of the carboplatin derivative in the
acidic environment of the endosome may also have contributed to the poor biological activity of
the compound. Therefore, our strategy in the present study was to synthesize a folic acid
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conjugate based on a platinum(IV) platform with a shorter linker. Use of platinum(IV) affords a
more stable compound with the potential to release unmodified cisplatin upon intracellular
reduction.20 The shorter tether also alleviates problems associated with poor release of PEG-
conjugates frorn endosomes. This chapter describes the synthesis and biological activity of the
target folate-tethered platinum(IV) complex.
Experimental
Materials. Potassium tetrachloroplatinate(11) was a gift from Engelhard. Cis, cis, trans-
diamminedichlorodisuccinatoplatinum(IV) was prepared as described previously. ° N-Boc-4 7,
10-trioxatridecane- 1, 13-diamine (BOC-TDA) was prepared as described in the literature and its
purity was confirmed by H NMR spectroscopy.21
Synthesis of Trioxatridecanediamine-folate (TDA-folate, Scheme 5.1). DCC (0.52 g, 2.5
mmol) and pyridine (190 [tL, 2.4 mmol) were added to a stirred solution of folic acid (1.2 g, 2.7
mmol) in 100 rnL of DMSO. After 15 min, BOC-TDA (1.7 g, 5.3 mmol) was added and the
solution was allowed to stir in the dark for 24 h at RT. The pyridine was removed under reduced
pressue and the DMSO by lyophilization to yield a sticky orange solid, which was washed with
30% acetone in ether. The BOC protecting group was removed by stirring in 10% TFA in
dichloromethane (100 mL) and the solvent under reduced pressure to afford an orange oil. The
crude product was resuspended in an aqueous solution of ammonium hydroxide (pH 9) for 2 h,
isolation by centrifugation, and dried in vaciuo to give a yellow solid (0.75 g, 1.2 mmol, 48%
yield); mp, decomposes above 150 C. H NMR (d6-DMSO, 300 MHz): 6 8.63 (s, H, ArH),
7.85 (m, IH, NH-), 7.60 (m, 3H, ArH), 7.00 (bt, IH, NH), 6.63 (d, 2H, ArH), 4.49 (d, 2H, CH,),
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4.20 (m, 1H, CH), 3.33 (m, 18H, CH,), 2.81 (t, 2H, CH2), 1.5-2.0 (m, 4H, CH,). HRMS (ESI)
calculated for [M+H] + 644.3151 amu, found 644.3165 amu.
Synthesis of a Monofolate-Tethered Platinum(IV) Complex (PMF, Scheme 5.2). A solution
of EDC (0.085 g, 0.44 mmol), NHS (0.051 g, 0.44 mmol), and cis, cis, trans-diamminedichloro-
disuccinatoplatinum(IV) (0.096 g, 0.22 mmol) was prepared in 10 mL of HO and allowed to stir
for 10 min. A solution of TDA-folate (0.11 g, 0.17 mmol) in water (10 mL) was added and the
solution was allowed to stir for 15 h at RT in the dark. The reaction solution was dialyzed against
5 mM sodium bicarbonate buffer (pH 9.0) to remove unreacted starting material (2-4x) and
subsequently desalted by dialysis against water (2x). A hydrated yellow powder (0.18 g, 0.15
mmol, 90% yield) was isolated upon lyophilization; mp, decomposes at 222 C. H NMR (D0,
500 MHz): 8.73 (s, 1H, ArH), 7.67 (d, 2H, ArH), 6.81 (d, 2H, ArH), 4.65 (s, 2H, CH,), 4.27 (m,
1H, CH), 2.63 (t, 4H, CH,), 2.40 (t, 4H, CH,). HRMS (ESI) calculated for [M+H]+ 1160.2970
amu, found 1160.2954 amu.
HPLC Analysis of CPG-Mediated Cleavage of TDA-folate. Carboxypeptidase-G (CPG)
digestion was carried out following a previously published methodology.22 Briefly, 500 ,LL of a
155 [tM TDA-folate solution in Tris buffer (150 mM, pH 7.3) was incubated with 0.5 units of
CPG in 250 L[L of Tris buffer for 24 h at 30 C. The cleavage of glutamic acid was followed by
RP HPLC (100% H20 to 50% acetonitrile over 30 min), monitoring absorbance at both 254 and
280 nm.
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FITC Conjugation of TDA-folate. A solution of TDA-folate (33 mg, 0.051 mmol) and FITC
(20 mg, 0.051 mmol) in 5 mL DMF was allowed to stir for 24 h at RT in the dark. An additional
75 mg (0.12 mmol) of TDA-folate was then added to ensure that no free FITC remained. The
FITC-conjugated TDA-folate was isolated by lyophilization and used without further
purification. The ratio of [folate]:[FITC] was found to be 3.65 as determined by UV/vis
spectrophotomeltry (folate £,82=22,600 M-lcm1 ; FITC E 4 9 4 =68,000 M-lcm-).
Cell Culture. HI-uman breast cancer MCF-7 and cervical cancer HeLa cells were purchased from
the American Type Culture Collection. BG-I ovarian carcinoma cells were a gift from J. Barrett
(NIH, MD). MCF-7, HeLa, and BG-I cells were grown in DMEM (GIBCO/BRL) supplemented
with 10% FBS (Hyclone), 1 mM sodium pyruvate, 100 units/mL penicillin, and 100 wtg/mL
streptomycin. All cells were incubated at 37 C under a 5% CO, atmosphere.
Uptake of FITC-Conjugated TDA-folate. Cells were grown to 80% confluence in 6-well plates
and incubated with 2.5 [tM of FITC-conjugated TDA-folate at 37 C for 0-6 h. Following
incubation, the cells were harvested, and washed extensively with PBS. For each sample, 104
cells were analyzed by fluorescence-activated cell sorting (FACScan, Beckton Dickinson) and
the resultant data were analyzed with CELL QUEST. Non-treated cells were referenced as the
control, with less than 5% of the cells exhibiting native fluorescence.
Whole Cell Uptake of Cisplatin and PMF. Cells were seeded onto 10-cm plates and grown
until 80-90% confluent. Cells were incubated with 10 [iM PMF for 4 h at 37 C, harvested, and
washed extensively with PBS. The total protein content was determined by the bicinchoninic
152
acid protein assay and platinum concentration by AAS. The degree of PMF uptake was
expressed as a ratio of platinum concentration (mg/L) to the total protein concentration (mg/L) of
the isolated cell pellet.
Cytotoxicity Studies. In a 96-well plate, cells were seeded at a density of 1000 cells per well in
100 LL of DMEM. After 24 h, the cells were either treated with 0-10 [LM cisplatin or 0-3 !M
PMF. The cells were incubated for 96 h at 37 C and evaluated for survival by the MTT assay.
Briefly, cells were treated with 20 [tL of 5 mg/mL MTT (PBS) and incubated for 5 h at 37 C.
The media was removed and the cells resuspended in 100-200 [tL of DMSO after which the
absorbance of each well was measured at 550 nm by a plate reader (SpectraMax 340 pc,
Molecular Devices). Percent cell survival was calculated for each concentration as the ratio of
the measured absorbance to that of the untreated wells.
Results and Discussion
Synthesis and Characterization of PMF
Initial attempts to prepare a platinum(IV) folate conjugate involved the use of an
ethylenediamine linker; however, the linker-modified folic acid compound had poor solubility in
most aqueous and organic solvents. Therefore, a longer, more hydrophilic linker was chosen. As
shown in Scheme 5.1, the linker-modified folate, TDA-folate, was readily obtained from the
DCC-mediated coupling of folic acid and BOC-TDA. HRMS confirmed the presence of the
desired linker-modified folic acid; the experimentally determined mass was in excellent
agreement with the calculated value (0.0002%).
153
The reaction of BOC-TDA with folic acid yields two isomers: ca- and y-linked
conjugates. In general, modification of the y-carboxyl group occurs more readily; however,
because the folate receptor binds y-modified folic acid more readily than c-modified conjugates,
it is necessary to quantify the ratio of the two isomers.22 LC-MS analysis of the TDA-folate
compound reveals the presence of two species of equal mass (m/z 644.3) with retention times of
11.8 (6 5%) and 13.4 (3 5%) min, indicating that both ct- and y-isomers are present. The ratio of
c- to y-isomers was determined by a CPG digestion assay; the enzyme cleaves only y-modified
folic acid.:2 As illustrated in Figure 5.2, upon incubation with CPG, the peak with a retention
time of 11.8 rain disappears, while the species with a retention time of 13.4 min remains
unchanged. Therefore, it is clear that the TDA-folate compound is 65% y-modified, which is
consistent with literature values for other folic acid synthetic conjugates. ~
C'is, cis, tr-ans-Diamminedichlorodisuccinatoplatinum(lV) and TDA-folate were coupled
to afford the desired folic acid conjugate using standard peptide coupling reagents (Scheme 5.2).
Purification of the conjugate is facile and achieved by dialysis against sodium bicarbonate buffer
(pH 9) using molecular weight 1000 cut-off dialysis tubing. When EDC and NHS were used to
prepare the folic acid conjugate, greater than 90% of the mono-substituted platinum(IV) complex
(PMF) was isolated before purification. The presence of PMF was confirmed by H NMR
spectroscopy and ESI-HRMS. The PMF compound is only moderately soluble in DO, so a high
quality NMR spectrum was not obtained; however, the results provide quantitative evidence for
the presence of one folate moiety for each platinum center. As shown in Figure 5.3, the
integration of the succinate protons (H6 and H7) is twice that of the integration of the p-
aminobenzoic acid protons (H3 and 1-H4). Finally, the experimentally determined mass was in
excellent agreement with the calculated value (0.0001%). The purity of PMF as evaluated by
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HPLC is shown in Figure 5.4. When subjected to HPLC, significant decomposition of PMF
occurs. Product decomposition was proven by comparing the chromatographs of the original
PMF sample (Fig. 5.4, left trace) to that of a HPLC-purified sample (Fig. 5.4, right trace). Both
traces contain extraneous peaks with similar retention times.
Cellular Uptake of FITC-Conjugated TDA-Folate
The expression of the FR was evaluated by monitoring the uptake of FITC-conjugated TDA-
folate in BG-1, MCF-7, and HeLa cells by FACS. In general, the expression of the folate
receptor correlates with the uptake of folic acid. 1- 9' 22" ' 3 Cells were incubated with 2.5 [tM FITC-
conjugated TDA-folate for 0-6 h at 37 C and the cellular fluorescence was subsequently
determined. As illustrated in Figure 5.5, the uptake of the FITC-labeled TDA-folate is
moderately cell-line dependent. The level of folate uptake increases as MCF-7<HeLa<BG-I.
After a 6 h incubation 67% of BG-I have internalized the modified folic acid, compared to only
57% of MCF-7 cells.
Cytotoxicity of Cisplatin and PMF Toward HeLa, MCF-7, and BG-1 Human Cancer Cells
The cytotoxicity of PMF was determined in HeLa human cervical cancer, MCF-7 human breast
cancer, and BG-I human ovarian cancer cells and compared to the biological activity of
cisplatin. These three cell lines were chosen because of known overexpression of the folate
receptor in cervical, breast, and ovarian cancers. Figures 5.6, 5.7, and 5.8 show cell survival plots
for cisplatin and PMF in BG-1, HeLa, and MCF-7 cells, respectively. It is evident that PMF is
significantly more cytotoxic than cisplatin in each cell line. In addition, the PMF compound is
100-fold more cytotoxic than the previously reported folate-tethered carboplatin analogue. 19
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Examination of the ratio of IC5so (M) values for cisplatin and PMF reveals a cell line-
dependent trend (see Table 5.2). Furthermore, the cytotoxicity data correlate with the uptake of
the FITC-conjugated TDA-folate. In BG-I cells, PMF is nearly 10 times more cytotoxic than
cisplatin, whereas, PMF is only 6 times as active as cisplatin in MCF-7 cells. This observation
supports the conclusion that PMF activity is a consequence of folate-receptor mediated uptake. It
is noteworthy that PMF is particularly active against the BG-1 human ovarian cancer cell line.
As mentioned earlier, overexpression of the folate receptor is a marker for ovarian cancer. A
compound that could selectively target ovarian cancer cells would be extremely valuable given
the fact that ovarian cancer causes more deaths than any other cancer of the female reproductive
system.'4 In 2005, it is expected that over 20,000 new cases of ovarian cancer will be diagnosed
and more than 40,000 woman will succumb to the disease. 24
Mechanism of Action
The cytotoxicity of PMF can be attributed to folate receptor-mediated uptake of the cytotoxic
agent, and not related to any additional biological activity conferred by folic acid. To test this
hypothesis, the effect of folic acid on the cytotoxicity of cisplatin was independently examined.
Cotreatment of' HeLa, BG-1, and MCF-7 cells with folic acid and cisplatin did not alter the
cytotoxicity of the platinum compound (data not shown). Therefore, the cytotoxicity of PMF is
probably not affected by release of the modified folic acid. However, amide hydrolysis of TDA-
folate to yield folic acid inside the cell is expected to be slow; so additional control experiments
with cotreatment of cells with TDA-folate are planned.
The cellular uptake of PMF in HeLa, BG-1, and MCF-7 was evaluated and compared to
that of cisplatin. Cells were incubated with 10 LtM PMF, 10 tM PMF + 200 itM folic acid, or
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10 [tM cisplatin for 4 h at 37 C, washed with PBS, and harvested. The whole-cell platinum
content was determined by platinum AAS and compared to total protein in the isolated cell
pellet, estimated by the BCA assay. The results are summarized in Table 5.3. In MCF-7 and
HeLa cells, uptake of PMF is essentially equivalent to the uptake of cisplatin. In addition, the
uptake of PMF is unaffected by the addition of free folic acid. In BG-I cells, the amount of
PMF internalized is twice that of cisplatin; however, the uptake of PMF is only slightly affected
by competition with free folic acid. It is not surprising that PMF uptake is greatest in BG-1 cells,
the most sensitive cell line. Previous studies of cisplatin passage into in an ovarian cell line
revealed that the rate of passive diffusion was -5x107 molecules per cell per hour, which is over
200 times faster than folate receptor-mediated endocytosis.25 Therefore, comparison of PMF and
cisplatin uptake levels may not allow for differentiating passive diffusion from an active
transport mechanism. It seems unlikely, however, that PMF uptake would occur by passive
diffusion because the molecule has a molecular weight over 1000 and is a dianion at pH 7.
Similar uptake experiments with the anionic P MF precursor cis, cis, trans-
diamminedichlorodisuccinatoplatinum(IV) did not reveal any detectable internalization of the
compound, supporting an active transport mechanism for PMF.
Based on their similar uptake levels, it is unclear why PMF is more cytotoxic than
cisplatin. One possibility is a difference in stability in culture media between the two
compounds. Over time, platinum(II) compounds are inactivated in culture media through binding
to components of fetal bovine serum, such as albumin.:6 On the other hand, platinum(IV)
compounds are exceedingly stable in culture media.26 Therefore, during long incubation times
cells will continue to internalize biologically active PMF, while cisplatin will be protein-bound
and unable to bind to DNA. It is possible that the enhanced cytotoxicity of PMF is due both to
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increased stability of the platinum(IV) compound and to folate receptor-mediated uptake.
Another possibility is that cisplatin is not internalized as efficiently as PMF and binds to the
cellular membrane. In order to evaluate this possibility, experiments to determine nuclear
platinum levels after cisplatin and PMF treatment are planned.
Conclusions and Future Directions
The folic acid-tethered platinum(IV), PMF, was synthesized and characterized by HRMS and
HPLC. Its cytotoxicity was evaluated in MCF-7, HeLa, and BG-I human cancer cell lines and
compared to the biological activity of cisplatin. PMF is significantly more cytotoxic than
cisplatin in each cell line. Furthermore, the ratio of cisplatin to PMF cytotoxicity correlates with
the ability of each cell line to internalize FITC-conjugated folic acid. PMF had enhanced cellular
uptake as compared to cis, cis, trans-diamminedichlorodisuccinatoplatinum(IV), but had uptake
levels similar to those of as cisplatin. The mechanism of PMF cytotoxicity remains to be
determined.
The in vitro cytotoxicity of PMF may be enhanced by purification of the y-conjugated
isomer. As discussed earlier, the ca- and y-conjugated TDA-folate compound can be separated by
HPLC and subsequently allowed to react with cis, cis, trLans-diamminedichlorodisuccinato-
platinum(IV). Additional in vitro studies should also be carried out in cell lines that express little
to no folate receptor. If the mechanism of action of PMF involves enhanced uptake, then cell
lines without the folate receptor should be less sensitive to PMF.
The ability of PMF to selectively target cancer cells can be further tested by animal
studies. One concern with PMF is whether it is stable enough in the blood to allow for selective
targeting of tumors. Biotransformation studies with c is, trans, cis-
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[PtCl2(OAc)2NH3(c-C6HIINH,)], or JM216, revealed that the compound is reduced to a variety
of platinum(lI) metabolites in blood within 15 min.27 On the other hand, two trans-dihydroxy
platinum(IV) compounds were stable in the blood serum and reduced intracellularly to yield the
active platinum(11) metabolites.27 In order to achieve selective targeting in vivo the platinum folic
acid conjugate must remain intact until it is internalized by folate receptor-mediated endocytosis.
Therefore, a compound with a lower reduction potential may be valuable to test in animal
studies. As shown in Figure 5.9, two other folate-tethered platinum complexes have been
designed to obtain a compound with greater stability in blood serum. The first compound,
PMFII, is based on PMF with one axial succinate ligand being replaced with a hydroxyl group.
This modification should afford the PMFII complex with a lower reduction potential than that of
PMF. The second compound, PMFIII, is based on the previously reported carboplatin folic acid
conjugate; however, PMFIII contains the smaller trioxatridecanediamine linker instead of the
PEG-based linker used in the previously described compound. 19 Furthermore, the platinum(II)
folate complex will be oxidized with hydrogen peroxide yielding a stable trans-dihydroxy
platinum(IV) compound. The resultant platinum(IV) folic acid conjugates (PMF-PMFIII)
should afford valuable a series of compounds for in vivo evaluation.
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Table 5. 1. Expression of FRu and FRfi is normal and malignant tissue. The levels of FRca and
FRf are given in arbitrary units that reflect the receptor mRNA levels with respect to an internal
standard. Adapted from Ross, J.F., Chaudhuri, P.K., and Ratnam, M., Cancer (1994), 73, 2432-
2443.
Tissue
Normal ovary
Ovarian carcinoma
Normal uterus
Uterine carcinoma
Normal colon
Colon carcinoma
Normal kidney (case 1)
Normal kidney (case 2)
Normal kidney (case 3)
Kidney carcinoma (case 1)
Kidney carcinoma (case 2)
Normal lung
Lung carcinoma (case 1)
Lung carcinoma (case 2)
Normal brain
Meningioma (brain tumor)
Osteosarcoma
Uterine sarcoma
Lymrphoma (case 1)
Lymnphoma (case 2)
FRcc FRfi [ 3H] Folic acid bound
(pmol/mg protein)
0.3 2.2 0.6
30.9 4.9 28.4
<0.2 3.5 <0.2
58.5 2.5 72.1
0.9 3.2 1.3
1.1 0.8 0.6
7.2 0.8 NDa
2.6 2.3 ND
<0.2 0.8 ND
23.3 1.5 ND
3.5 1.7 ND
7.1 0.8 ND
92.0 10.5 ND
0.6 1.1 ND
0.7 3.5 0.4
3.2 45.0 21.0
<0.2 45.3 16.0
<0.2 24.9 10.6
0.3 10.7 4.2
13.8 8.7 23.0
a ND: Not determined
I· _ _ _ _ _ _
_____ ILI
·· __ ____
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Table 5.2. IC50o (M) values for cisplatin and PMF in BG-1, MCF-7, and HeLa cells
Cell line Cisplatin PMF Cytotoxicity Ratio
(Cisplatin:PMF)
BG-1 2.4-0.4 0.25±0.04 9.6
MCF-7 1.4+0.01 0.22±0.04 6.4
HeLa 1.6±0.2 0.22±0.04 7.3
163
Table 5.3 Uptake of cisplatin and PMF in MCF-7, HeLa, and BG-I cells. Uptake levels are
expressed as the ratio of platinum (mg/L) to protein concentration (mg/L).
Sample [platinum]/[protein] x 105
MCF-7 Cells
Cisplatin 2.0
PMF 1.7
PMF + folic acid 2.0
HeLa Cells
Cisplatin 1.9
PMF 1.6
PMF + folic acid 2.5
BG-1 Cells
Cisplatin 1.3
PMF 3.0
PMF + folic acid 2.8
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Figure 5.1. Folate receptor-mediated uptake of folic acid conjugates. Folic acid binds the folate
receptor and is subsequently internalized by an endocytotic pathway. The pH of the endosome
drops, thereby releasing folic acid from the receptor and then the endosome. Folic acid that
remains receptor-bound is recycled back the the extracellular environment. Adapted from
Yingjuan, L., Low, P.S., Advanced Drug Delivery Reviews (2002),54,675-693.
y-conjugated
/
. a-conjugated
/
167
a-conjugated
digestion
/products
~ooo n.0I .. ~ .. "00 MOl 2201 24 .. 2100 Hoe ....
Figure 5.2. Analysis of the CPG digestion of TDA-folate by RP HPLC (100% H20 to 50%
acetonitrile over 30 min). The left panel shows the HPLC trace before digestion and clearly
reveals the presence of two species. Mass spectrometry confirmed that the two peaks were of the
two isomers. The right panel shows the HPLC chromatogram following CPG digestion. The y-
conjugated isomer is completely digested, while the a-isomer remains unchanged. The
distribution of isomers is 35% a- and 65% y-conjugated.
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Figure 5.3. IHNMR (500 MHz) of PMF in D20.
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Figure 5.4. Purity analysis of PMF by HPLC. The left chromatogram shows the trace of PMF
purified by dialysis, while the right trace is of PMF further purified by HPLC. Peaks labeled
with an asterisk on the left trace are attributed to product decomposition on the HPLC column
because they also appear on the trace of the HPLC-purified sample (right).
170
* HeLa
*BG-I
A MCF-7
.
.
U
A
.
A
A
1 2 3 4
Time (h)
5 6
Figure 5.5. Uptake of FITC-conjugated folic acid as monitored by flow cytometry. Cells were
incubated with 2.5 tM FA-FITC at 37 C for 0-6 h, harvested, and analyzed by FACS.
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Figure 5.6. Cytotoxicity of cisplatin and PMF in BG- I1 human ovarian cancer cells as determined
by the MTT assay.
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Figure 5.7. Cytotoxicity of cisplatin and PMF in HeLa human cervical cancer cells. Percent cell
survival determined by the MTT assay.
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Figure 5.8. Ctotoxicity of cisplatin and PMF in MCF-7 human breast cancer cells as
determined by the MTT assay.
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Figure 5.9. Schematic diagram of two proposed platinum folic acid conjugates designed to have
greater in vivo stability.
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Chapter 6
Effect of Ex ogenous HMGB1 on the Sensitivity of HeLa and MCF-7 Cells to
Cisplatin and trans-DDP
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Introduction
HMGB1 is a ubiquitous and abundant (106 copies per cell) nuclear protein that contains two
tandem homologous DNA-binding domains and a glutamate- and aspartate-rich C terminus.
HMGB 1 binds primarily to the minor groove of DNA with little or no sequence specificity, but
preferentially recognizes distorted structures including 4-way junctions and cisplatin-damaged
DNA. Although the exact function of HMGB1 in the nucleus is unknown, its interaction with
transcription factors such as Hox and Pou proteins, p53, TBP, and steroid hormone receptors
increases their binding affinity with their respective target DNA sequences.2 HMGB1 has long
been thought to act only as an intracellular architectural transcription factor; however, recent
research has revealed its role as an extracellular cytokine, uncovering an unexpected new
function of the protein.'
HMGB1 is loosely associated with chromatin and readily leaks into culture medium
when a cell is permeabilized or undergoes necrosis.3 Conversely, HMGB I remains tightly bound
to chromatin during apoptosis.3 Monocytes and macrophages actively secrete HMGB I by hyper-
acetylating the protein in order to direct it for export.4 Once secreted from the cell, binding of
HMGB1 to RAGE, the receptor for advanced glycation end products, signals for a variety of
cellular events that ultimately effect cell motility, metastatic pathways, activation of NF-KB, and
the production of other cytokines. 1 '25 '7 The extracellular presence of HMGB1 has been
connected to a variety of disease states, such as inflammation, sepsis and arthritis.8'"' Both
RAGE and HMGB1 are overexpressed in a variety of tumors, including colorectal, breast,
prostate, and gastrointestinal cancers, and are suggested to be important in cancer
progression. 6 7,1 Furthermore, inhibition of RAGE/HMGBI signaling cascades slows tumor
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growth and metastasis in human tumor xenograft bearing mice.6 As a cytokine, HMGB1 appears
to be a mediator of inflammation, sepsis, and stem cell recruitment. '0 " ' 3
HMGBI has been connected to the biological activity of cisplatin in a number of
studies.'4 ' Formation of cisplatin 1,2-d(GpG)-intrastrand cross-links distorts the DNA duplex,
giving rise to a wide and shallow minor groove that serves as a recognition site for HMG domain
binding.'6 Interaction of HMGBI with cisplatin-damaged DNA prevents nucleotide excision
repair (NER) of the platinum adducts in vitro and therefore is proposed to drive apoptosis in
v'ivo. 17 NER of DNA damaged by the clinically inactive isomer tran.s-DDP is not affected by the
presence of HM4GB1.17 In support of such a repair-shielding hypothesis, steroid hormone-
induced overexpression of HMGB1 sensitizes cells by a factor of two to cisplatin, but not to
trians-DDP treatment.I s Furthermore, silencing of HMGB1 expression by RNA interference in
HeLa human cervical cancer cells decreases cisplatin sensitivity by 2.8-fold.' 9 On the other hand,
overexpression of HMGB I has been linked to cisplatin-resistance and inhibition of apoptosis in
mammalian cells, suggesting dual roles or cell-type specific action of the protein. ° '
The ability of HMGB I to act as a cytokine leads us to propose a mechanism by which the
extracellular protein might mediate the cisplatin sensitivity of solid tumors. As shown in Figure
6. 1, the vasculature of malignant growths cannot support the entire tumor and, as a result, the
core is starved of nutrients and oxygen and dies by a necrotic pathway. The necrotic core of the
tumor passively releases HMGBI, which could enter surrounding cells and enhance the
cytotoxicity of cisplatin, either by preventing NER of platinum-DNA adducts or otherwise
interfering with tumor cell biology. HMGBI has been demonstrated to be a non-viral gene
delivery agent, suggesting that the protein can indeed permeate cells. 23 To evaluate our
hypothesis, we investigated in the present study the consequences of exogenous HMGB1 on
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HeLa human cervical and MCF-7 human breast cancer cells by flow cytometry and western blot
analysis. In addition, the ability of extracellular HMGB1 to sensitize cells to cisplatin and the
clinically ineffective isomer trans-DDP was examined.
H3N,. Pt' ' Cl,,. pt,,,NH 3
H3 N'" ClI H3N ' 'Cl
cisplatin trans-DDP
Experimental
Materials. Recombinant rat HMGB 1 was expressed and purified from Escherichia coli.2 4 The
expression of HMGBI was silenced in HeLa cells by constitutively expressing short hairpin
RNA from a plasmid vector.19 MCF-7 and HeLa cells were purchased from ATCC. Cisplatin and
trans-DDP were prepared according to literature procedures from potassium
tetrachloroplatinate(11), a gift from Engelhard.'5 6
Cell Culture. MCF-7 and HeLa cells were grown in DMEM (GIBCO/BRL) containing 10%
FBS (GIBCO/BRL), 4 mM glutamine, 100 units/mL penicillin, and 100 [tg/mL streptomycin.
HMGBl-silenced HeLa cells were grown in DMEM (GIBCO/BRL) supplemented with 10%
FBS, 100 [ig/mL zeocin (Invitrogen), 4 mM glutamine, 1 mM sodium pyruvate, and 100
units/mL penicillin, and 100 [tg/mL streptomycin. All cells were incubated at 37 C under a 5%
CO, atmosphere.
Monitoring Expression Levels of HMGB1 by Immunofluorescence Microscopy. HeLa cells
were grown to 70% confluence on 12-mm glass cover slips in 24-well plates. The cells were then
treated with 2-4 nM HMGB1 and incubated for 0 to 48 h. The cells were then permeabilized with
25% acetic acid in methanol for 10 min at RT, washed with PBS, and incubated with a 1:100
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dilution of anti-HMGB polyclonal antibody (PharMingen) for I h at 37 C. The cells were
subsequently treated with a 1:100 dilution of goat anti-rabbit IgG conjugated to FITC (Biosource
International) for I h at 37 C. The coverslips were then placed on microscope slides, fixed with
glycerol containing 0.1% p-phenylenediamine, and incubated at 4 C for 12 h. HMGB1 levels
were then visualized under a fluorescent light Nikon Eclipse TS100 microscope using a FITC-
HYQ filter cube (excitation 460-500, bandpass 510-560 nm). Images were captured using an RT
Diagnostics camera operated with Spot Advanced software.
Fluorescent Microscopy of Cells Treated with FITC-conjugated HMGB1. Recombinant
HMGBI was fluorescently labeled using FluoReporter FITC protein labeling kit (Molecular
Probes). Briefly, 200 [tl, of 2.5 mg/mL HMGBI were mixed with 20 [tL of I M sodium
bicarbonate buffer (pH 9). Reactive dye solution in DMSO (37 glL) was added to the stirring
protein solution and the reaction was allowed to stir for an additional I h at RT in the dark. The
FITC-conjugated protein was purified by extensive dialysis and analyzed by UV-visible
spectroscopy.
HeLa cells were grown to 70% confluence on 12-mm glass cover slips in 24-well plates.
The cells were treated with 2 nM to I KUM portions of HMGB I and incubated for 4-48 h at 37 C.
The cells were then washed with PBS and HO, mounted on microscope slides using glycerol
containing 0.1% p-phenylenediamine, and stored at 4 C for 12 h. Cells were imaged as
described above.
Uptake of Extracellular HMGB1 by Flow Cytometry. MCF-7 and HeLa cells were incubated
with 100 nM FITC-conjugated HMGBI at 37 C for 1-48 h, harvested by trypsinization, and
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washed copiously with PBS. For each sample, 10,000 cells were analyzed by fluorescence-
activated cell sorting (FACScan, Beckton Dickinson) and the resultant data were manipulated by
using CELL QUEST. Non-treated cells were gated as the control, with approximately 1% of the
cells exhibiting native fluorescence.
Uptake of Extracellular HMGBI by Western Blot Analysis.
Preparation of Nuclear and Cytosolic Extracts. HMGB1-silenced HeLa cells were grown to
70% confluence in 10-cm dishes and then for an additional 48 h in the presence or absence of 10-
500 nM extracellular HMGBI . The cells were harvested, collected by centrifugation for 5 min at
450 x g, and washed twice with PBS. The cells were resuspended in 100 tIL of lysis buffer (10
mM Hepes pH 7.9, 1.5 mM MgCI2, 10 mM KCI, 1 mM DTT, and 1 mM PMSF) and incubated
on ice for 15 min. The cell suspension was centrifuged for 5 min at 420 x g. The supernatant was
discarded and the cell pellet was resuspended in 20 LtL of lysis buffer. The cell pellet was
subsequently disrupted with 10 strokes from a narrow-gauge needle and centrifuged at
10,000 x g for 20 min at 4 C. The supernatant (cytosolic extract) was transferred to a new tube,
snap frozen, and stored at -80 C until use. The resultant crude nuclear pellet was resuspended in
10 tL of extract buffer (25% glycerol, 0.2 mM EDTA, 420 mM NaCl, 1.5 mM MgCI2, 20 mM
Hepes pH 7.9, 1 mM DTT, and I mM PMSF) and disrupted as described above. The suspension
was shaken at 4 C for 30 min, centrifuged at 20,000 x g for 5 min, and the supernatant (nuclear
extract) was transferred to a fresh tube, snap-frozen, and stored at -80 C until use.
Western Blot Protocol. For examination of HMGB I levels, cytosolic and nuclear extracts were
thawed and allowed to come to 4 C before analysis. For analysis of RAGE expression, whole
cell pellets were lysed in SDS-PAGE sample buffer (60 mM Tris-HCI pH 6.8, 10% glycerol, 2%
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SDS, 0.025% bromophenol blue, and 0.7 M 2-mercaptoethanol) at 95 C for 15 min. Proteins
were separated by SDS-PAGE for 90 min at 150 V on a BioRad 4-20% Tris-HCl Ready-Gel. The
separated proteins were then transferred to a PVDF membrane at 100 V for 60 min, blocked with
TTBS + 5% milk for 90 min, and probed with a 1:2,000 dilution of anti-HMGB1 polyclonal
antibody (Upstate), a 1:20,000 dilution of anti-actin polyclonal antibody (Upstate), or a 1:1000
dilution of anti-RAGE polyclonal antibody (Chemicon) O/N at 4 C. The PVDF membrane was
washed with TTBS + 5% milk and incubated with a 1:3,000 dilution of anti-rabbit-HRP
(HMGB1 and RAGE, Amersham Biosciences) or anti-mouse-HRP (actin, Bio-Rad) secondary
antibody for I h at RT. The PVDF membrane was then incubated with ECL western blotting
detection solution (Amersham Biosciences) for 90 sec and blotted dry. Proteins were then
detected by exposing the PVDF membrane to BioMax MR autoradiography film (Eastman
Kodak Co.).
Cytotoxicity Assays. Cell survival was analyzed by the MTT assay.27 Cells were seeded into 96-
well plates at a density of 250-500 cells per well. After 24 h, cells were treated with 2 nM-I ftM
of HMGB I or were left untreated and further incubated at 37 C for 48 h. Cells were then treated
with either 0-20 tM cisplatin or 0-500 ptM trans-DDP. After incubation for 96 h, 20 ItL of a 5
mg/mL NITT (Sigma) solution in PBS was added to each well and incubated at 37 C for 5 h.
The media was then removed from each well and the cells redissolved in 100-200 tL of DMSO.
The absorbance of each well was measured at 550 nm by a plate reader (SpectraMax 340pc,
Molecular Devices). Percent cell survival was calculated for each concentration by the ratio of
the measured absorbance to the absorbance of the untreated cells.
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Effect of MAPK Inhibitors on the Cytotoxicity of Cisplatin and trans-DDP. Cytotoxicity
assays were setup as described in the previous section. After incubation of MCF-7 or HeLa cells
with 10 nM or I tM of HMGBI for 44 h, the cells were further treated with either 1 [tM of SKF-
86002 (Calbiochem), 40 nM of JNK Inhibitor 11 (Calbiochem), or 2.5 LiM of ERK Activation
Inhibitor Peptide I (Calbiochem) for 4 h at 37 C before treatment with cisplatin or trans-DDP.
Cell survival was determined by the MTT assay.
Effect of Necrotic Media on the Cytotoxicity of Cisplatin and trans-DDP. MCF-7 or HeLa
cells (75 cm2 flask, -10 7 cells) were frozen at -80 C and then rapidly thawed at 37 C. This
cycle was repeated 4 to 6 times, after which the cells were incubated at 37 C for an additional I
h. The media bathing the necrotic cells was isolated by centrifugation of the cellular suspension
at 1,500 rpm for 10 min at 4 C and filtering the supematant through a 0.2 A[m Millipore filter.
The media was used immediately for cytotoxicity assays. Cells were seeded into 96-well plates
at a density of 250-500 cells per well in 100 tL regular or necrotic media. After 48 h, cells were
treated with 0-20 [tM cisplatin and allowed to incubate for an additional 96 h. Cell viability was
assayed by the MTT assay.
Results and Discussion
The chromasomal protein HMGBI is actively secreted as a pro-inflammatory cytokine from
macrophages and monocytes and passively released from necrotic cells.' 4 We have examined the
ability of extracellular HMGB I to be taken up in cultured cells and to mediate the cytotoxicity of
cisplatin and trans-DDP. The effect of extracellular HMGB I on the cytotoxicity of platinum
compounds depends on the cell line and the mechanism by which HMGB I alters the cytotoxicity
of cisplatin and trans-DDP is platinum-compound specific.
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Cellular Uptake of Exogenous HMGB1
The levels of exogenously administered HMGBI were examined in HeLa cells by
immunofluorescence microscopy. HeLa cells were incubated with 2-4 nM HMGB1 for 0.5 h-48
h. As shown in Figure 6.2, the fluorescence signal from the antibody-labeled HMGB 1 increases
after 41.5 h and maximizes at 48 h. Because of the high background associated with
immunoftilorescence techniques, HMGBI was labeled with a fluorescent tag to facilitate the
imaging of its uptake. As shown in Figure 6.3A, micromolar concentrations of the FITC-labeled
-MGBI were required for imaging. Time-course experiments showed that intracellular HMGB1
levels begin to increase after as little as 4 h. Figure 6.3B illustrates that uptake of FITC-HMGB I
increases with longer incubation times and appears to maximize at -50 h. The FITC-labeled
HMGBI appears to accumulate in both the nucleus and the cytoplasm. Wheras the
immunofluorescence and fluorescent microscopic data provide evidence for HMGB 1 uptake, the
kinetics seemed slow and assignment of the cellular localization of the labeled protein was
tenuous, at best. Therefore, the HMGB I uptake was further investigated by flow cytometry and
western blot analysis.
The kinetics of HMGB1 uptake in MCF-7 and HeLa cells were analyzed by flow
cytometry. In -leLa cells, HMGB1 internalization maximizes after 8-10 h incubation with the
FITC-labeled protein. More than 80% of HeLa cells incorporate FITC-labeled HMGB I after 8 h,
and the levels of HMGBI remain constant for 48 h. As shown in Figure 6.4, the kinetics of
HMGB1 uptake are considerably slower in MCF-7 cells. Maximum uptake of FITC-HMGB1
occurs after incubation for 18 h at 37 C. In addition, the number of MCF-7 cells that take up
FIT'C-HMGBI is much lower than for HeLa cells. After an 18 h incubation period with FITC-
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HMGB1, only 40% of the MCF-7 cells internalize the extracellular protein. The level of
HMGB 1I uptake remains constant after incubation for 48 h.
Uptake of extracellular HMGBI was also confirmed by western blot analysis. HeLa-
HMGB1 silenced cells were incubated with either 0 nM, 20 nM, 100 nM or 500 nM of HMGB1
for 48 h. Accumulation of HMGBI was readily observed in whole cell extracts of HMGBI-
silenced HeLa cells (see Figure 6.5A). The distribution of HMGB1 was further examined by
preparation of nuclear and cytosolic extracts from HMGB 1-silenced HeLa cells treated with 500
nM of HMGB I (see Figure 6.5B). The western blot of cell extracts from HMGB I-silenced HeLa
cells show the presence of protein in both the cytoplasm and the nucleus of the protein-treated
cells.
The utility of HMGB 1 as a non-viral gene delivery agent was previously explored. 2 3'2 It
is therefore not unexpected that HMGB I would be cell permeable. DNA packaged with HMGB 1
was efficiently transfected into several mammalian cell types and was observed to accumulate in
the nucleus of the transfected cells. In mouse Ltk- cells, approximately 40% of transfected cells
accumulated the HMGB1/DNA complex in the nucleus, which is similar to the degree of uptake
observed in MCF-7 cells in the present study.' 8 The variable degree of HMGB1 uptake
demonstrates a potentially critical difference between MCF-7 and HeLa cells. Endocytosis has
been proposed as the mode of HMGB1 uptake; however, both the mechanism of HMGBI
facilitated transfection and uptake have yet to be elucidated. 3' 28
HMGB1 is known to bind RAGE, but it is not clear whether RAGE mediates the uptake
of the extracellular protein or is only involved in mediating signal transduction pathways. '930
The expression of RAGE was examined and compared to actin in MCF-7 and HeLa cells (see
Figure 6.5C). RAGE is present primarily as a transmembrane receptor, but also occurs as several
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truncated soluble forms.' These species account for the presence of the three bands observed by
western blot analysis. The expression levels of RAGE in MCF-7 and HeLa cells do not parallel
the uptake of IHMGB1 in the two lines. Although MCF-7 and HeLa cells express equivalent
levels of RAGE, internalization of HMGBI is twice as efficient in HeLa cells. Therefore, it
seems unlikely that RAGE is responsible for mediating the uptake of HMGB 1. Other candidates
for receptor-mediated HMGBI uptake are the Toll-like receptors. HMGBI has recently been
established as a ligand for TLR2 and TLR4; however, to our knowledge neither receptor has
been connected to uptake of extracellular molecules. 31 As with RAGE, TLR2 and TLR4
facilitate signal transduction pathways induced by extracellular cytokines. 31
Effect of Extracellular HMGBI on the Cytotoxicity of Cisplatin and trans-DDP
The ability of exogenous HMGBI to be taken up by HeLa and MCF-7 cells suggested that its
presence in the extracellular medium may alter their sensitivity to cisplatin. In HeLa cells,
control experiments with HMGB I showed no protein-induced toxicity at concentrations up to I
[ItM. Cotreatment of HeLa cells with 10 nM-I [tM HMGBI and cisplatin did not effect the
cytotoxicity of the latter over the 0-10 [M concentration range. Pretreatment of HeLa cells for
48 h with I LtlvI HMGB 1, however, led to increased sensitivity toward the drug. As shown in
Figure 6.6A, 48 h pretreatment of HeLa cells with I [tM HMGB I enhances cisplatin activity by
1.8-fold at the IIC5) value and by more than 5-fold at IC70.
Modulation of cisplatin cytotoxicity by extracellular HMGB I was also studied in MCF-7
cells. Control experiments with HMGBI revealed that the protein is not cytotoxic in these cells
at low concentrations (less than 10 nM); however, treatment with 100 nM or I LtM HMGB1
reduces cell viability by 30%. Pretreatment with 2 nM HMGBI does not effect cisplatin
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cytotoxicity, whereas incubation with 5-10 nM HMGB1 for 48 h sensitizes MCF-7 cells towards
cisplatin exposure (Figure 6.7A). As summarized in Table 6.1, a 3.0-fold enhancement in
cisplatin cytotoxicity at C50 was achieved upon pretreatment with 10 nM HMGB 1.
The mechanism of HMGB1-induced sensitization of cells to cisplatin is cell-line
dependent. One possibility is that the exogenous HMGBI in the nucleus recognizes and binds to
the cisplatin-DNA 1,2-intrastrand cross-links, shielding them from NER. Evidence for the repair-
shielding hypothesis has been previously demonstrated in both cell lines. HeLa cells with
HMGB1 expression silenced by RNAi are nearly 3-fold resistant to cisplatin compared to wild-
type cells.' 9 In MCF-7 cells, steroid hormone-induced overexpression of HMGB I enhances the
cytotoxicity of cisplatin treatment by two-fold. 8 Although HeLa cells accumulate more HMGB 
than MCF-7 cells, it seems that the protein is not as available for DNA binding in the former
cells. A large amount of protein (1 E[M) is required to sensitize HeLa cells to cisplatin, whereas
as little as 5 nM exogenously administered HMGBI significantly enhances cisplatin cytotoxicity
in MCF-7 cells. It is possible that, in HeLa cells, HMGB1 must be post-translationally modified
in order to interact with cisplatin-modified DNA. In fact, acetylated-HMGB1 binds cisplatin-
damaged DNA with greater affinity than the unmodified protein.32
Co-treatment of MCF-7 or HeLa cells with HMGB I1 and cisplatin does not sensitize them
to the drug. This observation suggests that uptake of HMGBI is a prerequisite for achieving
enhanced cisplatin cytotoxicity. Previous studies demonstrated the importance of the kinetic
factors for HMGBI upregulation as a determinant of cisplatin-induced cytotoxicity.l8 In order
for repair-shielding to occur, the levels of HMGB 1 must be sufficiently elevated at the time of
platinum-damage formation so that HMGB I binding can occur prior to repair of the platinum-
damaged DNA. Therefore the need to pre-treat the MCF-7 and HeLa cells with HMGB in order
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to achieve maximally enhanced cisplatin cytotoxicity can be explained by the relatively slow (8-
1 8h) uptake of the protein. Thus repair shielding is a viable model to explain these results.
In order to evaluate further the repair-shielding hypothesis, the effect of extracellular
HMGBI on the cytotoxicity of trans-DDP was determined. Unlike cisplatin, trcans-DDP is
unable to form 1,2-(GpG)-intrastrand DNA cross-links. Therefore, trln.s-DDP DNA adducts are
not recognized by HMGB1. 2 4 In the present study, we discovered that HMGB1 sensitizes HeLa
but not MCF-7 cells to tans-DDP. Pretreatment with 1 M HMGBI enhanced the cytotoxicity
of tralns-DDP by nearly an order of magnitude (Figure 6.6B and Table 6.1). Even co-treatment
with I tM HMGBI and trans-DDP sensitized HeLa cells by 4-fold.
The observation that the cytotoxicity of trans-DDP is not modulated by exogenous
HMGB 1 in MCF-7 cells supports the hypothesis that addition of the protein to the extracellular
media affects the repair of cisplatin-DNA adducts by the shielding mechanism described above.
Conversely, the results for HMGBI and trans-DDP treatment of HeLa cells suggest that a
different mechanism may be involved.a Repair-shielding of a trans-DDP DNA adduct seems
unlikely especially since the degree of HMGB l-induced sensitization is significantly greater than
for cisplatin in HeLa cells. Furthermore, as mentioned above no evidence exists to support a
interaction betwveen HMGBI and trans-DDP damaged DNA. Since co-treatment with 1 LtM
HNIGB I in HeLa cells affects tans-DDP, but not cisplatin, cytotoxicity, we conclude that
HMGBI sensitizes HeLa cells to the two diamminedichloroplatinum(1l) isomers platinum
compounds by different mechanisms.
'Because of the need for high levels of HMGB 1, repair-shielding of DNA damaged by trans-DDP may
occur in HeLa cells. HMGB1 binds with modest affinity to cisplatin interstrand cross-links and to
interstrand cross-links on DNA damaged by a polynuclear trans-platinum complex. ' 4 Moreover,
IIMGBI is thought to modulate the repair of psoralen interstrand cross-links through formation of a
ternary complex with replication protein A (RPA). 3'
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Effect of MAPK Inhibitors on HMGB1-induced Enhancement of trans-DDP Cytotoxicity
From the foregoing results we wondered whether HMGB1 might sensitizes cells to trans-DDP
by functioning as a cytokine. HMGBI binding to the RAGE receptor induces several signal
transduction pathways including translocation of NF-KB to the nucleus and phosphorylation of
the MAP kinases ERK, JNK, and p38. '29 Activation of NF-KB is typically associated with the
prevention of apoptosis, but a number of genes that it regulates are pro-apoptotic.3 6 The balance
of pro-survival and pro-apoptotic signals induced by the HMGB1/RAGE interaction may be
modified by platinum treatment. The ability of HMGB1 treatment alone to induce cell death in
MCF-7 cells suggests that the protein may induce pro-apoptotic signal transduction pathways. In
support of this supposition, exposure to HMGB 1I induces apoptosis in macrophages via a
proposed JNK pathway.37
We therefore investigated the ability of p38, JNK, and ERK inhibitors to modulate the
ability of exogenous HMGB 1 to render trans-DDP more cytotoxic toward HeLa cells. The ERK
inhibitor was inherently cytotoxic and treatment with the p38 inhibitor did not effect HMGB I-
induced sensitization to trans-DDP. As illustrated in Figure 6.8, however, the INK inhibitor
dramatically reversed the sensitization of HeLa cells to trans-DDP following HMGBI
pretreatment. Conversely, pretreatment of the cells with the JNK inhibitor had no effect on the
ability of HMGB1 to sensitize HeLa cells to cisplatin (data not shown).
Several studies have previously connected JNK activation to trans-DDP cytotoxicity.38-40
Treatment of mouse keratinocytes with trans-DDP induces transient phosphorylation of JNK, a
phenomenon typically associated with a pro-survival cellular response.3 9'4" Prolonging JNK
activation by treatment with sodium orthovanadate, a tyrosine phosphatase inhibitor, increases
mouse keratinocyte sensitivity to trans-DDP.3 9 Perhaps in HeLa cells, exogenous HMGB1
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prolongs JNK activation and thereby sensitizes cells to trans-DDP in an analogous fashion. The
fact that treatment with a JNK inhibitor reduces the sensitivity of HMGB I-treated HeLa cells to
trans-DDP is consistent with this proposal.
Effect of Necrotic Media on the Cytotoxicity of Cisplatin
inchlction of Necrosis. As discussed earlier, HMGBI is passively released from necrotic cells. It
was therefore of interest to examine the effect of exposing cells to media harvested from necrotic
cell cultures. Necrosis can be induced by subjecting cells to 4-6 rapid freeze/thaw (-80 C/37 C)
cycles followed by incubation at 37 C for 1 h.41 In a typical experiment, -10 7 cells grown in 12
mL, of media were made necrotic and the surrounding media were harvested and used for
cytotoxicity assays. Assuming that the majority of the 10 7 cells undergo necrosis and release
their entire supply of HMGBI (106 molecules/cell), the media will contain approximately 8x 10'
HMGB1 molecules per mL of media, or 1.4 nM.
EfJclf of Afel'ia front Necrotic C'ell C'ltures on Ci.splatin Sensitivity. The computed
concentration of HMGBI in the necrotic media is considerably lower than the amount of the
exogenous protein required to sensitize HeLa and MCF-7 cells to cisplatin. However, as shown
in Table 6.2, cells grown in media bathing necrotic cell cultures were more sensitive to cisplatin
treatment. HeLa cells were sensitized by a factor of two to cisplatin, and the cytotoxicity of
cisplatin toward[ MCF-7 cells was enhanced 3-fold.
Mechanism of Cisplatin7 Sensitization. It remains to be proved whether HMGBI alone is
responsible for the cellular sensitization to cisplatin following exposure to necrotic cell media,
but preliminary observations support this premise. The cytotoxicity of trans-DDP toward MCF-7
cells remained unchanged when they were grown in necrotic cell media. Necrotic media was also
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prepared from HMGBl-silenced HeLa cells, which should contain little or no released HMGB1.
HeLa cells grown in such media were actually resistant to cisplatin (IC50 = 5.2±0.2 FM)
compared to cells grown in regular media (Cs 0 = 2.6±0.3 riM). This result supports the
hypothesis that it is the HMGB1 released from necrotic cells that sensitizes HeLa cells to
cisplatin, but it also underscores the complexity of the components released from necrotic cells.
As mentioned earlier, the maximum concentration of HMGB1 released into 12 mL of media
would be 1.4 nM, which is significantly lower than the concentration of recombinant protein
used to sensitize MCF-7 and HMGB 1 cells to cisplatin. This result might be a consequence of
other released necrotic factors that sensitize cells to cisplatin. Alternatively, HMGB1 released
from necrotic cells may differ from the recombinant protein added extracellularly. HMGB1
actively secreted from monocytes is hyperacetylated in order to direct the protein for export, but
HMGB1 passively released from necrotic cells is not.4 However, HMGB1 exists in several
acetylated forms in vivo.3 Therefore, it is possible that such post-translational modifications of
HMGB I enhance uptake and activity of the protein.
Conclusions and Future Directions
The ability of extracellular HMGB 1 to mediate the cytotoxicity of platinum compounds was
evaluated in MCF-7 human breast cells and HeLa human cervical cancer cells. Externally added
HMGBl permeates the cell membrane and localizes in both the nucleus and cytoplasm of HeLa
cells. Extracellular HMGBI sensitizes cells to platinum compounds in a cell line-dependent
fashion. In HeLa cells, 1 [LM of HMGB is required to enhance the cytotoxicity of cisplatin.
Pretreatment with HMGBl also sensitizes HeLa cells to trans-DDP through a JNK-dependent
mechanism. Pretreatment with 10 nM HMGB1 sensitizes MCF-7 cells to cisplatin, but not to
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irans-DDP. These observations support the hypothesis that HMGB1 mediates the cytotoxicity of
cisplatin by a repair-shielding mechanism. The ability of HMGBI to sensitize HeLa cells to
trans-DDP is proposed to occur via a signal transduction mechanism involving JNK.
Media from necrotic cell cultures sensitizes MCF-7 and HeLa cells to cisplatin treatment,
presumably through the release of HMGBI. In support of this hypothesis, media that bathed
necrotic HIMGB31-silenced HeLa cells actually rendered HeLa cells less sensitize to cisplatin.
These observations raise many interesting questions concerning the mechanism of cisplatin
cytotoxicity enhancement by necrotic media. Future work could involve immunoprecipitation of
HMGB 1I from necrotic media or examination of the role of HMGB2. These experiments also
suggest that post-translational modifications of HMGB I may be important in achieving cisplatin
sensitization. Future experiments should use native HMGB1 instead of recombinant protein in
order to evaluate this possibility. In addition, HMGBI released from necrotic cells could be
characterized by mass spectrometry.
The question of whether HMGBI sensitizes cells to platinum treatment by a repair-
shielding or signal transduction pathway could be explored by using truncates of the protein.
Previous work showed that the cytokine function of HMGB I was localized to the B box, and
more specifically required amino acids 89-108.4- Different protein truncates should be screened
and evaluated for their ability to bind platinum-damaged DNA and to sensitize cells to platinum
treatment.
More evidence for HMGBI sensitizing cells to cisplatin treatment via a repair-shielding
mechanism could be obtained by examination of Pt-DNA adduct levels. Numerous attempts to
acquire such data through quantifying platinum levels by Pt AAS have failed; however, it may be
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possible to use monoclonal antibodies raised against cisplatin-modified DNA to examine repair
of platinum damage.
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Table 6.1. IC50 values (M) for cisplatin and trans-DDP in HMGBl-pretreated HeLa and MCF-7
cells.
HMGB I No Protein 10 nM 100 nM I [tM
Concentration
HeLa cells
cisplatin 2.6 + 0.3 2.0 0.6 2.1 0.3 1.4 0.4
trans-DDP 90 + 13 80 10 50 8 10 ± 2
HMGB I No Protein 2 nM 5 nM 10 nM
Concentration
MCF-7 cells
cisplatin 5.8 0.8 6.5 + 0.1 3.4 + 0.2 1.8 ± 0.2
trans-DDP 55 + 15 78 + 6 68 + 10 67 + 10
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Table 6.2. Effect of necrotic media on the cytotoxicity of cisplatin in MCF-7 and HeLa cells as
monitored by ICo (IM) values.
Media Type Regular Necrotic
HeLa cells
cisplatin 2.6±0.3 1.2+0.2
MCF-7 cells
cisplatin 5.8±0.8 1.8±0.3
. .. .. . . . . .~~~~~~~~~~~~~~~~~~~~~~~~~~~~
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Figure 6.1. Schematic representation of a solid tumor with a necrotic core. HMG B1 is passively
released from necrotic cells and interacts with surrounding viable tumor tissue. Figure modified
from www.lillie.insenn.fr/mordon/tumorOl.jpg.
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Figure 6.2. Cellular levels of HMGB I as detected by immunofluorescence (40X magnification).
HeLa cells were treated with 2 nM HMGB I and incubated at 37 C for 0-48 h. Fixed cells were
treated with an anti-HMGB I primary antibody followed by treatment with a FITC-conjugated
secondary antibody to allow for HMGB I visualization.
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Figure 6.3. Fluorescence microscopy images of cells incubated with FITC-HMGB 1 (40X
magnification). (A) Determination of minimal FITC-HMGB 1 concentration required for
HMGB I detection. HeLa cells were treated with 0-1 ~lM HMGB I for 48 h at 37 C. (B) Kinetics
of FITC-HMGB 1 uptake in He La cells. Cell were treated with 500 nM HMGB 1 and incubated at
37 C for 0-54 h. Both phase contrast and fluorescent images are shown.
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Figure 6.4. Uptake of FITC-labeled HMGB 1 as monitored by flow cytometry. HeLa and MCF-7
cells were incubated with 100 nM FITC-HMGBI at 37 C for 0-48 h, harvested, and analyzed
by FACS.
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Figure 6.5. (A) Western blot analysis of HMGB I levels in whole cell extracts of HMGB 1-
silenced HeLa cells treated with 0 (lane 2), 2 (lane 3), 20 (lane 4), 100 (lane 5), or 500 (lane 6)
nM of exogenous recombinant HMGB I. Lane I is recombinant HMGB I alone as a positive
control. (B) Western blot of HMGB I expression levels in HMG B I-silenced HeLa cells. Lanes I
and 3 are the cytosolic and nuclear extracts of HMGB I-silenced HeLa cells, respectively. Lanes
2 and 4 are the cytosolic and nuclear extracts of HMGB I-silenced HeLa cells allowed to
incubate with 500 nM HMGB I for 48 hat 37 C, respectively. (C) Expression of RAGE in HeLa
(lane I) and MCF-7 (lane 2) cells. Actin was lIsed as the loading control.
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Figure 6.6. Cytc)toxicity of cisplatin (A) and trans-DDP (B) in HeLa cells as monitored by the
MTT assay. Cells were incubated with I tiM HMGBI for 48 h before platinum treatment. Error
bars represent one standard deviation.
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Figure 6.7. Cytotoxicity of cisplatin (A) and trans-DDP (B) in MCF-7 cells as monitored by the
MTT assay. Cells were incubated with 10 nM HMGB I for 48 h before platinum treatment. Error
bars represent one standard deviation.
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Figure 6.8. Effect of MAPK inhibitors on the cytotoxicity of trcans-DDP in HMGBI-pretreated
H-eLa cells. Cells were incubated for 44 h with I tM HMGBI and for 4 h with MAPK inhibitors
before platinum treatment. Cell survival was determined by the MTT assay and error bars
represent one standard deviation.
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Appendix A
Post-Translational Modifications of Histone H4 Following Platinum
Treatment
207
Introduction
Cells treated with cisplatin, cis-diamminedichloroplatinum(ll), respond to the resultant DNA
damage in a variety of ways, and many of which remain to be established.' In addition to
initiating DNA-damage recognition and repair mechanisms, cisplatin treatment activates signal
transduction cascades, including mitogen-activated protein kinase (MAPK) pathways.' In HeLa
cells, exposure to cisplatin results in the phosphorylation of histone H3 at Ser- O1 and Ser-28 and
acetylation of H4, the former being mediated by the p38 MAPK pathway.2 Histone modifications
alter chromatin structure, which increases the accessibility of nucleosomal-packaged DNA to
proteins that process the genome.2 Elucidating cisplatin-induced post-translational modifications
of histones is important for understanding how cells respond to and repair platinum-damaged
DNA.
Experimental Procedures
General Considerations. The isolation of histones from harvested nuclei and their mass
spectrometric analysis were carried out by Mike Boyne and Professor Neil Kelleher at the
University of Illinois at Urbana-Champaign (UIUC), in the manner described previously.3
Cell Culture. Human MCF-7 and HCC-1937 breast cancer, NTerall testicular carcinoma, and
HeLa cervical cancer cells were purchased from the American Type Culture Collection. MCF-7
and HeLa cells were grown in DMEM (GIBCO/BRL) supplemented with 10% FBS (Hyclone), 1
mM sodium pyruvate, 100 units/mL of penicillin, and 100 tig/mL streptomycin. NTeraII and
HCC-1937 cells were grown in RPMI-1640 media (ATCC) containing 10% FBS, 2 mM L-
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glutamine, mM sodium pyruvate, 100 units/mL penicillin, and 100 tg/mL streptomycin. All
cells were incubated at 37 C under a 5% CO, atmosphere.
Treatment of Cells. Cells were grown to 90% confluence in 175 cm2 flasks (-2x 107 cells) and
treated with either 100 ptM sodium butyrate, 5-20 LtM cisplatin, 100 [tM trans-DDP, or 10 LtM
cis-[PtCl,(DACH)] for 16 h at 37 C. Cells were then washed with cold PBS, harvested, snap
frozen, and stored at -80 C until the isolation of their nuclei.
Preparation of Nuclei. NIB-250 buffer was prepared with the following components: 15 mM
Tris-HCI pH 7.5, 60 mM KCI, 15 mM NaCI, 5 mM MgCl2, 1 mM CaC1,, 250 mM sucrose, 1
mM DTT, 10 mM sodium butyrate and 0.5 mM PMSF. Frozen cell pellets were thawed and
allowed to reach 4 C. Cells were suspended in NIB-250 buffer supplemented with 0.3% NP-40
(2x107 cells/mL of buffer) and incubated on ice for 5 min. The nuclei were pelleted by
centrifugation at 600 rcf for 5 min at 4 C and the supernatant was discarded. The nuclear pellet
was resuspended in NIB-250 buffer without NP-40 (2x107 cells/mL of buffer) and centrifuged at
600 rcf at 4 C for 5 min. The supernatant was discarded and the cells were again resuspended in
NIB-250 buffer (2x107 cells/mL of buffer). Samples (I mL) were apportioned into 1.5 mL
microcentrifuge tubes and centrifuged at 600 rcf at 4 C for 5 min. Finally, the supernatant was
discarded and the nuclei were resuspended in an equal volume of NIB-250 supplemented with
20% glycerol, snap frozen, and stored at -80 C. Samples were sent to UIUC on dry ice.
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Results and Their Significance
Nuclei were isolated from HeLa, MCF-7, NTerall, and HMGB -silenced HeLa cells treated with
either cisplatin or sodium butyrate (see Table A. 1 for treatment conditions) and post-translational
modifications of histone H4 were monitored by mass spectrometry.3 Sodium butyrate is a histone
cleacetylase inhibitor, so cells treated with this compound served as a positive control. As shown
in Figures A.1 and A.2, cells treated with sodium butyrate contain several acetylated forms of
histone H4 that are not observed in untreated cells. Conversely, cells treated with cisplatin,
carboplatin, or trmns-DDP have essentially the identical histone H4 patterns as untreated cells. In
addition, the ratio of acetylated to unmodified histones is unchanged upon platinum treatment.
Therefore, it appears that treatment with cisplatin does not effect the post-translational
modification of histone H4. Alternatively, any differences in post-translational modifications
may be below the detection limit of the current mass spectrometric analyses. The detection limit
of mass spectrometric techniques is dependent upon sample preparation and instrument
sensitivity. For analysis of histone modifications, the detection limit is between 50:1 and 300:1.4
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Table A. 1. Treatment conditions for samples analyzed by mass spectrometry.
Cell Line
HeLa
MCF-7
NTeraII
HeLa-HMGB I
silenced and
-pcDNA control
Treatment Conditions
Untreated
100 CpM sodium butyrate, 16 h
5 tM cisplatin, 16 h
10 tiM cisplatin, 16 h
20 [tM cisplatin, 16 h
100 [LM carboplatin, 48 h
100 [IM trans-DDP, 16 h
10 [EM cis-[PtC1l(DACH)], 16 h
Untreated
100 [tM sodium butyrate, 16 h
5 [tM cisplatin, 16 h
10 [tM cisplatin, 16 h
20 E[M cisplatin, 16 h
Untreated
100 [tM sodium butyrate, 16 h
5 [tM cisplatin, 16 h
10 gtM cisplatin, 16 h
20 [tM cisplatin, 16 h
Untreated
100 IM sodium butyrate, 16 h
10 [LM cisplatin, 16 h

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Figure A.l Mass spectrometry of histone H4 from cisplatin-treated MCF-7 nuclei. Acetylated
histone H4 isoforms of interest are indicated by an asterisk.
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Figure A.2. Mass spectrometry of histone H4 isolated from platinum-treated BeLa cells.
Acetylated histone H4 isofonns of interest are indicated by an asterisk.
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Appendix B
Expression of HMGB1 in Paraffin-Embedded Seminoma Tissue from Human
Cancer Patients
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Introduction
Formerly defined vaguely as an architectural protein, HMGB1 has recently been shown to have
an extracellular role as a cytokine.' The protein is actively exported from the nuclei of
macrophages and monocytes and is passively leaked from necrotic cells to induce a variety of
signal transduction cascades. 4 This newly discovered signaling role of HMGB1 inspired the
hypothesis that the extracellular protein may mediate the cytotoxicity of cisplatin in solid tumors
(Chapter 6). Externally added HMGB1 is taken up by HeLa and MCF-7 human cancer cells
grown in culture (Chapter 6). Furthermore, pretreatment with the extracellular protein sensitizes
HeLa and MCF-7 cells to cisplatin (Chapter 6).
In order to assess the potential clinical relevance of our hypothesis, the expression level
of HMGB 1 was evaluated in paraffin-embedded human tumor tissue. More than 90% of patients
with testicular cancer are cured with cisplatin treatment. We therefore chose to examine the
expression of HMGBI in testicular seminomas. This appendix describes the histological
evaluation of testicular seminoma tissue performed by our collaborators Dr. Robert Colvin and
Dr. J.P. Bissonnette at Massachusetts General Hospital. In addition, determination of HMGB1
expression in paraffin-embedded tumor tissue by western blot analysis is discussed.
Experimental Procedures
Materials. Microscope slides with thin slices (-5 [tM) of paraffin-embedded formalin-fixed
seminoma tissue were provided by the Pathology Department at Massachusetts General Hospital
(10 slides per case). Histology staining with haematoxylin and eosin characterized the samples as
either predominately viable or necrotic. HMGBI levels were visualized using standard
immunohistochemical techniques. Table B. I1 summarizes sample information.
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Preparation of Extracts from Paraffin-Embedded Formalin-Fixed Tissue. The preparation
of protein extracts was based on a previously reported methodology.5 Tissue slices were washed
with xylene to remove the paraffin and then hydrated by washing in ethanol and water. This
procedure was repeated 2-3 times and the tissue was allowed to dry in the air. The tissue tfrom
each case was scraped from the microscope slide using a razor blade and resuspended in 200 FL
of RIPA buffer ( mM NaH 2PO4 , 10 mM NaHPO 4, 154 mM NaCI, 1% triton x-100, 12 mM
sodium deoxycholate, 2% SDS, 0.2% NaN 3, 0.95 mM NaF, 2 mM PMSF, 5 Eig/mL aprotinin, 5
g/L leupeptin). RIPA buffer can be prepared without the protease inhibitors (PMSF, aproptinin,
and leupeptin) and stored at 4 C, these protease inhibitors should be added immediately before
use. The tissue suspension was heated at 100 C for 20 min, and allowed to incubate at 60 C for
2 h. The tissue lysates were centrifuged at 13500 rpm at 4 C for 15 min and the supernatant was
collected and analyzed for protein content by the bicinchoninic acid assay. The extracts were
then concentrated to -50 E[L, snap frozen, and stored at -80 C until further analysis.
Western Blot Analysis. For examination of HMGB 1 levels, the tissue extracts were thawed and
allowed to come to 4 C before analysis. Proteins were separated by SDS-PAGE for 90 min at
150 V on a BioRad 4-20% Tris HCI Ready-Gel. The separated proteins were transferred to a
PVDF membrane at 100 V for 60 min, blocked with TTBS + 5% milk for 90 min, and probed
with a 1:2,000 dilution of anti-HMGBl polyclonal antibody (Upstate) or a 1:20,000 dilution of
anti-actin polyclonal antibody (Upstate) O/N at 4 C. The PVDF membrane was washed with
TTBS + 5% milk and incubated with a 1:3000 dilution of anti-rabbit-HRP (HMGB 1, Amersham
Biosciences) or anti-mouse-HRP (actin, Bio-Rad) secondary antibody for h at RT. The PVDF
membrane was then incubated with ECL western blotting detection solution (Amersham
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Biosciences) for 90 sec and blotted dry. Proteins were then detected by exposing the PVDF
membrane to BioMax MR autoradiography film (Eastman Kodak Co.). The expression level of
HMGB 1 was compared to that of the loading control standard actin for each sample. The ratio of
HMGB 1 to actin expression was determined by measuring the number of pixels in each protein
band from the immunoblot using Quantity Analysis Software (BioRad, version 4.5.0).
Results and Discussion
The expression levels of HMGB 1 were evaluated in testicular seminoma tissue by histological
techniques and by western blot analysis. Clinical samples were chosen based on their distribution
of viable and necrotic tissue. As summarized in Table B.l, the seminoma tissue was
characterized as either predominately viable or necrotic.
Histological Evaluation
Two clinical cases were examined by haematoxylin and eosin staining and by
immunohistochemistry in order to determine the levels of viable/necrotic tissue and HMGB I
expression, respectively. As shown in Figure B. 1, Case MS-04-X41943 is a testicular seminoma
characterized by patchy areas of necrosis surrounded by viable tumor tissue. The distribution of
HMGB1 correlates with the histology of the tumor, with the necrotic tissue having less HMGBI
expression than the viable region. This observation is consistent with a report that necrotic cells
passively release HMGB1.6 There was no direct evidence for selective uptake of HMGB1
released from necrotic cells by the viable tissue, however. Cells farthest away from and adjacent
to the necrotic region appear to contain equivalent levels of HMGB 1.
Case MS-04-D60785 is a testicular seminoma with large areas of necrotic and viable
tissue. This case is particularly interesting because the necrotic and viable regions are separated
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by a fibroinflammatory rind (Figure B.2). The necrotic tissue shows only patchy expression of
HMGBI, wheras the fibroinflammatory rind is intensely stained for HMGBI. It is possible that
HMGB1 release from the necrotic tissue acts to recruit inflammatory cells to respond to the
region of damaged cells.6 7 The viable cells adjacent to the fibroinflammatory rind also stain
positive for HMGBI expression. Again, there was no evidence for selective HMGB1 uptake
exists in this case; however, a clinical pattern of significant levels of HMGB1 in testicular
seminomas was demonstrated.
Western Blot Analysis
In an attempt to obtain evidence for cellular uptake of extracellular HMGB1, the level of the
protein was compared in predominantly viable versus necrotic seminoma tissue. HMGB1
concentrations were normalized to the amount of actin in each sample. As shown in Figure B.3,
all nine of the seminoma samples contain HMGB 1 regardless of the tissue histology. Figure B.4
summarizes the ratio of HMGBI to actin in the seminoma samples. In general, there is no
correlation between HMGB 1 level and the identity of the tissue as necrotic or viable. Case MS-
04-D60785 is particularly valuable since the tumor contains adjacent necrotic and viable tissue
(Figure B.2). The viable region of the seminoma sample MS-04-D60785 does contain slightly
more HMGBI than the necrotic region of the tumor; however, it is unclear whether this
difference is significant.
Conclusions and Future Directions
Both histological and immunoblotting techniques demonstrated that HMGBI is present in
testicular seminomas; however, direct evidence for internalization of extracellular HMGB 1 was
not obtained. Visualization of HMGBI by western blot analysis is somewhat problematic given
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the large amount of tissue required for analysis. For example, tissue from 10 microscope slides
was harvested for each case. In addition, true quantification of protein levels from clinical
samples is difficult. Nevertheless, this study provides an impetus for further investigation of
HMGB1 expression levels in seminomas. Since HMGB1 overexpression has been associated
with cisplatin resistance and anti-apoptotic signals, it is possible that a tissue-type dependence
exists for this phenomenon.89 It is tempting to speculate that the regions of necrosis in testicular
seminomas sensitize the surrounding viable tissue to cisplatin through the release of HMGB 1.
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Table B. 1. List of clinical testicular seminoma samples examined in this study. Samples were
provided as paraffin-embedded formalin-fixed tissue attached to microscope slides. Histology
was determined at Massachusetts General Hospital Pathology Department.
Sample/Lane Case Number Histology
Number
MS-04-D39239, block A3 Predominately viable
2 MS-04-X41943, block A5 Predominately viable
3 MS-04-D60785, block A9 Predominately viable
4 MS-05-D7074, block A 13 Predominately viable
5 MS-04-X5902 1, block A I Predominately necrotic
6 MS-04-X59021, block A4 Predominately necrotic
7 MS-04-D60785, block A3 Predominately necrotic
8 MS-04-D60785, block A4 Predominately necrotic
9 S02W39192, block P Markedly necrotic
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Immunohistochemistry for
HMGBI
Figure B.I Histochemistry for Case MS-04-X41943, testicular seminoma with patchy areas of
necrosis surrounded by viable tissue (40X magnification). The left panel is tissue stained with
haematoxylin and eosin (H&E) for differentiating viable (black) and necrotic (pink) tissue. The
right panel shows HMGB I expression levels as visualized by immunohistochemistry. The blue
arrows indicate select areas positive for HMGB I expression (brown nuclei).
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Figure B.2. Histochemistry for Case MS-04-D60785, a testicular seminoma with a large area of
necrosis that is separated from viable tumor tissue by a fibroinflammatory rind (top panel, 2X
magnification). The center panel is tissue (lOX magnification) stained with haematoxylin and
eosin (H&E) for differentiating viable (black) and necrotic (pink) tissue. The bottom panel (lOX
magnification) shows HMGB I expression levels as visualized by immunohistochemistry. The
blue arrows indicate select areas positive for HMGB 1 expression (brown nuclei). The necrotic
area has patchy, diffuse HMGB 1 expression, wheras the fibroinflammatory rind is mostly
positive for HMGB 1expression.
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Figure B.3. Expression levels of actin and HMGB I in testicular seminoma samples. See Table
8.1 for lane assignments.
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Figure B.4. A bar chart showing the ratio of HMGBI to actin expression levels in testicular
seminoma samples with variant histology. The ratios were determined by western blot analysis.
See Table B. 1 for lane assignments. Bars marked with an asterisk (*) are from the same patient.
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Appendix C
Solid Phase Synthesis of a Platinum(IV)-RGD Peptide Conjugate
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Introduction
Angiogenic tumor blood vessels express CiP3 and avs3 integrins, which specifically recognize
RGD and NGR tripeptide motifs.' Recent work from our laboratory afforded a series of
platinum(IV) peptide conjugates prepared to target angiogenic endothelial cells through
interaction with such integrin receptors.2 The platinum(IV) peptide conjugate containing the
RGD peptide motif was particularly active against bovine capillary endothelial cells. Although
the Pt(IV)-RGD conjugate was not as cytotoxic as cisplatin, it was more active than related
platinum(IV) compounds tethered to non-specific peptides.2 In order to evaluate the targeting
potential of the Pt(IV)-RGD conjugate, animal studies are planned. Unfortunately, current
synthetic methodologies only yield 1-5 mg quantities of the Pt(IV)-RGD conjugate and several
hundred milligrams of material are required for animal studies. This appendix describes an
imlproved solid.-phase synthesis of the Pt(IV)-RGD conjugate that yields 20 mg of pure material.
Experimental Procedures
Materials and Methods. Cis, cis, tratns-Diamminedichlorodisuccinatoplatinum(IV) was
synthesized as described previously.3 Rink amide resin and all peptides were purchased from
NovaBiochem.
Solid-Phase Synthesis of a Mono-Substituted Pt(IV)-RGD Conjugate.
Synthesis of RC;D. Rink amide resin (0.17 g, 0.61 mmol/g resin, 0.10 mmol) was washed with
DMF and soaked in 20% piperidine/DMF for 5 min to remove the Fmoc protecting group
(deblocking step). For the first coupling reaction, Fmoc-Asp-(OtBu)-OH (0.44 g, 1.1 mmol) was
dissolved in a solution of DIPC (140 [tL, 0.89 mmol) and HOBt (0.13 g, 0.99 mmol) in DMF (5
mL) and allowed to stir for 5 min before addition to the resin. After 90 min, the resin was rinsed
226
with DMF and the deblocking procedure was repeated. The coupling reaction was repeated with
Fmoc-Gly-OH (0.31 g, 1.1 mmol), DIPC (140 tL, 0.89 mmol) and HOBt (0.13 g, 0.99 mmol) in
DMF (5 mL) and the Fmoc protecting group was removed with 20% piperidine/DMF. The last
peptide coupling reaction was carried out with Fmoc-Arg-(Pbf)-OH (0.67 g, 1.0 mmol), DIPC
(140 tL, 0.89 mmol), and HOBt (0.13 g, 0.99 mmol) and the deblocking procedure was
repeated. Finally, the resin-linked RGD peptide was washed with DMF.
Platinum(IV) Cojugation. Cis, cis, trans-Diamminedichlorodisuccinatoplatinum(IV) (1.1 g, 2.0
mmol) was activated with DIPC (270 [tL, 1.7 mmol) and HOBt (0.24 g, 1.8 mmol) in DMF (5
mL) for 5 min at RT. The activated platinum(IV) compound was added to the resin-linked RGD
peptide and the reaction was allowed to stir at RT in the dark. After 14 h, the resin was rinsed
with DMF, methanol, and methylene chloride. The product was cleaved from the resin by
stirring in 10 mL 95% TFA in water for 1.5 h at RT in the dark. Crude product was isolated by
ether precipitation, resuspended in H,O, and lyophilized to dryness. The mono-substituted
Pt(IV)RGD conjugate was purified by reverse-phase HPLC (C18 semi-preparative column, 40
mm x 250 mm, linear gradient from 100% H20 to 15% acetonitrile over 30 min) and isolated as
a pale yellow powder (21 mg, 0.025 mmol, 24% yield). As shown in Figure C.1, comparison of
the HPLC traces shows that the solid phase methodology yields a much cleaner reaction mixture.
Isolation of the desired Pt(IV)-RGD conjugate was confirmed by LC-MS.
Significance
The manual solid phase synthesis of the mono-substituted RGD-conjugated diamminedichloro-
platinum(IV) compound represents a significant improvement over the previous procedure for
the preparation of peptide-tethered platinum(IV) compounds. The previous methodology
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involved automated solid-phase synthesis and subsequent purification of peptide. The peptide
was then allowed to react with the platinum complex to afford product in 11% yield (4.3 mg)
after purification. The manual solid phase synthesis (see Scheme C.1) affords the pure RGD-
conjugated platinum(IV) compound in 24% yield (21 mg) and only requires one purification
step. The ability to isolate larger quantities of the Pt(IV)-RGD conjugate is essential for in vivo
evaluation of its cytotoxicity. Further improvements could involve purification of the Pt(IV)-
RGD conjugate by dialysis instead of HPLC.
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Figure C.I. HPLC chromatographs of crude RGD-conjugated Pt(IV) complex. The mono-
substituted conjugate is indicated as 2a, and the his-substituted product is labeled as 2b. The top
panel is the HPLC trace from a previous reaction2 and the bottom panel is the trace from the
current work.
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